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General introduction 
HIV-infection and AIDS 
In 1981, the first cases of Acquired Immune Deficiency Syndrome (AIDS) were discovered in 
gay men. Two years later, the human immunodeficiency virus (HIV) was isolated and 
recognized as the causative agent of AIDS. Uncontrolled infection with HIV imminently leads 
to AIDS and ultimately to death. Due to its long latency time until disease manifestation the 
virus can easily spread unnoticed. A high turn-over and rapid mutation rate lead to 
continuous viral changes, which have complicated the development of durable effective 
therapeutic interventions (1 ). 
The natural course of HIV-infection 
HIV is a ribonucleic acid (RNA)-containing retrovirus of the lentivirus-subfamily. It has an 
affinity for C04 cell receptors, which are mainly present on helper T -lymphocytes of the 
immune system but also occur on other cells (2). Through these receptors and with the help 
of chemokine co-receptors (CCR5 and CXCR4) (3-6), viral RNA is released into the cell 
cytoplasm where it is converted into deoxyribonucleic acid (DNA) by virus-encoded reverse 
transcriptase (Figure 1 ). 
The resulting proviral DNA is transferred into the cell nucleus and incorporated into 
the host genome (7). Hence, HIV-infected progeny is generated at each cell division and 
proviral RNA and viral precursor polyproteins are produced through regular cellular 
transcription and translation processes. HIV-encoded proteases subsequently cleave the 
polyprotein precursors, yielding mature core polypeptides and essential enzymes, which are 
assembled into new infectious HIV-virions (7-10) (Figure 1). 
Eventually, infection leads to C04 cell depletion and impaired immune function 
effectively leading to AIDS (11), The number of circulating HIV-RNA particles and CD4 
positive lymphocytes are used for the monitoring of HIV-infection, representing the degree 
of viral activity on the one hand and the degree of immune deficiency on the other hand 
[12-15), 
Antiretroviral treatment 
The enzymes reverse transcriptase and protease are fundamental to the survival and 
multiplication of HIV and therefore constitute important targets for antiretroviral treatment. 
Reverse transcriptase inhibitors were the first agents used for the treatment of HIV-infection 
(16-18), but failed to significantly change the course of infection (19), 
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Figure 1 life-cycle of HIV and action of antiretroviral agents 
In 1996 the first HIV-protease '1nh·1bitors became available (20-25). Short term studies showed 
that the combination of reverse transcriptase inhibitors and HIV-protease inhibitors was able 
to suppress HIV-RNA to undetectable levels and improve the immune system (24, 25). 
Optimal treatment of HIV-infection nowadays involves the chronic administration of 
multiple drugs, which attack the virus from different angles, also referred to as highly active 
antiretroviral therapy (HAART) (26-28) (Figure I). HAART usually consists of two nucleoside 
analogue reverse transcriptase inhibitors (NRTis) for optimal inhibition of HIV-encoded 
reverse transcriptase, and an HIV-protease inhibitor. The aim of this treatment is to intercept 
both the infection of new and the production of new infectious HIV-particles [Figure 1) (9, 
29]. HAART has shown to inflict a steep reduction in HIV-related morbidity and mortality in 
populations in which such treatment was made available (30-32). By the turn of the century 
the focus of care for HIV-infected patients in Western countries had shifted from treating 
opportunistic diseases and in-hospital care to providing antiretroviral treatment and 
monitoring HIV-infection in an outpatient clinic setting. 
Issues in ontiretroviral therapy 
An important risk of HAART concerns the selective production of resistant viruses in case of 
insufficient viral suppression, which eventually may accumulate into treatment resistence 
and viral breakthrough (1, 9, 15, 33-36]. Patients experiencing such treatment failure have 
4 
General introduction 
only a limited number of options for treatment switches due to the existence of cross-
resistance between antiretroviral agents, especially between agents of the same class {28, 
37-41). 
Adequate drug concentrations have shown to be essential for an optimal 
treatment effect. Suboptimal plasma concentrations of HIV-protease inhibitors may fail to 
achieve sufficient viral suppression and hence facilitate viral resistance (42-44). To reduce 
the risk of low plasma concentrations, good treatment compliance should be maintained 
(45-47). 
High plasma concentrations. on the other hand, increase the risk of adverse effects 
(44, 48]. Adverse effects constitute a major limiting factor in antiretroviral treatment. Many 
patients experience gastro-intestinal problems and other adverse effects on a continuous 
basis. This may eventually influence the willingness and ability to maintain optimal 
compliance. 
Finally, it is well recognized that current HAART regimens are unlikely to achieve 
complete efim'1nation of HIV because of the existence of HJV-sanctuary sites and latent 
infected CD4 positive cells (49-53). Sustained viral suppression below the detection limit, 
therefore, remains the primary goal of HAART (54). Thus, the cornerstone of present HAART is 
optimal compliance. To facilitate this, improvement of treatment schedules and 
minimization of adverse effects can play a pivotal role. 
H!V-protease inhibitors 
HIV-protease inhibitors were introduced worldwide to the market after accelerated 
registration procedures. This happened under high pressure from the field. because 
treatment combinations with these agents were the first to show substantial efficacy against 
HIV-infection. At the time of introduction, however, knowledge regarding long-term effects 
and safety of this entirely new generation of drugs was sparse and insufficient. 
Clinical information about the first HIV-protease inhibitors was based on clinical trials 
examining relatively small patient populations over a period of one to two years {55-60]. 
These clinical trials were designed to show clinical benefit in terms of HIV-suppression in 
particular, mostly based on surrogate parameters. Clearly, the relatively small number of 
selected patients examined over relatively short periods of time (Table 1 ), was insufficient to 
uncover the full picture of the r"ISks involved with the use of HIV-protease inh.lb.ltors. In 
addition, clinical trials provided little insight into the severity, risk factors and impact of 
adverse effects. 
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Table 1 Product license information on HIV-protease inhibitors 
Compound Saquinavir Ritonavir lndinavir Nelfinavir 
mesylate sulphate mesylate 
Alternative names Ro 31-8959 ABT-538, MK-639, AG1343, 
lnvirase® Norvir® Crixivan® Viracept® 
EMEA approval 40ct 1996 27 Aug 1996 4 Oct 1996 22 Jan 1998 
Formulation 200 mg hard gel 100 mg capsules; 200 mg and 400 250mg 
capsules or soft 80 mg/mL mg capsules tablets 
gel capsules suspension 
Clinical trials prior to 302 patients 24 84 patients 32 11 65 patients 38 65 patients 28 
registration weeks(55), weeks(56), weeks(58], doys{118) 
978 paf1ents 16 1090 patients 24 97 patients 24 33 patients 24 
weeks weeksfll7l weeks weeks(119l 
General characteristics of HIV-protease inhibitors 
HlV-encoded proteose displays structural similarity to human aspartic proteases, pepsin and 
renin (8, 10). This knowledge served as a basis for the computer-aided development of HIV-
protease inhibitors (7, 61-65), which exert their antiretroviral effect through specific inhibition 
of viral proteose V 9, 29, 66), 
The first HIV-protease inhibitors which became available were saquinavir, ritonavir 
and indinavir. Three quarters of a year later, a fourth HIV-protease inhibitor nelfinavir was 
introduced. Only recently lopinavir and amprenavir have been added to the repertoire, 
these HIV-protease inhibitors will not be described here. Saquinavir, ritonavir, indinavir and 
nelfinavir are chemically related compounds (Figure 2). The most important characteristics 
in the context of this thesis are summarized in table 2. Like many other drugs, HIV-protease 
inhibitors are given in standard dose frequency schedules. Depending on the type of HIV-
protease inhibitor, presence (saquinavir. ritonavir, nelfinavir) (25, 67-70) or absence 
(indinavir) (71-74) of food around the time of ingestion improves absorption. Once 
absorbed, HIV-protease inhibitors are subjected to extensive first-pass metabolism (75, 76). 
The net bio-availability varies from 4% for saquinavir to 60-80% for other HIV-protease 
inhibitors. 
In plasma, HIV-protease inhibitors are highly protein bound [60% for indinavir, >95% 
for other HIV-protease inhibitors) as a result of which renal clearance through glomerular 
filtration is generally low. The primary metabolic pathway for HIV-protease inhibitors is 
oxidation through the liver cytochrome P450 system isoenzyme 3A4 (77-80). None of the 
resulting metabolites, except for one metabo~te of ritonavir and nelfinavir, has anf1retrovkal 
activity of any significance (81-83). The short half-life of HIV-protease inhibitors demands 
frequent dosing regimens ranging from two (ritonavir) to three times daily (other HIV-
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protease inhibitors}. Typically, plasma concentrations of HIV-protease inhibitors have a high 
peak (Cmax) and steep decline to a low trough level. 
Figure 2 Crystal structure of HlV-protease inhibitors saquinavir, ritonavir, indinavir and nelfinavir 
(kindly provided by: WlNAp Geneesmiddelinformatie, lnformatorium Medicamentorum, 's 
Gravenhage: Koninklijke Nederlandse Maatschappij ter Bevordering der Phormacie. 2002) 
Table 2 Physico-chemical and pharmacokinetic properties and adverse reactions of HIV-protease 
inh.lbitors 
Compound Saquinavir Ritonavir lndinavir Nelfinavir 
mesylate sulphate mesylate 
Chemical Lipophilic, weak Lipophilic, weak base Hydrophilic, Lipophilic, weak 
characteristics base weak bose acid 
Protein binding >98% 98-99% 60% ?:98% 
Urine excretion 1% 11% 20% 1-2% 
Metabolic CYP3A4 CYP3A4/2C9/2C19/2D6, CYP3A4, N- CYP3A4, 
route N-glucuronidation glucuronidation (CYP2C19/2D6) 
Active None lsopropylthiazole None hydroxy+ 
metabolites oxidation metabolite butylamide 
(M2) metabolite (M8) 
Bio-availability 4% 66-75% 60-65% >75% 
Half life 1-2 hours 3.2 hours 1.8 hours 3.5-5 hours 
nmetocmax 3.8 hours 4 hours 0.8 hour 2-4 hours 
Recommended 1200 mg tid with Dose escalation day 1-9, 800 mg tid 750 mg tid or 
dosing food 600 mg bid with food fasting (low 1250 mg bid 
gastric pH) with food 
Adverse effects Diarrhoea, Nephrolithiasis*, Diarrhoea 
nausea, gastro- bilirubin j 
intestinal 
discomfort, CPK j 
7 
Chapter 1 
Due to their dependence on cytochrome P450, HIV-protease inhibitors are susceptible to 
interactions with other agents that influence this system (84-87) [Table 3). Stimulation of 
cytochrome P450 leads to a faster clearance, to lower plasma concentrations and 
therefore to reduced treatment effects, whereas inhibition may lead to adverse effects as a 
consequence of reduced clearance and elevated plasma concentrations (88, 89). The 
potential for drug interaction is- especially daunting for patients with a more advanced 
stage of HIV-infection or concurrent diseases, who are more likely to concomitantly use 
interfering drugs. In order to avoid interactions, the full medication-history of patients should 
be known. In the Netherlands such information is available through community pharmacies, 
who keep electronic records of all drug dispensings. Alternatively, the possibility of HIV-
protease inhibitor plasma concentration monitoring [83. 90-98) has facilitated the safe use 
of drug combinations. 
Apart from being metabolized by cytochrome P450 enzymes, HIV-protease 
inhibitors may influence this system themselves (Table 3). Especially ritonavir is known for its 
strong inhibition of isoenzyme 3A4 {99. 1 00). This properly of ritonavir is used to improve the 
pharmacokinetic profiles of other HIV-protease inhibitors. By slowing down the metabolism 
of one HIV-protease inhibitor with a minor dose of ritonavir, dosing frequencies can be 
reduced to tvvice daily and even once daily instead of three times daily (99, 101-1 06). 
Characteristics of soquinavir 
Saquinavir is a generally well-tolerated HIV-protease inhibitor. It is delivered in 200 mg hard 
gelatine capsules which have 4% bio-availability if taken together with food (67). The 
defined daily dose used to be 600 mg three times daily, but has been increased to 1200 mg 
three times daily in the past years. Presently, a soft gelatine capsule formulation is available. 
which is claimed to have similar bio-equivalence but higher bio-availability. hence allowing 
lower dosages {1 07). Both the hard gel and soft gel capsules are commercially available. 
After first being used as a single HIV-protease inhibitor in HAART. saquinavir is now 
mainly used in combination with ritonavir or nelfinavir, to improve its bio-availability by 
reducing clearance (106, 108, 109]. Treatment with a combination of saquinavir and 
ritonavir is usually administered in dosages of 400 mg tvvice daily of each compound. 
Characteristics of ritonavir 
Ritonavir is available in both liquid formulation (80 mg/ml) and 1 00 mg capsule formulation. 
of which the capsules are the most widely used. Although ritonavir has a favorable dosing 
schedule of 600 mg tvvice daily as opposed to three times daily, its gastro-intestinal adverse 
effects, triglyceride elevations and extensive drug interactions {70) limit widespread use. 
Slow induction of the cytochrome P450 system by ritonovir demands dose escalation from 
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300 mg twice daily to 600 mg twice daily over a period of nine days, in order to prevent 
severe adverse effects at the start of treatment. 
Ritonavir has become especially popular as a booster of other HIV-protease 
inhibitor regimens, because of its strong inhibitory effect on cytochrome P450 isoenzyme 
3A4. Apart from its effect on cytochrome P450, ritonavir has an inhibitory effect on p-
glycoprotein, which acts as a filter for the blood brain barrier and potentially other barriers 
to sanctuary sites for HIV {llO).Jnhibition of p-glycoprotein may lead to increased access of 
drugs to these sites. Thus, the addition of ritonavir to an HIV-protease inhibitor increases the 
cerebrospinal fluid concentrations of this drug leading to increased antiviral activity (111 ). 
Characteristics of indinavir 
lndinavir is a widely used potent HIV-protease inhibitor, available in a 200 and a 400 mg 
capsule formulation. Its formal dosing regimen is 800 mg three times da.1ly to be taken two 
hours after a meal or with a low fat meal since absorption is dependent on a low gastric pH. 
Diet restrictions are a major draw back of this HIV-protease inhibitor. These restrictions, 
however, are no longer necessary if indinavir is given in combination with ritonavir {99). 
Moreover, ritonavir boosted indinavir regimens can be given twice daily or even once daily 
instead of three times daily (101, 102. 105, 112, 113). 
lndinavir is the only HIV-protease inhibitor with substantial renal clearance {20%), 
although the primary clearance route is the liver {80%} {72, 80}. Due to poor solubility in 
aqueous solutions of high pH, such as urine, a unique complication of indinavir treatment is 
formation of renal crystals and stones due to indivavir crystallisation. This adverse effect 
requires patients to ensure sufficient fluid intake (114}. Renal complications are the main 
treatment-limiting adverse effect of indinavir. 
Characteristics of nelfinavir 
Nelfinavir was the last of four HIV-protease inhibitors to be registered for treatment of HIV-
infection as part of HAART. It is marketed as a tablet formulation containing 250 mg of 
nelfinavir. The recommended dose frequency is 750 mg three times daily (69), but dosing 
schedules of 1250 mg twke daily are being applied as well. Like other HIV-protease 
inhibitors, cytochrome P450 isoenzyme 3A4 is the primary metabolic route of nelfinavir (86, 
100}. Oxidative bio-transformation of nelfinavir forms an active metabolite, which is equally 
effective as the parent molecule and represents an appreciable proportion (25%) of the 
circulating plasma concentraf1on (81-83}. Like r'ltonavir, nelfinavir may reduce plasma 
concentrations of other drugs because of cytochrome P450 enzyme induction. 
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Table 3 Characteristics HIY·protease inhibitors: potential and known interactions 
Compound 
Agents 
increasing 
clearance 
Agents 
slowing 
down 
clearance 
Agents of 
which 
clearance is 
increased 
Agents of 
which 
clearance is 
slowed 
down 
Saquinavir Ritonavir 
mesylate 
Nevirapine. Rifampin 
rifabutin. 
Rifampin. 
carbamazepine*, 
dexamethasone*, 
phenobarbital*, 
phenytoin* 
Delavirdine. 
ketoconozole. 
ranitidine, 
ritonavir, indinavir, 
nelfinavir 
Astemizole*, 
calcium·channel 
blockers*. 
clindamycin*, 
cisapride*, 
dapsone, 
midazolam*, 
quinidine*. 
sildenafil*, 
terfenadine*. 
triazolam* 
ethinyl estradiol, 
meperidine. 
methadone, 
theophylline 
Clarithromycin, 
desipramine. 
ergotamine. indinavir, 
ketoconazole. rifabutin, 
saquinavir, sildenafil, 
warfarin. alprazolam*, 
amiodarone*, 
astemizole*. calcium-
channel blockers*, 
carbamazep·lne*. 
ciclosporin*, cisapride*, 
clorazepate*, 
dexamethasone*, 
diazepam*, encainide*, 
eythromycine*. 
flecainide*, fluoxetine*, 
flurazepam*, 
itraconazole*. 
loratadine*. 
mefloquine*. 
midazolam*, 
paroxetine*. pethidine*, 
pimozide*, piroxicam*, 
prednisolone*, 
propofenone*. 
propoxyphene*, 
quinidine*, sertraline*, 
terfenadine*, 
trazodone*, triazolam*, 
zoldi em* 
*theoretical interaction 
10 
lndinavir sulphate Nelfinavir 
mesylate 
Fluconazole. Rifabutin, 
nevirapine, Rifampin 
Rifabutin, Rifampin. 
carbamazepine*, 
dexamethasone*, 
phenobarbital*. 
phenytoin* 
Clarithromycin, 
delavirdine, 
Ketoconazole, 
nelfinavir ritonavir. 
itraconazole 
Clarithromycin, 
rifabutin, 
soquinavir, 
astemizole*. 
terfenadine*, 
cisapride*. 
pimozide*, 
quinidine*, 
alprazolam*, 
triazolam*, 
midazolam*, 
sildenafil* 
lndinavir, 
Ritonavir 
Ethinyl estradiol 
indinavir, 
rifabutin, 
saquinavir, 
tertenadine. 
astemizol*, 
calcium· 
channel 
blockers*, 
cisapride*. 
HMGCoA 
reducatase 
inhibtors*, 
midazolam*, 
pimozide*, 
sildenafil*, 
tracrolimus*, 
triozolam* 
General introduction 
Since nelfinavir was marketed later than saquinavir, ritonavir and indinavir, it was initially 
used predominantly as second-line or rescue treatment. The most important treatment 
limiting adverse effect is diarrhoea (60, 115, 116). 
Post-marketing surveillance 
The HIV-protease inhibitors were introduced abruptly under special circumstances, whereas 
they represented a completely novel type of medicines. The usual delays of approximately 
six months for accepting new agents in the Dutch medicine reimbursement system were 
overcome by a special financial allowance from the health authorities. Hence, the HIV-
protease inhibitors were available free of charge immediately after formal registration by 
the health authorities, which allowed for immediate widespread use among HIV-infected 
persons. The special circumstances surrounding the introduction of the HIV-protease 
inhibitors demanded the implementation of post-marketing surveillance more than usual. 
Clinical trial populations, on which the available data for registration are based, 
represent highly selective patient groups. Strict inclusion and exclusion criteria generate 
relatively healthy (exclusion of active disease, pregnant women, children and abnormal 
laboratory values) and motivated groups {written informed consent}. The number of 
patients studied is usually too low to detect events with relatively low incidences. For 
example, clinical trials with HIV-protease inhibitors for registration purposes generally 
involved less than 1000 patients {55, 56, 58, 117-119]. Assuming normal distribution and 95% 
confidence, these trials were able to detect events with a cumulative incidence of at least 
4 in 1 000 patients {0.4%) within the observation period of the trial. 
Follow-up periods of clinical trials are short compared to the actual periods of 
treatment needed {one to two years versus life time exposure or follow-up) as a 
consequence of which long term toxicity can easily be missed. In the context of clinical 
trials, patients are monitored more closely and more regularly than in daily practice. Finally, 
the options for and effects of toxicity management are usually not the objective of 
research. 
For these reasons, post-marketing research is warranted for all new medicines (120, 
121 }. Manufacturers are instructed to conduct post-marketing research and to report all 
adverse effects to the authorities. However, in view of potential conflicts of interest 
independent follow-up of new agents must be performed as well. 
There are a number of research methods for post-marketing surveillance.ln the Netherlands, 
physicians and pharmacists are encouraged to report adverse effects to the national 
pharmaco-vigilance foundation of the Netherlands (LAREB). Unusual and 
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severe underreporting of adverse effects, especially in highly specialized areas such as 
HIV I AIDS. Nevertheless, case reports arising from such a system can be informative and may 
trigger further studies. Epidemiological studies in well-defined populations. on the other 
hand, provide better insight into incidences of and risk factors for adverse effects under 
everyday circumstances and into potentially preventive and curative strategies (122. 123). 
The ATHENA cohort 
In November 1997, the National Health Insurance Council provided a grant for a project on 
the ·Implications for the course of HIV-dlsease, public health and health care as well as the 
costs and benefits of the new antiretroviral treatment. This led to the set up of the ATHENA 
cohort. a nationwide observational cohort including patients treated with HIV-protease 
inhibitors or other new antiretroviral agents. The project was carried out in a collaborative 
action of all 22 hospitals ·tn the Netherlands, which prov'1de antketrovkal treatment to HIV-
infected individuals. The resulting cohort. which covers a well-defined patient population, 
provided a unique opportunity for the conduct of epidemiological studies on antiretroviral 
agents in the post-marketing setting. 
Outline of this thesis 
The objectives of this thesis were to provide more insight into the risk and risk factors of 
adverse drug reactions associated w·1th HIV-protease inhib'1tor treatment under non-
experimental everyday circumstances. By recognition of risk factors, patients at risk can be 
identified beforehand and risk management can be targeted more efficiently, hence 
ultimately improving the safety of HIV-protease inhibitor treatment. In the studies presented 
in this thesis we applied multiple research strategies. ·tn which the naf1onw'tde ATHENA cohort 
played a central role. 
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Chapter 2.1 
Papillary necrosis associated with HIV-
protease inhibitor indinavir 
Chapter2.1 
Summary 
Background: HIV-protease inhibitor indinavir may cause nephrotlithiasis and interstitial 
nephritis. The renal consequences of indinavir associated nephrotoxicity are uncertain. We 
report a case of papillary necrosis in a patient treated with indinavir. 
Patient and methods: An asymptomatic HIV-infected woman experienced right-sided renal 
colicky pain during treatment with indinavir. She passed a non-solid stone and continued 
indinavir treatment. Intravenous pyelogram twenty months later following an episode of left-
sided colicky pain showed right-sided papillary necrosis. lndinavir associated nephrolithiasis 
and chronic interstitial nephritis were the only possible causes identified in this patient. 
Conclusion: Physicians should be aware that indinavir nephrolithiasis may cause papillary 
necrosis 
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Introduction 
The HIV-protease inhibitor indinavir causes symptoms of nephrolithiasis in 4-16% of patients 
and crystalluria in up to 20% of patients treated with indinavir 800 mg three times daily as 
part of Highly Active Antiretroviral Treatment (HAART} (1 ). Although crystalluria may remain 
asymptomatic, it is potentially harmful as illustrated by reports of interstitial nephritis with 
indinavir crystals in the interstitium (2). In addition, long term exposure to indinavir may be 
associated with renal atrophy (3}. We report a case of papillary necrosis in a patient treated 
with indinavir. 
Patient and methods 
A non-symptomatic 34-year-old caucasian woman was diagnosed as having HIV-1 infection 
and hepatitis C virus infection, contracted through intravenous drug abuse. Since 1997, she 
received HAART, comprising of zidovudine (250 mg twice daily), lamivudine (150 mg twice 
daily} and indinavir {800 mg three times daily) because of a high viral load (7.5lxl04 HIV-1 
RNA copies/mL Roche Amplicor, detection limit 500 copies/ml) and a declining CD4 cell 
count (370 cells/~L}. Her viral load has since been below the detection limit and her CD4 
cell count has increased to 670 cells/~L. The patient also took 1 mg lorazepam daily and the 
occasional use of cocaine could not be excluded. 
Results 
Three months after starting HAART, patient complained of recurrent colicky pain in the right 
flank associated with gross haematuria. Symptoms improved after passing a non-solid stone, 
which unfortunately was lost. Twenty months later, two years after starting HAART, she 
reported left-sided colicky pain without gross haematuria or other urinary symptoms. She 
again passed a stone after which symptoms resolved. Again the stone was lost. 
Throughout the course of HAART, urinalysis showed repeated pyuria of more than 
75 cells/~L and mild microscopic haematuria with normal urine pH of 5 and negative nitrite 
tests for bacteria. Intermittent crystalluria of one to two crystals per 40 times magnified field 
was observed. Urine culture was repeatedly negative. There was mild albuminuria {albumin 
3 to 6 g/mol creatinine, normal range <3.5 g/mol creatinine} and indinavir plasma 
concentrations were borderline increased (10.1 mg/L at 1 h after indinavir intake, 6.8 mg/L 
at 2.5 h and 0.3 mg/L at 8 h). Haematology and serum chemistry. including serum 
creatinine, were unremarkable. Abdominal X-ray, performed two years after starting HAART 
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Figure Intravenous pyelogram of the right 
kidney showing unilateral papillary necrosis 
of the lower pole calyx of the right 
kidney:smooth-margined saccular calyceal 
cavity formation. 
during the last episode of renal colic did not show any stones, which is consistent with the 
radiolucent characteristic of indinavir stones {4). Subsequent intravenous pyelogram {IVP) 
did not reveal any residual stones either, but did show papillary necrosis in the right kidney 
{figure). There were no calcifications or other abnormalities. 
Discussion 
The assessment of a causal relationship between an adverse event and a drug requires 
knowledge of the temporal relationship and adequate exclusion of other potential causes. 
The onset of flank pain, passing a stone and pyuria after starting HAART and the temporal 
relationship are compatible with a causal relationship. Potential causal factors of papillary 
necrosis include the use of large amounts of non-steroidal anti-inflammatory drugs (NSAIDs) 
and phenacetin-containing analgesics. Other possible causes are diseases leading to renal 
ischemia such as diabetes mellitus, nephrolithiasis, chronic interstitial nephritis, urinary tract 
infection, tuberculosis, sickle cell haemoglobinopathy, anorexia nervosa and severe 
dehydration {5). Even though our patient had a history of drug abuse, the use of 
nephrotoxic medication or nephrotoxic drugs as the cause of papillary necrosis of our 
patient is unlikely because of its one-sided and localised presence. The patient admitted 
inadequate fluid intake prior to the first episode of renal colic, but was never severely 
dehydrated. Urine culture did not reveal any infection that could explain the continuous 
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pyuria. Because of the absence of other probable causes and the fact that the papillary 
necrosis was of a localised nature, HAART-attributed nephrolithiasis and interstitial nephritis 
were considered as the most probable cause of papillary necrosis in our patient. Given the 
concordance between the side of papillary necrosis and the side of first symptoms and the 
non-solid constitution of the first stone. we consider it likely that the papillary necrosis was 
caused by an indinavir stone. lndinavir-induced chronic interstitial nephritis might have 
contributed. Physicians should be aware that papillary necrosis is a potential consequence 
of nephrolithiasis caused by indinavir. 
References 
1. Kopp JB, Miller KD, Mican JA. Feuerstein IM, Vaughan E, Boker C. Pannell LK, Fa I loon J: Crystalluria 
and urinary tract abnormalities associated with indinovir. Ann lntem Med 1997;127:119-125. 
2. Tashimo KT, Horowitz JD, Rosen S: lndinovir nephropathy. N Eng I J Med 1997;336:138-140. 
3. Honabuso H. Togami H, Hatoya H: Renal atrophy associated with long-term treatment with 
indinavir. N Engl J Med 1999;340:392-393. 
4. Bloke SP, McNicholas MM, Roptopoulos V: Nonopaque crystal deposition causing ureteric 
obstruction in patients with HIV undergoing indinavir therapy. AJR Am J Roentgenol 1998;171 :717-
720. 
5. Bach PH, Nguyen TK: Renal papillary necrosis-40 years on. Toxicol Pothol 1998;26:73-91. 
27 

Chapter 2.2 
Urologic complaints in relation to indinavir 
plasma concentrations in HIV -infected patients 
Chapter 2.2 
Abstract 
Objective: to assess the association between indinavir associated urologic complaints and 
indinavir plasma concentrations. Design: case-series, comparing indinavir plasma 
concentrations in cases with average concentrations in a control group. 
Methods: patients taking 800 mg indinavir tid, who presented with overt urologic complaints 
(renal colic, flank pain and/or hematuria) were selected for the study. Plasma indinavir 
concentrations were measured by means of a standardized high performance liquid 
chromatography method. Plasma samples taken at 1.5-8 hours after the last indinavir 
ingestion were included for evaluation. Results were compared with the full 
pharmacokinetic curves of indinavir plasma concentrations from a control group of 14 
patients taking 800 mg indinavir tid without urologic complaints, and expressed as 
concentration ratios. A ratio of 1 indicated a plasma concentration equalling the average 
concentration in the control population at the same point in time following indinavir intake. 
Results: 17 patients {5 women) were enrolled and indinavir concentrations of 15 patients 
could be evaluated. 14 {93%) patients had a concentration above the mean of the controls 
and 12 {80%) patients had a concentration above the upper 95%-confidence limit (95%CL), 
and 1 (7%) had a concentration below the lower 95%CL. The mean indinavir concentration 
in patients with urologic complaints (ratio range 0.55-11.49) was significantly higher than the 
average concentration and the upper 95%CL of the control group (p<0.05). The results 
could not be explained by differences in weight. gender or drug interactions. Two patients 
had chronic active hepatitis B infection. In 6 patients with indinavir concentrations above 
the upper 95%CL, indinavir was reduced to 600 mg tid. Upon repeat measurement after the 
dose adjustment their indinavir plasma concentrations fell wHhin the 95'7'o-confidence 
interval around the mean of the control population. All 6 patients remained asymptomatic 
and had viral loads <500 copies/ml after a follow-up of 5-16 months. 
Conclusions: urologic complications occurring during indinavir treatment were associated 
with elevated indinavir plasma concentrations in 80% of patients in this study. lndinavir 
plasma concentrations should be monitored upon presentation of urologic complaints on 
the basis of which dose reductions may be applied if brief interruption and increased 
hydration are ineffective. 
30 
Urologic complaints and indinavir concentrations 
Introduction 
Antiretroviral treatment with the HIV-protease inhibitor indinavir is associated with urologic 
complaints. Urologic complications occur in approximately 8% of patients on an indinavir 
dosage of 800 mg tid and vary from nephrolithiasis {3-4% of all patients) to symptomatic 
crystalluria with dysuria or back pain {7% of all patients) {1, 2). These adverse reactions can 
usually be resolved by hydration and short treatment interruption of 1 to 3 days, but may 
occasionally lead to acute renal failure which requires urologic intervention to relieve 
obstruction {3-5). In a majority of indinavir users with recurrent renal colic episodes, 
treatment with indinavir is abandoned [6). 
Independently of the indinavir concentration, up to 20% of absorbed indinavir is 
excreted into the urine, more than half of which is excreted in the intact form {1. 7). Due to 
this route of elimination. high indinavir plasma concentrations result in high indinavir urine 
concentrations, depending on the urine volume. which may induce indinavir precipitates it 
urinary solubility is exceeded. Accordingly, the calculi voided by patients are of a 
radiolucent. gelatinous nature and consist of indinavir base monohydrate {intact indinavir) 
{2. 5, 6, 8). Apart from dilution of urine through higher fluid intake, to prevent and relieve 
urologic symptoms, avoidance of high indinavir plasma concentrations may be an 
important measure for reducing the rate of urologic complications. In this study, we 
investigated the relationship betvveen indinavir plasma concentrations and urologic 
complaints occurring during indinavir treatment ·In HIV-infected patients. 
Methods 
Case series 
The patient population of the Erasmus Medical Centre Rotterdam {EMCR) comprises 
approximately 500 adult HIV-infected patients. 104 {21 women, 20%) of whom currently 
receive indinavir treatment. lndinavir treated patients, who presented with overt urologic 
complaints betvveen January and December 1997, were enrolled in the study. These 
patients received indinavir at a dosage of 800 mg three times a day (tid] as part of the 
Highly Active Antiretroviral Therapy {HAART) tor HIV-infection. Urologic complaints were 
defined as episodes of renal colic, flank pain, dysuria and/or hematuria. Information on viral 
load, assessed by HIV-RNA polymerase chain reaction (Amplicor HlV-1 monitor, Roche, 
Basel), urinalysis, routinely performed by semi-quantitative dipstick test (Rapignost® total-
screen L dipstick. Behringwerke AG. D-35001 Marburg, Germany), and concomitant 
medication was retrieved retrospectively from patient records. All assessments were done 
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during the regular outpatient clinic visit of each patient, which did not necessarily coincide 
with the manifestation of urologic symptoms. 
Control patients 
lndinavir concentrations in patients with urologic complaints were compared to a standard 
concentration curve as derived from the full pharmacokinetic curves of 14 HIV-infected 
patients (2 women) from the University Hospital Nijmegen, taking 800 mg of indinavir tid (Rg. 
1 ). This control group had an average age of 41.4 ± 7.3 years (range 31-52) and an average 
weight of 72.1 ± 9 kg {range 61-89). After an average duration of indinavir therapy of 6.9 ±3.3 
months (range 1-12), 10 patients had <200 copies/ml HJV-RNA. All control patients were free 
of overt signs of intoxication (including urologic complications). The pharmacokinetic 
parameters of this group (AUC, Cmax, Cmin] were consistent with the data as presented in 
the Cr"1xivan® product monograph (1 ). 
Sample collection 
A blood sample was collected from each patient with overt urologic complaints at variable 
time points after the last ingestion of indinavir. The time of last ingestion was based on 
patient interview. The time lapse be1ween the occurrence of urological symptoms and 
indinavir concentration assessment was not assessed. In order to attain comparable 
indinavir concentrations be1ween cases and controls, samples were evaluable only if drawn 
at least 1.5 h after the last intake, to avoid variance due to absorption, and less than 8 h 
after the last intake, as there were no measurement points for control patients after 8 h. 
Seven ml of blood was drawn from an antecubital vein into a lithium heparin vacutainer, 
from which plasma was separated by centrifugation which was stored in the refrigerator 
until transfer to the Department of Clinical Pharmacy at the University Hospital Nijmegen. 
Analytical methods 
lndinavir concentrations in plasma were determined using a validated High Performance 
Liquid Chromatography (HPLC) assay, which has been described previously (9). In brief, 
plasma is m·1xed with acetonitrile before centrifugation. The subsequent supernatant is 
evaporated to dryness, the residue of which is dissolved in eluent and injected into the HPLC 
system. The system contains an Octadecyl column with a mobile phase of acetonitrile-water 
and uses ultraviolet detection at 210 nm. 
Results of indinavir plasma concentration measurements were expressed as 
'concentration ratios'. The ratio was calculated by dividing the indinavir concentration in 
each patient with urologic complaints by the average concentration of the control group 
at the same or nearest time interval following indinavir intake. For this purpose, 
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concentration means of the control group were extrapolated to 15 minute time intervals so 
that the maximum time difference between controls and cases was 7.5 minutes. 
Statistical Analysis 
Continuous variables such as age, weight and duration of therapy, were tested with a 
Mann-Whitney U test. The average concentration ratios of patients with urologic complaints 
was analysed for statistical significance against the expected concentration ratio of 1.0 by 
calculating the 95%-confidence intervals around the mean ratio of patients with urologic 
complaints, based on a student-distribution, after normalising the distribuf1on by log-
transformation. A ratio of 1.0 indicated an indinavir concentration equalling the mean 
concentration of the control population at the same time interval following indinavir 
ingestion. We also did a sensitivity analysis in which the upper 95%-confidence limit instead 
of the mean of the control group was chosen as the denominator in the ratio. 
Results 
Seventeen patients with overt urologic complaints, 12 men and 5 women, representing 16 % 
of the population treated with indinavir at the EMCR, were included in the study. Their mean 
age was 37.4 ± 8.6 (range 27-57), their mean weight was 65.6 ± 9.2 kg (range 46-85) and 
they had been on indinavir treatment for an average duration of 7.1 ± 4.8 {range 0.4-14.8) 
months (table 1). In 15 (88%) patients the plasma HIV-RNA had been reduced to< 500 
copies/mi. 
Table 1 Baseline characteristics 
Characteristic# 
Mole(%] 
Female(%) 
Age (years± SDJ 
Weight {kg± SO) 
Duration of indinavir therapy {months± SO) 
Undetectable HIV-RNA (%) 
# SD= standard deviation 
detection limit 200 copies/ml 
¥ detection limit 500 copies/mL 
Control 
12{86) 
2{14) 
41.4± 7.3 
72.1 ± 9 
6.9 ± 3.3 
10 (71 )' 
Cases 
12{71) 
5{29) 
37.4± 8.6 
65.6 ± 9 
7.1 ± 4.8 
15 (881¥ 
p-value 
p=0.1521 
p= 0.1029 
p= 0.8580 
Table 2 provides an overview of the results. Twelve (71%) cases occurred during the spring 
and summer. Fifteen patients had an evaluable indinavir concentration measurement. 
Concentration ratios ranged from 0.55 to 11.49 (Fig. 1). Except for 1 patient, all (93%) had a 
concentration above the mean of the controls and 12 (80%) patients had a concentration 
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above the upper 95%-confidence limit of the control population [Fig.l ). The log-corrected 
mean ratio was 2.64 (95%-confidence interval 1.68-4.14), which was significantly different 
from the expected ratio of 1.0. In the sensitivity analysis the log-corrected mean ratio was 
1.96 (95%-confidence intervall.23-3.03). 
Table 2 Test results of patients with indinovir associated urologic complaints 
Assessments Results 
Major Complaint* Renal colic n (%) 7 [41] 
Flank pain n [%] 6 [35] 
Hematuria n [%] 3 [18) 
Dysuria n (%) 1 [6] 
Urinalysis# PH [n=11) Mean (range) 5.9 [5-9) 
Leucocyturia (n=ll) n (%) 10 [91] 
Hematuria (n=ll) n [%) 8 [73] 
Proteinuria (n=lO] n (%) 9 [90] 
Concentration ratio¥ 800 mg tid [n=15] Mean (range) 2.64 [0.55- 11.49] 
95r~cr 1.68-4.14 
600 mg tid (n=6] Mean (range) 0.88 [0.63- 1.37] 
95%-CI 0.63- 1.23 
Most severe complaints ore listed, patients may have suffered o combination of symptoms 
# Semi-quantitative dipstick test (Rapignosto total-screen L dipstick); leucocyturia: > 15 cells/L; 
hematuria:> 10 cells/L; proteinuria: >0.15 g/L 
¥ Ratios are calculated by d"1vid"1ng the measured concentraf1on by the concentration mean of 
controls at the same point in time following lost indinavir intake; means ore log-corrected; Cl= 
confidence inteiVals. 
~ Six patients had o dose reduction and subsequent repeat indinavir concentration assessment 
The average urine pH was 5.9 [n=11, range 5-9). Urinalysis (semi-quantitative dipstick test) 
further revealed the presence of leucocytes (ie. > 15 leucocytes/[JL} in 10 of 11 (91 %) cases in 
absence of infection (ie. dipstick test negative for bacteria}, and erythrocytes {ie. >10 
erythrocytes/~L) in 8 of 11 (73%) cases. Nine of 1 0 (90%) patients showed slight proteinuria of 
0.15-0.30 g/L. All symptoms cleared without urologic intervention. Concomitant medication 
included co-trimoxazole, diclofenac, haloperidoL cetirizine, dapson, megestrol, metoprolol, 
fluconazol, clindamycin, psylliumseed and butylscopolamin, none of which is known to 
significantly affect indinavir concentrations. In 1 patient occasional use of heroin could not 
be excluded. 
In 6 patients with urologic symptoms and an indinavir concentration higher than 
the upper 95%-confidence limit [ratio range 2.25-11.49), the dose of indinavir was reduced 
to 600 mg tid. Repeat indinavir concentration ratios, measured at 58± 44 days after dose 
reduction. approached 1.0 (range 0.63-1.37) in all 6 patients (table2). five out of 6 remained 
free of urologic symptoms and one patient remained free of urologic symptoms when 
having extra fluid intake. All 6 continued to have viral loads <500 copies/ml following 
indinavir dose reduction for follow-up periods of 5-16 months. As for the other patients, six 
discontinued indinavir treatment five because of gastro-intestinal complaints, 3 of whom 
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Figure 1 lndinavir plasma concentrations as a function of time following lost ingestion 
The solid line represents the average phormacokinetic curve of a control 
group (n=l4). Broken lines represent the 95%*confidence bonds of the 
concentration means in the control group. Bullet markers indicate 
measurement points in the control group. Square markers indicate indinavir 
plasma concentrations as measured in 15 individual patients with urologic 
complaints. All patients took indinavir at a dosage of 800 mg three times a 
day,measurements were done after ingestion of 800 mg indinovir. 
had first tried dose reductions other than 600 tid, and one because of lipodystrophy. Two 
had modified the dose to a twice daily regimen and suffered residual urologic complaints. 
One patient continued indinavir at 800 mg tid without major problems, but HIV-RNA had 
raised to 2560 copies/ml after 8.5 months. There may be a problem with compliance in this 
patient. As for the two patients with non-evaluable indinavir concentration assessments, one 
reduced the dose to 400 mg tid, but later appeared to have a low indinavir plasma 
concentration and high viral load for which reason indinavir was stopped. The other patient 
had no dose reduction, but indinavir treatment was withdrawn due to gastro-intestinal 
intolerance. 
Discussion 
The relationship between indinavir exposure and antiretroviral effect has been reported, but 
an exposure-toxicity relationship has not been described, so far (L 10, 11). The present 
results suggest an association between indinavir plasma concentrations and the 
occurrence of urologic complaints during indinavir containing antiretroviral therapy. 
Patients with urologic complaints in this study consistently presented with high indinavir 
plasma concentrations in comparison to a control group without urologic complaints. 
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Although this study did not analyse urinary crystals, it was shown that complaints 
often coincided with sterile leucocyturia, hematuria and proteinuria, consistent with a 
pattem of mucosal irritation due to (micro)lithiasis. As indinavir urinary concentrations and 
clearance were not measured in this study, it is not known as to how these relate to high 
indinavir plasma concentrations and the occurrence of indinavir associated urologic 
symptoms. The process of indinavir crystal formation has been reported to be enhanced by 
high urinary pH and low urinary volume (2, 12}. All patients were advised to drink at least 1.5 
L/day. Although most patients claimed that their intake was maximal, precise intake and 
urinary volumes are not known. In fact, many urologic complaints occurred during periods 
of hot weather when optimal hydration may have been difficult to achieve ( 13). Therefore, 
we cannot exclude urinary volume as the cause of urologic complaints in our patients. 
High indinavir plasma concentrations may have a multifactorial origin. Oral 
absorpfton of indinavir is pH-dependent and subsequent elimination depends on the liver 
cytochrome P-450 system (iso-enzyme CYP3A4) and urinary clearance (12, 14). None of the 
patients used any drugs known to significantly affect the indinavir pharmacokinetics. Two 
patients had a chronic active hepatitis B infection, with possibly impaired liver clearance of 
·1n~:f1navir. None of the patients was known wHh impa"1red renal function, but renal clearance 
may have been reduced by insufficient hydration. It is not known how this would affect the 
plasma concentration of indinavir as the kidneys play a minor part in indinavir clearance. 
The high indinavir plasma concentrations could not be attributed to low weight, as the 
patients with urologic complaints and patients from the control group had s·lm.tlar weights. A 
recent study observed an influence of gender on pharmacokinetics of indinavir, which 
would suggest higher propensity for women to develop urologic complications (15). 
Importantly, patients remained free of urologic complaints following dose 
reduction to 600 mg tid. Subsequent indinavir plasma concentrations fell within the limits of 
the control group and viral suppression was maintained during follow-up. Thus, indinavir 
dose reduction may be a useful and safe control measure for urologic complaints 
associated with a high plasma indinavir concentration. Although indinavir concentration 
may not predictive of urologic complaints. it might be worthwhile to perform a cost-benefit 
analysis of monitoring indinavir concentrations in all patients in the prevention of urologic 
complaints. 
In this pilot study indinavir concentrations were compared to an historical control 
group. More research is needed to confirm the findings and to learn the long-term effects of 
dose reduction in patients with high indinavir plasma concentrations. Further research 
should also be aimed at finding an explanation for the high incidence of urologic symptoms 
seen in our patient population. The cumulative incidence was 16%. which is much higher 
than reported so far (1, 2). This might reflect population characteristics or may be a 
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consequence of close patient monitoring (13. 15}. In addition, the following points should be 
recognised. Rrst, urologic complaints, occurring during indinavir treatment, may not always 
be attributable to indinavir. Second, possible causes of increased indinavir plasma 
concentrations, that can be removed, should be taken into account before applying any 
dose adjustment. Evidently, dose reductions should only be applied on the basis of indinavir 
plasma concentration measurements. Finally, it should be noted that this study compared 
single point measurements of indinavir plasma concentration in individual patients with the 
average concentration of an independent control group. The results of this control group 
were believed to be a proper reference, but it is not known how single point measurements 
of indinavir plasma concentrations relate to other pharmacokinetic parameters. 
In conclusion, this study showed that urologic complaints, occurring during indinavir 
treatment. are associated with elevated indinavir plasma concentrations. If urologic 
complaints persist despite maximal fluid intake and indinavir plasma concentration is above 
the upper 95%-confidence limit, dose adjustment may be considered. so that patients can 
safely continue taking indinav"tr. In our patients a dose reduction to 600 mg tid was found to 
be effective. More research is needed to further elucidate the relationship between 
indinavir plasma concentrations and urologic complaints and to learn the long term effects 
of dose reductions. The influence of climate on indinavir pharmacokinetics and indinavir 
related urologic complaints should be clarified. 
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Risk factors for urological symptoms in a 
cohort of users of HIV-protease inhibitor indinavir. 
The ATHENA cohort. 
Chapter 2.3 
Abstract 
Background: Nephrolithiasis is a well-known complication of indinavir treatment and may 
result in a variety of urological symptoms [US} ranging from renal colic to renal insufficiency. 
In order to be able to adequately prevent or resolve US, further knowledge regarding the 
incidence and risk factors is needed. 
Methods: The present study was performed in the ATHENA cohort, a cohort of HIV-infected 
patients on antiretroviral therapy in the Netherlands. The incidence rate of US was estimated 
in a sub-cohort of patients starting PI-treatment otter 1996 [n=1219). US were defined as the 
first report of nephrolithiasis, renal colic, flank pain, hematuria, renal insufficiency or 
nephropathy. Risk factors for US during indinavir-treatment were subsequently studied 
among the subset of patients who started indinavir otter 1996 [n=644), using multivariate 
Cox's regression analysis. 
Results: The incidence of US was 8.3 per 1 00 treatment years of indinavir versus 0.7 per 1 00 
treatment years with other Pis. Risk factors for US during indinavir were low weight (RR:2.1, 
95%CI:l.l-3.9). low lean body mass [LBM) [RR:l.7. 95%CI:l.0-2.9). undetectable HIV-1 RNA 
when starting indinavir (RR:3.2, 95%CI:l.5-6.0), prior treatment change due to intolerance 
[RR:2.4. 95%CI:l.2-S.l ). indinavir-regimens of 2:1000 mg bid [RR:3.1. 95%CI:l.3-8.2) and high 
environmental temperatures {RR:3.9, 95%CI:1.7-8.8). Risk estimates were highest among 
patients with a low LBM. 
Conclusions: Increased alertness for US is warranted for patients with viral successful 
suppression when starting indinavir, patients with a low LBM, during indinavir-regimens of 
2:.1000 mg bid and during warm weather periods. 
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Introduction 
Adverse effects of HJV-protease inhibitor-containing Highly Active AntiretroviraJ Treatment 
(HAART} constitute a threat to the quality of life, and treatment adherence of HIV-infected 
patients (1-3). 
Nephrolithiasis is a well-known complication of treatment with indinavir, 20% of 
which is cleared by the renal system (4-6}. Symptoms range from renal colic, flank pain, 
dysuria and gross hematuria to the passing of a stone. Other symptoms related to the renal 
effects of indinavir are crystalluria and renal insufficiency, which may go undetected 
without specific monitoring. Symptoms may occur early or late during treatment and 
occasionally occur even after treatment discontinuation {7-12}. The incidence of urological 
symptoms among patients who used indinavir 800 mg three times daily (tid] was estimated 
at 4% in clinical trials and 8-16% in other studies (4, 9-13). 
It is generally assumed that urological symptoms are secondary to sludging of 
indinavir crystals in the urinary tract. probably due to the low solubility of indinavir in aqueous 
conditions (14, 15). Therefore, the major risk factor for urological symptoms seems to be 
insufficient fluid intake, which leads to concentrated urine and a diminished urinary flow, 
thus facintating indinavir precipitation and crystal aggregation (4, 16). Nevertheless, 
abundant fluid intake is not always sufficient for the prevention of urological symptoms, 
which suggests that other factors play a role as well (12}. 
High env·tronmental temperatures, female gender, concurrent hepatitis C infection, 
and high indinavir plasma concentrations have also been suggested as risk factors for 
urological symptoms (8, 9, 13, 17-20}. lndinavir plasma concentrations depend on the 
indinav"tr dosing reg·tmen used, gastr"lc pH, distr"tbution volume, and both hepatic and renal 
clearance (5, 6, 21-23). Any factors affecting these aspects are potential determinants for 
the development of urological symptoms. 
We performed a population-based cohort study to esftmate the ·tncidence of 
urological symptoms among patients using an HIV-protease inhibitor as part of HAART and 
to identify potential risk factors for urological symptoms during the use of indinavir. We 
studied the role of various indinavir dosing regimens, environmental temperatures and lean 
body mass (LBM) in particular. 
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Patients and methods 
Selling 
We conducted a cohort study within the ATHENA-cohort. This is a large national cohort of 
HIV-infected patients in the Netherlands, who have been or are being treated with at least 
one of the antiretroviral drugs which were introduced after July 1996 (all HIV-protease 
inhibitors, all non-nucleoside reverse transcriptase inhibitors and the newer nucleoside 
analogue reverse transcriptase inhibitors such as lamivudine and stavudine) and who gave 
written informed consent. Patient entry effectively started in May 1998 and continues to 
date. All 22 Dutch hospitals providing treatment to HIV-infected patients participate in the 
ATHENA-project. The project has been approved by the Ethics Committees of all 
participating centres. 
According to the national guidelines for HIV-treatment in the Netherlands, patients 
are seen at approximately three-monthly intervals for regular follow-up (24). Data for the 
ATHENA-cohort are collected from the medical records on standardised forms by trained 
research nurses and treating physicians. This is done retrospectively for the period prior to 
consent and prospectively thereafter and continues to date. The resulting database 
contains information on gender, age, route of HIV-transmission, height and weight. Start and 
stop dates as well as dose frequency of any antiretroviral medication and prophylactic 
treatment against opportunistic infections, reasons for stopping such treatments, date of 
onset and resolution of HIV-related diseases, CD4-cell counts, plasma HIV-1 RNA load and 
abnormal laboratory values are all recorded in a standardised manner. Information on 
adverse events in the ATHENA database comprises all events that lead to a change in 
antiretroviral treatment and a number of pre-specified adverse events, among which 
nephrolithiasis. In addition, physicians are requested to report otherwise remarkable events 
and laboratory abnormalities. On site data monitoring of at least 1 0% of completed study 
forms by central data monitors takes place at regular time intervals. In addition, central 
data verification through automated database consistency checks are performed, the 
resulting queries of which are resolved by local research nurses. Data that had been 
entered, monitored and verified before March 2000 were available for the present analysis. 
Cohort definition 
On the basis of the treatment data in the ATHENA database we selected two cohorts. The 
first cohort of patients commencing treatment with any one of the HIV-protease inhibitors 
was used to estimate the incidence rate of urological symptoms during use of different HIV-
protease inhibitors. Patients were eligible for entry if they started the first HIV-protease 
inhibitor no earlier than 1997, when the HlV-protease inhibitors became available as 
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prescription drugs through community pharmacies in the Netherlands. Patients entered the 
cohort upon the start of the first HIV-protease inhibitor and were followed until development 
of urological symptoms, death, loss to follow-up or the date of last data collection, 
whichever came first. Cohort participants were allowed to change between HIV-protease 
inhibitors and to have treatment interruptions during the follow-up period. The duration of 
use of each H!V-protease inhibitor was calculated. Consequently, each person could 
contribute to multiple specific protease inhibitor exposure categories. 
Since urological symptoms occur primarily in indinavir users we formed a second 
cohort of indinavir users (the indinavir-cohort) to further specify incidence rates and to 
identify risk factors for urological symptoms during the use of indinavir. Patients entered the 
indinavir-cohort upon first start of indinavir in 1997 or thereafter, independent of previous 
HIV-protease inhibitor treatment and previous experience of urological symptoms. Follow-up 
lasted from the start of indinavir until the development of urological symptoms, 
discontinuation of indinavir, an interruption of indinavir for more than seven days, death, loss 
to follow-up or the date of last data collection whichever was earliest. 
Patients for whom we had inadequate information regarding treatment. or who 
had urological symptoms at cohort entry were excluded from both the HIV-protease 
inhibitor cohort and the indinavir-cohort. 
Outcome measure 
A wide range of symptoms has been attributed to the effects of indinavir on the renal 
system, including both clinical and sub-clinical symptoms. Given the way data are 
collected, it can be expected that the ATHENA-data capture most overt clinical symptoms. 
There may be a relative underreporting of sub-clinical symptoms, such as laboratory 
abnormalities and renal insufficiency, depending on the intensity of patient monitoring. 
Assuming that any resulting misclassification is random within hospitals, the primary outcome 
measure of this study was defined as the occurrence of urological symptoms ranging from 
nephrolithiasis. renal colic, flank pain and gross hematuria to a diagnosis of renal 
insufficiency, nephritis or nephropathy as made by the treating physician. The date of onset 
of first symptoms was defined as the index date. 
Co-variates 
Potential determinants for urological symptoms generally available in the ATHENA database 
are gender, weight, HIV-1 RNA load {lower limit of quantification was set at 1 ODD copies/ml 
for the purpose of this analysis), which might be considered as a marker for compliance, 
and high plasma concentrations, primary reason for prior treatment change (possible 
reasons including intolerance, treatment failure, patient request, pharmacological reason, 
43 
Chapter 2.3 
other reason with specification, or unknown), concomitant use of ritonavir and co-
trimoxazole, and dosing regimen of indinavir. Body mass index (BMI [kg/m2]) and lean body 
mass [LBM, [[height in cm-152)'0.9+50 for men, [height in cm-152)'0.9+45.5 for women]) 
were calculated from available data. Other factors investigated were the route of HIV-
transmission, CDC-disease classification (25). CD4 cell counts, the occurrence of any type of 
hepatitis. calendar time and concomitant use of other antiretroviral medications. The 
monthly average environmental temperatures from 1997 until the end of 1999 were 
retrieved from the internet-site of the Royal Netherlands Institute of Meteorology (KNMI, 
www.knmi.nll. 
lndinavir-regimens were divided into the standard regimen of 800 mg tid, 800 mg 
indinavir combined with 100 mg ritonavir bid (800/1 00 mg bid], 400 mg indinavir combined 
with 400 mg ritonavir bid [400/400 mg bid), I 000 mg or more bid [2: I 000 mg bid), any other 
indinavir-regimen (including combinations with other HIV-protease inhibitors or non-
nucleoside NRTis). Continuous variables were dichotomised based on the lower quartile or 
the median. 
Analysis 
Crude incidence rates of urological symptoms with 95%-confidence intervals (95%CI) and 
relative risks {RR) were calculated based on a Poisson distribution. The one-year cumulative 
incidence was estimated using life table analysis. Potential risk factors for urological 
symptoms in the indinavir cohort were identified by means of univariate and multivariate 
Cox-regression analysis with the duration of indinavir use as follow-up time. We matched by 
treatment centre in order to control for potential bias from selective prescribing behaviour 
combined with increased diagnostic attention for urological symptoms or intensity of patient 
monitoring. Factors that may vary over time and potentially alter the risk of urological 
symptoms (weight. BMI, CD4 cell count, HIV-1 RNA load, indinavir-regimen, type of 
nucleoside reverse transcriptase inhibitors (NRTI) and environmental temperature) were 
included in the models as time-varying co-variates. Effect modification was explored by 
means of stratified multivariate Cox-regression analysis. All analyses were conducted with 
SPSS 8.0 for Windows. 
Results 
The ATHENA source population comprised a total of 2470 patients, 2362 (96%) of whom ever 
used an HIV-protease inhibitor. In total 1239 (52%) patients started the first HIV-protease 
inhibitor in 1997 or. thereafter. We excluded 18 patients because of incomplete data on HIV-
protease inhibitor treatment and 2 because of presence of urological symptoms at the start 
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of HIV-protease inhibitor treatment. The final HIV-protease inhibitor cohort therefore 
comprised 1219 patients, 445 of whom used indinavir at any time. 
For the indinavir-cohort, we included all 445 patients from the HIV-protease inhibitor 
cohort who used indinavir. In addition, we included four patients who had incomplete data 
on initial HIV-protease inhibitor treatment but complete data on indinavir treatment and 195 
patients who started HIV-protease inhibitors before 1997 but who had the first prescription for 
indinavir in 1997 or thereafter. The final indinavir-cohort therefore comprised 644 patients. 
Incidence of urological symptoms 
Within the HIV-protease inhibitor cohort, a first occurrence of urological symptoms was 
reported for 49 (4%) patients, 45 (92%} of whom developed these symptoms during the use 
of an HIV-protease inhibitor. Other reasons for end of follow-up {right censoring} were death 
(3%). loss to follow-up (0.4%} and last data collection (93%]. The overall incidence rate of 
urological symptoms was 2.8 {95%CI: 2.0-3.6} per 100 person years of HIV-protease inhibitor 
treatment. Table 1 shows the HIV-protease inhibitor specific incidence rates. The majority of 
cases (73%} occurred during treatment with indinavir. The risk of urological symptoms during 
use of indinavir-containing regimens was 8.7 fold higher (95%CI: 7.4-1 0.2) than during use of 
regimens without indinavir. 
The indinavir-cohort was larger than the indinavir component in the HIV-protease 
inhibitor cohort because patients were allowed to have used another HIV-protease inhibitor 
before 1997. Conversely, the indinavir-cohort had relatively shorter follow-up because 
follow-up was ended upon discontinuation of indinavir. The indinavir-cohort was used for 
further specification of the incidence rates during the use of indinavir and the identification 
of risk factors for indinavir-associated urological symptoms. 
A first occurrence of urological symptoms during the use of indinavir was reported 
for 58 (9%} patients. Symptoms ranged from nephrolithiasis (n= 38}, renal colic or flank pain 
(n= 6), gross hematuria (n= 6). renal insufficiency (n= 6), nephritis (n= 1} to nephropathy [n= 
1). Other reasons for end of follow-up [right censoring} were discontinuation of indinavir 
(33%), interruption of indinavir for more than 7 days (6%), death (2%), loss to follow-up (1%) 
and last data collection (50%). 
The overall incidence rate of urological symptoms was 8.3 {95%CI: 6.3-1 0.8] per 100 
person years of indinavir treatment. The highest incidence rate was observed during 
indinavir-regimens of 1000 mg or more tvvice daily (bid) and during the first six months of 
indinavir-treatment (Table 2]. Following the first six months, urological symptoms continued 
to occur but at a steady lower rote as is illustrated in figure 1. 
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Table 1 Incidence rates of urological symptoms {events) during the use of specific HIV-protease 
inhibitors 
Type of treatment Potientsa Person Events Events per 1 00 person 
ears ears 
N (%) N N (%) IRb (95%CI) 
Using any PI 1219 (100) 1619.4 45 (92) 2.8 (2.0-3.7) 
Any IDV-contoining 445 (37) 511.4 36 (73) 7.0c: (4.9-9.8) 
IDV 382 (31) 462.3 34 (69) 7.4 (5.1-10.3) 
IDV/RTV 82 (7) 44.6 2 (4) 4.5 (5.0-16.0) 
IDV /other PI (s) 9 (1) 4.5 0 (OJ 0 (0-73.3) 
Non-IDV-contoining 950 (78) 1108.0 9 (18) o.ac (0.4-1.5) 
SQV/NFV 44 (4) 44.9 1 (2) 2.2 (0.03-12.4) 
NFV 289 (24) 186.1 2 (4) 1.1 (0.1-3.9) 0 
RlY/SQV 374 (31) 402.2 4 (8) 1.0 (0.3-2.5) 0 
RlY 237 (19) 279.4 2 (4) 0.7 (0.1-2.6) 0 
SQV 170 (14) 193.6 0 (OJ 0 (0-1.9)' 
Other Pl(s) 6 (1) 1.8 0 (0) 0 (0-183) 
Not using a Pld 602 (49) 305.2 4 (8) 1.3 (0.4-3.4)' 
Overall PI-cohort 1219 (100) 1924.6 49 (100) 2.5 (1.9-3.4) 
including periods with 
and without Pis 
IDV- indinavir; NFV- nelfinovir; PI- HIV-protease inhibitor; RTV- ritonavir; SQV- soquinovir 
a Total does not odd up since patients may have used more than one HIV-protease inhibitor at 
different points in time 
b IR= incidence rate per 100 person years, 95'7'o-confidence intervals based on o Poisson distribution 
c Relative risk during the use of IDV versus the use of other PI= 8.7 {95%CI: 7.4-1 0.2) 
d HIV-proteose inhibitor treatment interruption or after discontinuation 
e Statistically significantly lower than IDV regimens with and without other Pl(s) 
Table 2 Incidence rates of urological symptoms (events) during the use of different indinavir-regimens 
and during sequential follow-up periods 
Type of IDV treatment Patients0 Person Events Events per 1 00 person 
ears ears 
N (%) N N (%) IRb (95%CI) 
IDV-regimen 
800 mg tid 486 (75) 539.2 37 (64) 6.9 (4.8-9.5) 
:::1000 mg bid 63 (10) 28.9 7 (12) 24.2 (9.7-50) 
800/1 00 mg bid 48 (7) 20.9 2 (3) 9.6 I 1.1-34.41 
400/400 mg bid 61 (9) 31.2 0 (0) 0 (0-11.8) 
Other IDV-regimen 154 (24) 75.8 9 (16) 11.9 (5.4-22.5) 
Treatment period 
0 to 6 months 644 (100) 273.9 31 (53) 11.3 (7.7-16.1 I 
6 to 12 months 451 (70) 190.4 12 (21) 6.3 (3.3-11.0) 
12 to 18 months 312 (48) 127.6 8 (14) 6.3 (2.7-12.3) 
18 to 24 months 206 (32) 72.6 6 (10) 8.3 (3.0-17.9) 
24 to 30 months 83 (13) 26.4 1 (2) 3.8 (0.1-21.4) 
30 to 36 months 31 (5) 8.2 0 (0) 0 (0-46) 
Overall 644 {100) 696.0 58 {100) 8.3 {6.3-10.8) 
IDV indinavir::::. 1000 mg IDV dosages of 1000 mg or more; 800/100 mg 800 mg IDV combined with 
100 mg ritonovir; 400/400 mg= 400 mg IDV combined with 400 mg ritonovir 
a Total does not odd up since patients may hove used more than one IDV-regimen 
b IR= incidence rate per 100 person years based on a Poisson distribution 
46 
Risk factors for urological symptoms 
30 
- 25-
0 
0 
E 20-
'E 
"' N ~ 15 -
" -~ 
" :; E 
::> 
ll 
10 
5 
0 
-----· 
0 N 
" "' "' 
,._ 
"' 
~ ~ 
"' "' 
,._ 
"' "' " "' "' 
N 
~ N 
"' " "' "' 
,._ 
"' Time on IDV (days) 
Figure 1 Hazard of urological symptoms during the use of indinavir 
Solid bold line represents the hazard of urological symptoms 
over time. Dotted lines represent the standard error. The 
straight horizontal line indicates the cumulative hazard times 
100 over one year of indinavir treatment, which was 9.0 (957.,.-
confidence interval: 6.3-11.8). 
Table 3 summarises the baseline characteristics of the indinavir-cohort. Overall, patients had 
a median age of 39 years, were predominantly male homosexuals with CDC-disease 
classification A or B. The median weight. BMI and LBM were 70 kg, 22 kg/m2 and 73 kg 
respectively. The majority had more than 200 CD4-cells/microl and more than 1000 HIV-1 
RNA copies/mL. Most patients had had prior antiretroviral treatment, started indinavir in 1997 
and the most common first indinavir dosing regimen was 800 mg indinavir tid combined with 
AZT and 3TC usually without concomitant co-trimoxazole. 
Risk factors for urological symptoms 
Baseline characteristics associated with urological symptoms were: LBM below the lowest 
quartile {68 kg}, undetectable HIV-1 RNA {~1000 copies/mL), absence of co-trimoxazole use 
and prior change of on antiretroviral treatment component due to any type of intolerance. 
Prior change due to ·Intolerance and the absence of use of co-trimoxazole were both 
closely related to low HIV-1 RNA (Pearson's Chi-square test. p=O.OOO and p=0.002) whereas 
low LBM was not (p=0.647). 
47 
Chapter 2.3 
Tobie 3 Baseline characteristics of the indinavir-cohort at start of indinavir 
Outcome P-Valueo 
Characteristic at start of IDV No us [n-586) US (n-58) Total (n=644) 
N (%) N (%) N (%) 
Follow-up (wks) Median (IQR) 54 [24-91) 23 (10-53) 50 (23-89) 
Age (years) Median (IQR) 39 (33-46) 39 (33-42) 39 (33-45) Ns 
Gender Female 87 (15) 9 (15) 96 (15) Ns 
Weight (kg) Median (IQR) 70 (63-90) 64 (61-75) 70 (63-79) Ns 
> 70 196 [33) 14 (24) 210 [33) Ns 
:5.70 200 (34) 23 [48) 228 [35) 
Missing 190 (32) 16 [28) 206 (32) 
BMI (kg/m') Median (IQR) 22 (20-25) 22 (20-24) 22 (20-25) Ns 
> 22 195 [33) 22 (38) 217 (34) Ns 
:022 175 (30) 20 (35) 195 (30) 
Missing 216 (37) 16 (28) 232 (36) 
LBM (kg) Median {IQR) 73 (68-78) 71.6 (66-76) 73 (68-78) Ns 
> 68 398 (68) 35 (60) 433 (67) 0.0638 
:o68 145 (25) 23 (40) 168 (26) 
Missing 43 (7) 0 (OJ 43 (7) 
Route of HIV- MSM 372 (68) 37 (67) 409 (68) Ns 
Transmission IV drugs 27 (5) 5 (9) 32 (5) 
Other 152 (28) 13 (24) 165 (27) 
Stage of HIV- Non-aids 523 (89) 52 (90) 575 (89) Ns 
infection Aids 63 (11) 6 (10) 69 (11) 
CD4-cells Median (IQR) 205 (72-359) 209 (75-423) 206 (75-360) Ns 
(1 0'/L) Missing 82 (14) 9 (16) 91 (14) 
HIV-1 RNA > 1000 425 (73) 37 (64) 462 (72) 0.0026 
(cop·tes/mL) .:s_lOOO 70 (12) 14 (24) 84 [13) 
Missing 91 (16) 7 (12) 98 (15) 
Ever any type of hepatitis 9 (2) 1 (2) 10 (2) Ns 
Prior urological symptoms 2 (0.3) 1 (2) 3 (0.5) Ns 
Co-trimoxazole 244 (42) 17 (29) 261 (40) 0.0425 
Prior ART 350 (60) 35 [60) 385 (60) Ns 
Reason prior None 318 (54) 26 [45) 344 (53) 0.0181 
change ART Other 200 (34) 19 (33) 219 (34) 
Intolerance 68 (12) 13 (22) 81 (13) 
Year of start IDV 1997 357 (61) 44 (76) 401 (62) Ns 
1998 163 (28) 12 (21) 175 (27) 
1999 66 (11) 2 (3) 68 (11) 
First IDV- 800 mg tid 424 (72) 48 (73) 472 (73) Ns 
regimen ::::1000 mg bid 27 (5) 3 (5) 21 (3) 
800/100 mg bid 21 (4) 0 (OJ 46 (7) 
400/400 mg bid 45 (8) 1 (2) 30 (5) 
Other 69 (12) 6 (9) 75 (12) 
NRTI AlT/3TC 256 (44) 32 (55) 288 (45) Ns 
combination 3TC/d4T 176 (30) 13 (22) 189 (29) 
d4T/ddl 68 (12) 8 (14) 76 (12) 
Other 79 (14) 5 (9) 84 (13) 
None 7 (1) 0 (0) 7 (1) 
Environmental Median (IQR} 9 (7-16) 10 (7-15) 9 [7-16) Ns 
temperature <15 420 (72) 44 (76) 464 (72) 
(oC) 15-18 142 (24) 14 (24) 156 (24) 
>18 24 [4) 0 0 24 4 
ART- anftretrovirol treatment; BMI- body moss "tndex; IDV- indinavir; IV drug- intravenous drug use: LBM-
leon body moss; MSM= man having sex with man; reason prior change ART= primal)' reason for 
changing prior ART (other includes failure, patient request pharmacologicaL other with specification or 
unknown); US= urological symptoms;:::: 1000 mg= IDV dosages of 1000 mg or more; 800/100 mg= 800 mg 
IDV combined with 100 mg ritonavir; 400/400 mg= 400 mg IDV combined with 400 mg ritonavir 
a Cox-regression w"tth days on IDV as follow-up time; Ns= p>O.l 
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Table 4 Risk factors for urological symptoms within the indinovir-cohort (n= 644) 
LBM (kg) 
Characteristic Crude0 Adjustedb ~68 > 68 
RR (95%CI) RR (95%CI) RR (95%CI) RR (95%CI) 
Baseline choracterislics 
LBM (kg) > 68 I I 
~68 1.7 (I.G-2.9) 1.6 (0.9-2.9) 
Missing 
HIV-1 RNA >1000 I I I I 
(copies/ml) SIOOO 3.2 (1.5-6.0) 3.1 (1.5-6.3) 33.6 (3.5-324.0) 2.1 (0.8-5.3) 
Missing 1.0 (0.4-2.3) 0,9 (0.4-2.3) 3.4 (0.7-15.6) 0.6 (0.1-2.8) 
Co-trimoxazole No I 
Yes 0.6 (0.3-1.0) 
Reason prior None I 
change ART Other 1.3 (0.7-2.4) 
Intolerance 2.4 (1.2-5.1 I 
Time dependent characteristics 
Weighl(kg) > 70 I 
~ 70 2.1 (1.1-3.9) 
Missing 1.8 (0.8-4.0) 
lOY-regimen 800 mg lid I I I I 
2: I 000 mg bid 3.1 (1.3-8.2) 3.2 (1.2-8.7) 8.7 (1.2-65.7) 2.0 (0.4-8.9) 
800/100 mg bid 1.0 (0.2-4.9) 1.1 (0.2-5.5) 7.0 (0.6-75.0) 
400/400 mg bid 
Other 1.7 (0.8-3.6) 1.9 (0.9-4.1) 3.8 (0.8-19.4) 1.3 (0.4-3.7) 
Environmental <15 I I I I 
temperature raqc 15-18 0.5 (0.2-1.2) 0.5 (0.2-1.2) 0.6 (0.2-2.4) 0.3 (0.1-1.1 I 
>18 3.9 (1.7-8.8) 4.1 (1.7-9.5) 6.4 (1.2-34.5) 2.7 (O.B-8.7) 
LBM-Ieon body moss; Reason prior change ART- primary reason for changing any prior antiretroviral treatment (other includes failure, patient request, 
pharmacologicaL other with specification or unknown); .2: 1000 mg= IOV dosages of 1000 mg or more; 800/100 mg= 800 mg lOY combined with 100 mg ritonovir; 
400/400 mg= 400 mg IOV combined with 400 mg ritonavir 
a Cox-regression analysis stratified for hospital with days on IOV as follow-up lime 
b Adjusted for HIV-1 RNA at baseline, LBM, lOY-regimen and environmental temperature 
c environmental temperature as average temperature in the month of the index dote (history of weather reports on internet VAVW.knmi.nl) 
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In addition to the baseline variables, we assessed whether time-varying co-variates such as 
weight, BMI. CD4-cell count, HIV-1 RNA load, indinavir dosing regimen, type of NRTis and 
environmental temperatures alt8red the risk of urological symptoms. Of these, low weight 
but not BMI, indinavir-regimens of ~ 1000 mg bid, and high environmental temperatures 
were associated with urological symptoms. 
Table 4 shows the crude and adjusted relative risks for all factors that were 
univariately associated with the development of urological symptoms at a p-value of 0.1. 
Adjustment for age and gender alone [data not shown] and adjustment for univariately 
associated variables did not change any of the associations. Weight was excluded from the 
multivariate analysis because of its close relation to LBM. 
Restricting the analysis to clinically overt symptoms such as nephrolithiasis, renal 
colic, flank pain or gross hematuria did not lead to different conclusions [data not shown). 
Unfortunately, the data did not allow further breakdown of urological symptoms due to 
small patient numbers. 
Stratification for LBM showed that the effects of undetectable HIV-1 RNA load [S 
1000 copies/ml), indinavir-regimens of ~ 1000 mg bid and 800/100 mg bid and 
environmental temperature above 18 oc were more pronounced in the low LBM stratum as 
reflected in higher RRs. 
A further description of the course of events was made to provide insight into the 
reversibility of symptoms. Twenty {34%) patients with urological symptoms discontinued 
indinavir, 16 [28%] of whom had subsequent resolution of their symptoms w·tth"tn a maximum 
of 86 days. On ther other hand, we observed resolution of urological symptoms for 37 (64%) 
patients without or before discontinuation of indinavir. For 5 [9%) patients resolution of 
urological symptoms had not been recorded, 4 of whom had discontinued indinavir. 
Discussion 
In this large population based cohort of HIV-infected patients in the Netherlands the risk of 
urological symptoms during the use of indinavir was eight-fold higher as compared to other 
HIV-protease inhibitors. The large difference in incidence between indinavir and other HIV-
protease inhibitors is an expected finding, although the incidence among indinavir users 
was lower than reported elsewhere (4, 9, 12, 13, 20). The majority of urological symptoms 
occurred within the first six months of indinavir-treatment, but the incidence remained 
elevated thereafter albeit at a reduced steady rate. 
Risk factors for urological symptoms were low LBM, undetectable HIV-1 RNA (S 1000 
copies/ml) at the start of indinavir and inherent to this prior stopping of an antiretroviral drug 
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due to any type of intolerance and the absence of concomitant co-trimoxazole use. In 
addition, indinavir-regimens of .:::_ 1 000 mg bid, low weight and monthly environmental 
temperatures above 18 oc were identified as risk factors. Neither gender nor concomitant 
use of co-trimoxazole, which have been suggested as risk factors before, were associated 
with urological symptoms in our study {8, 18). 
The finding that LBM rather than BMI was associated with urological symptoms can 
be explained by the fact that a low LBM reflects a low distribution volume which may lead 
to higher indinavir plasma concentrations. Moreover, indinavir has low lipid solubility resulting 
in low fatty tissue penetration and therefore little protective effect of the amount of fatty 
tissue (6). 
Patients with undetectable HIV-1 RNA at the start of indinavir represent a selection 
of patients who previously had successful treatment with ART. These patients are more likely 
to have therapeutic or even high plasma drug concentrations than patients without viral 
suppression. As a conSequence they may be more susceptible to plasma concentration 
dependent adverse effects such as indinavir associated urological symptoms 13. We can 
only speculate on this association since we did not measure indinavir plasma 
concentrations. However, a large proportion of patients with viral suppression had prior 
intolerance leading to a treatment change, which confirms the fact that these patients 
may indeed be more prone to development of adverse effects {26]. Another possible cause 
of urological symptoms in this group of patients might be for example nausea leading to less 
fluid intake and increased urine concentration. 
The finding that indinavir dosing regimens of.:::_ 1000 mg bid, which achieve higher 
indinavir plasma peak concentrations {Cmax] and larger areas under the curve {AUCJ, 
were associated with urological symptoms is consistent with earlier reports of the relation 
betvveen urological symptoms and high plasma indinavir concentrations [13, 27, 28]. It is not 
known which pharmacokinetic parameter, high Cmax or increased AUC, is the more 
important determinant of the risk for urological symptoms. Unfortunately the number of 
patients using the indinavir/ritonavir combination of 800/100 mg bid, a regimen with a Cmax 
comparable to that of indinavir 800 mg tid and a large AUC {28, 29}, was too small to 
differentiate betvveen the effects of high Cmax and large AUC. 
It has been reported before that a high environmental temperature increases the 
risk of urological symptoms {17, 20). As suggested before, reduced urine production as a 
consequence of increased perspiration is the most likely explanation for the association 
betvveen environmental temperatures and urological symptoms. The current advice for 
patients to drink at least 1.5 L per day may not be sufficient under warm weather 
circumstances (30). 
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Potential limitations of this study mainly concern information bias and bias due to 
diagnostic suspicion for urological symptoms among indinavir users rather than users of other 
HIV-protease inhibitors. We dealt with these biases as much as possible. To avoid information 
bias, we included only patients who started in 1997 or thereafter. thus eliminating a period 
of accustomisation to the new HIV-treatment entities and preventing major underreporting 
due to relative unawareness of the symptoms. Still, sub-clinical urological symptoms of 
indinavir such as mild renal insufficiency that goes undetected if renal function is not 
regularly assessed may have been underreported. Furthermore, certain urological 
symptoms may have been misdiagnosed as urinary tract infection. Underreporting or 
misclassification may have led to an underestimation of the incidence rate. It is however 
unlikely that it has affected the identification of risk factors for urological symptoms since we 
matched on treatment centre within which the degree of reporting and preference for 
indinavir-regimens can be expected to be equal between patients. Diagnostic suspicion 
bias is unlikely to have played a role in the identification of risk factors either as we restricted 
this analysis to indinavir users only. Potential effect modifying factors in the observed 
associations such as dietary changes and fluid intake were not available for analysis. 
Given the fact that indinavir plasma concentrations play an important role in the 
development of urological symptoms, inhibitors of the cytochrome P450 CYP3A4 as well as 
hepatic dysfunction might aggravate the effects observed in this study as effect modifiers 
(9, 16, 31-33). As the use of interacting drugs probably is rare, because of an automated 
warning system for ·Incompatible drug combinaf1ons as operated by the community 
pharmacists in the Netherlands (34), and the prevalence of clinically overt hepatitis is low in 
our cohort (2%], these factors are unlikely to have caused a major impact on our results. 
In conclusion, we found an incidence rate of urological symptoms of up to 8.3 per 
100 person years of indinavir treatment in this large population based cohort study. Low 
LBM, low HIV-1 RNA at the start of indinavir, the use of indinavir-dosing regimens higher than 
the standard dosing of 800 mg tid and warm weather days were all identified as 
independent risk factors for the development of urological symptoms. As high indinavir 
plasma concentrations appear to play a key role, it may be useful to include indinavir 
plasma concentration monitoring as a preventive strategy for urological symptoms. 
Alternative indinavir/ritonavir dosing regimens with lower Cmax and/or smaller AUCs may 
have to be considered. Our study focussed on the identification of risk factors for urological 
factors. Any of the proposed control measures will have to be tested for their ability to 
reverse and prevent urological symptoms. Finally, the results endorse the need for increasing 
fluid intake during warm weather days or comparable circumstances during which urine 
output may be decreased. 
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Abstract 
Objective: To determine the probable site of the nephron and the plasma indinavir {IDY) 
concentration at which intra-renaiiDV crystallisation occurs. 
Design: We performed in-vitro crystallisation experiments in IDV solutions simulating the 
conditions encountered in the nephron. 
Method: To determine intra-renal lOY concentrations at which the conditions in the nephron 
allow crystallisation, several concentrations of IDV base solutions {0-800 mM) were titrated 
from pH 4.0 to higher pH values until crystals occurred within one minute. Based on the 
combination of pH and ionic strength at which crystals occurred. the site of the nephron to 
which these apply was determined. Based on the concentrating capacity up to that site. 
the corresponding plasma IDY concentration was calculated. 
Results: Under conditions applying to the proximal tubule. pH 6.7 and ionic strength of 200 
mM, IDV crystallised at 200 mg/L. Under conditions applying to the loop of Henle, pH 7.4 and 
ionic strength of 200 mM. IDY crystallised at 125 mg/L, which would correspond to a plasma 
IDY concentration of 8 mg/L 
Conclusion: IDV crystallisation is most likely to occur in the loop of Henle and may already 
start at plasma IDV concentrations of 8 mg/L. Increasing hydration will not reduce the risk of 
JOY crystallisation in the loop of Henle, but rather prevent IDV crystallisation and 
aggregation in the lower urinary tract. It remains to be confirmed whether prevention of 
high IDY plasma concentrations will reduce the r"1sk of IDY crystallisation ·In the loop of Henle. 
56 
Origin of indinovir crystals 
Introduction 
Treatment with the widely prescribed HIV-protease inhibitor indinavir {IDV) is associated with 
renal intolerance, the spectrum of which ranges from a-symptomatic crystalluria {20-32%) 
and interstitial nephritis to symptomatic nephrolithiasis (4-12%} (1-4). Renal failure and renal 
atrophy have been described (5-1 0). 
Mass-spectrometry has shown that urinary crystals and calculi from IDV treated 
patients primarily consist of the IDV base monohydrate (3, 11 ). Little is known about the exact 
site of IDV crystal formation. IOV crystals have been found in the cortical and medullar 
collecting ducts and in interstitial cells of the kidney suggesting that IDV crystallisation may 
already start in the renal tubuli {3,6,8, 12-14). For the development of preventive strategies for 
renal complications from IDV it is important to understand where and under which 
conditions intra-tubular IDV-crystal formation may occur. 
Oral !DV is rapidly absorbed and 24% of the ingested dose is excreted and 
secreted into urine within 24 hours about half of which as the parent molecule, IDV 
monohydrate (12, 15, 16). IDV monohydrate is a weak base with pKa values of 5.9 and 3.7. It 
is poorly soluble in aqueous solutions of high pH {17). Given the physico-chemical properties 
of IDV, intra-tubular crystallisation of IDV most likely is supersaturation driven. 
During passage of the glomerular filtrate (GF} through the tubuli the fluid passes 
zones of varying pH-values and ionic strength (IS) while the GF is increasingly concentrated. 
These conditions have been described in a model taking into account normal glomerular 
filtration rate, tubular function, tubular reabsorption and secretion processes, tubular 
dimensions and tubular flow rates (table 1) (18-20].1n brief. the pH reaches a maximum of 
7.4 in the longest loops of Henle (LH), coinciding with an high IS and high GF concentration. 
Subsequently the pH gradually decreases to urine pH and the GF is further concentrated 
depending on the hydration status of the body. The model has been used previously for 
example to explain how calcium salt crystalluria can be a frequent finding while de novo 
calcium salt crystal formation in urine is difficult. The reason is that the conditions in urine do 
not reflect the intra-tubular conditions (18-20). 
The lowest solubility for IDV in the renal tubuli is probably reached in the LH due to 
the high pH values. Since the conditions in the respective parts of the nephron are relatively 
stable under normal physiological conditions, variations in the local IDV concentration 
depend primarily on variations in the unbound fraction of plasma IDV that is filtered by the 
glomeruli. Not taking into account the IS in the tubuli and assuming a two-fold secretion 
component it can be calculated that the fluid in the LH becomes saturated at plasma IDV 
concentrations of 1.5 mg/L (16,17). However. it is not known at which level of saturation 
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(supersaturation) crystallisation occurs, if IS affects the solubility of IOV and "If crystals can 
grow to a large enough size during the available time in the nephron. 
We performed crystallisation experiments taking into account the existing 
conditions in the nephron in order to determine the part of the nephron in which IOV 
crystallisation is most likely to occur and to determine the plasma JOV concentration 
needed for this. 
Methods 
In the crystallisation experiments the IS and the pH were varied to simulate the normal 
physiological conditions in the various segments of the nephron as described in the model 
presented in table 1. Based on the plasma IOV concentrations of patients with urological 
complaints and the known conditions in the tubuli, IDV concentrations of 105 mg/l to 260 
mg/L may be expected in the LH of these patients (Figure 1 ). 
Table 1 Model describing the chong"tng physiological conditions and fluid compositions during 
passage through the various ports of the nephron (19,20) 
Port of the nephron PH IS(mM) Passage 
time (s) 
Degree of 
concentration 
GF 7.25 136-145 0 0 
PT 6.7 140-200 24 3 
LH 7.4 200-870 40 20 
Ascending LH 6.7 870-73 1 DO 5-20 
DT0 Regulation to urine pH 73 to 30-50 31 5-20 
coo Regulation to urine pH 30-50 to 45-582 29-49 20-200 
GF- glomerular ultra filtrate, PT- proximal tubule, LH-Ioop of Henle, DT- distal tubule, CD- collecting 
duct, IS= ionic strength 
a Conditions largely depend on the hydration status of the body 
Crystallisation experiments 
Varying amounts of pure IOV base (JOY monohydrate) provided by Merck & Co., were 
dissolved to concentrations of 100. 125. 150, 200. 250, 500 and 750 mg/L in purified water 
solutions with IS of 0. 200, 400 and 800 mM NaCI at a low pH of 4.0. In a test run the pH 
required for supersaturation and particle formation was established. Particle formation was 
monitored by means of optical density of the solution (21). Subsequently, three runs of the 
same experiment were done in which the IOV solutions were titrated to higher pH-values 
with 0.1 mM NaOH to rapidly approach the state of supersaturation and titrated further with 
0.01 nM NaOH until particle formation (crystallisation) occurred within one minute. One 
minute was considered as the time that a given test solution must remain particle free in 
order to allow a safe passage through the specific part of the nephron ( 18, 19). The pH-value 
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at which particle formation occurred was recorded. Solutions were filtered through a 0.1 ).Lm 
nucleopore polycarbonate filter after one minute and the precipitate was examined for 
presence of IDV crystals by infrared spectrometry, light microscopy and scanning electron 
microscopy. All experiments were performed in triplicate at room temperature. Results were 
expressed as the average pH-value at which particle formation [crystallisation) occurred at 
a certain IS and IDV concentration. 
urine IDV concentration (mg/L) 
180 
160 
• Loop of Henle 
• Proximal tubuli 140 
• Glomeruli 
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80 
60 
40 
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4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 
plama IDV concentration {mg/L) 
Figure 1 indinovir (IDV) concentrations expected in the respective parts of the nephron given certain 
plasma IDV concentrations 
Figure shows the relationship between relevant IDV concentrations encountered in plasma {x-
axis) and the nephron {y-axis) as predicted by the model described in table 1. The glomeruli 
harbour a pH of 7.4. along the proximal tubuli the pH decreases to 6.7 and in the longest loops 
of Henle the pH reaches 7.4. Solubility data suggest that the fluid in the loop of Henle is 
saturated with lDVat all indicated plasma IDV concentrations (17). 
The part of the nephron to which this pH and IS applied was determined according to table 
1. The degree of fluid concentration present in this part of the nephron was then used to 
calculate the IDV plasma concentration at which crystallisation would first occur. assuming 
100% filtration of plasma IDV. a two-fold secretion component in the PT and 61% plasma 
protein binding of IDV (figure 2). 
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[I DY] nophronb 
[IDV]plc~mco= 
IDV secretionc * concentrating copacityd * fraction of filterable plasma IDVe 
Figure 2 Interpolation to plasma indinavir (IDV) concentrations 
a Plasma IDV concentration 
b IDV concentration in the part of the nephron of interest 
c IDV secretion in the proximal tubulus estimated at 2 (16] 
d Estimated concentrating capadty in the port of the nephron of interest (20 for the LH) 
e Estimated free fraction of filterable plasma IDV= 0.39 (39%) 
Results 
Table 1 shows the fluid compositions {IS and pH) during passage of GF through the various 
parts of the nephron. Up to the descending LH, the pH first decreases and then increases to 
arrive at a maximum of 7.4. The IS of the filtrate also increases to a maximum in the 
descending LH where the concentrating capacity is highest. From the ascending LH to the 
distal tubule the pH decreases to urine pH and the IS first decreases and then increases in 
the collecting ducts to its final urine value. 
Crystallisation occurred very rapidly after exceeding supersaturation. Table 2 shows 
the pH and IS at which certain IDV concentrations formed crystals within one minute. 
According to table 1 the only sites of the nephron to which these conditions of pH and IS 
apply are the PT and the LH. Crystallisation occurred at a local IDV concentration of 200 
mg/L and 125 mg/L in the PT and LH respectively. Light and scanning electron m·tcroscopy 
analysis demonstrated the typical starburst appearance of IDV crystals. which are also seen 
in IDV crystalluria [3,9,22,23). 
Assuming 39% unbound plasma IDV, a normal glomerular and tubular function and 
a two-fold secretion component, an IDV concentration of 200 mg/L at the end of the PT 
corresponds to a plasma IDV concentration of 85 mg/L, wh"tch is not attainable with current 
IDV dosing regimens. An IDV concentration of 125 mg/L at the end of the descending limb 
of the LH would correspond to a total plasma IDV concentration of 8 mg/L, which is 
attainable with current dosing regimens. These results imply that intra-tubular IDV 
crystallisation probably is unlikely to occur at plasma IOV concentrations below 8 mg/L, but 
might occur at plasma concentrations above th"ts level. Crystallisation first occurs at the 
bend of the LH and probably does not occur in the PT or the descending and ascending 
limbs of the LH. 
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Tobie 2 pH {SD) at which indinavir {IDV] crystals ore formed within one minute for a given IDV 
concentration and ionic strength 
[IDY]Gc [mg/L) Ionic Strength {mM) 
0 mM 200 mM 400mM 800mM 
125 7.36 (0.04) 7.41 (0.01)0 7.53 (0.04) 7.50 (0.02) 
150 7.08 [0.02) 7.23 (0.23) 0 7.34 (0.09) 0 7.44 (0.05) 0 
200 6.01 10.11 1 6.65 (0. 13)" 6.86 [0.041 6.80 (0.12) 
250 5.79(0.08) 6.10 (0.04) 6.31 [0.01) 6.29 (0.04) 
500 5.17(0.03) 5.41 (0.06) 5.65(0.02) 5.61 (0.03) 
750 4.95 (0.03) 5.31 10.021 5.47 10.05) 5.42(0.06) 
[IDV]GF IDV concentration in the glomerular filtrate. Values are pH-values with one standard deviation 
betv.reen brackets (n=3); bold italic print indicates physiological conditions present in the renal tubuli 
a Physiological conditions present in the loop of Henle 
b Physiological conditions present in the proximal tubuli 
Discussion 
The results of the crystallisation experiments support the hypothesis that the risk of lDV crystal 
formation in the nephron is highest under conditions existing at the bend of the LH. It was 
also shown that crystal formation occurs upon exceeding saturation and that crystals can 
grow rapidly within the available passage time once supersaturation is reached. Our data 
do not provide an exact upper limit for tolerable plasma IDV concentrations, but suggest 
that lDV crystallisation in the LH might already occur at IDV plasma concentrations of 8 
mg/L, which should be interpreted as an indication rather than a statement. 
Since concentrations of 8 mg/L are common with IDV regimens of 800 mg tid (24), 
intra-renal IDV crystallisation might be a frequent event not necessarily leading to clinically 
apparent nephrolithiasis. A previous study showed that clinical symptoms were associated 
with plasma IDV concentrations of more than iwice the population mean (25). Intra-renal 
crystallisation might even be more frequent with ritonavir boosted IDV regimens, such as 
iwice daily 800 mg IDV combined with small doses ritonavir, since plasma IDV peak 
concentrations are increased {16,26-29]. In addition, such boosted regimens yield an 
increased risk of IDV supersaturation in the lower urinary tract because of the longer periods 
of high plasma IDV concentrations, resulting in larger amounts of IDV excreted into urine 
(16,28). 
Increasing hydration, which is the current advice for controlling urological 
complications from IDV, will only increase the urine flow beyond the LH in the collecting 
duct and therefore be ineffective against the potential formation and effects of IDV crystals 
in the LH (1.7). The increased urine flow and dilute urine caused by increasing hydration 
rather is effective against crystal aggregation and new IDV crystallisation in the lower parts 
of the urogenital tract. Adequate hydration therefore is essential in the prevention and 
alleviation of urological complications, but may not always be sufficient. Given a direct 
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association between the free fraction of plasma IDV and the degree of supersaturation in 
the LH, avoidance of high plasma IDV concentrations by means of dose adjustments might 
be an effective control measure against IDV crystal formation in the LH. In doing so it must 
be ensured that adequate plasma IDV trough concentrations are maintained for optimal 
viral suppression (24), for which the combination of indinavir with ritonavir offers possibilities. 
The results of this study are based on a model that has been used successfully to 
explain calcium salt crystallisation processes {18). Obviously these results need substantiation 
in a clinical setting. In addition. the following points should be taken into consideration. First, 
the IDV concentration of 8 mg/L as the suggested upper tolerable concentration may need 
to be corrected for variations in plasma protein binding and secretion of IDV. We assumed a 
free fraction of IDV of 39% and a two-fold secretory component {1,12.16,28). The degree of 
plasma protein binding appears to vary from 54 to 70% and is lower at higher plasma IDV 
concentrations, suggesting an additive risk for high plasma peak concentrations (30). 
Second, we did not take into consideration the possibility of re-absorption of IDV. 
Weak bases l"lke JDV may have the capacity to migrate along the epithelium into the 
interstitium. Re-absorption in the PT would lead to lower intra-tubular IDV concentrations and 
less risk of crystallisation. 
Third, the exper"1ments were conducted at room temperature whereas physiologic 
temperature is 37°C. Since IDV solubility might be slightly better at higher temperatures the 
actual risk of IDV crystallisation might be slightly lower. Furthermore, we assumed that IDV 
crystall"lsation in the LH "1s a sole consequence of supersaturaf1on independent of any 
promoters or inhibitors. Other factors. such as proteins, might either promote or delay the 
IDV crystallisation process. Calcium phosphate crystals. which are usually present in the LH, 
might for example promote IDV crystallisation, whereas citrate may "tnh.ib.lt this process {31-
34). 
Finally, we assumed normal glomerular and tubular function. Reduced glomerular 
filtration would lead to lower intra-tubular IDV concentrations and hence a lower risk of 
intra-tubular crystallisation. Tubular dysfunction might lead to higher intra-tubular pH values 
and hence a higher risk of crystallisation. However, given the concentrating capacities of 
the various parts of the nephron, the pH in the PT needs to be extremely high to induce IDV 
crystallisation. In the distal tubuli a pH of 7.4 is needed to equal the risk of IDV crystallisation 
in the LH. In the collecting duct the risk of crystallisation may easily be increased at higher 
pH because of the high JDV concentrations reached. An association between urine pH and 
IDV crystals has indeed been described elsewhere [2.34.35). 
In conclusion, the results suggest that plasma IDV concentrations of 8 mg/L may 
already cause IDV crystallisation in the LH, the conditions of which cannot be influenced by 
modifying hydration. Therefore, dose adjustments to minimise the maximum plasma IDV 
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concentrations while maintaining adequate trough concentrations might be indicated for 
patients with urological adverse effects from IDV. The conclusions are based on the 
assumptions that the model employed is an accurate approximation of the changing 
conditions in the nephron, that there is no tubular re-absorption of IDV, normal renal function 
and no influence of promoters and inhibitors. It remains to be confirmed whether avoidance 
of plasma lDV concentrations of 8 mg/L reduces the risk of lDV associated urological 
complications in a clinical setting. 
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Persistent leukocyturia and loss of renal 
function in a prospectively monitored cohort of 
HIV-infeded patients treated with indinavir 
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Abstract 
Background: Symptomatic nephrotoxicity is a well-known complication of indinavir. 
However, little is known about the clinical relevance of leukocyturia during use of indinavir. 
Objectives: To estimate the prevalence of leukocyturia and to determine risk factors for 
persistent leukocyturia and changes in renal function. 
Methods: Consecutive patients on indinavir visiting three adult outpatient clinics, undef'Nent 
urinalysis at each regular visit (once every three months) between August 1998 and 
September 2000. Urinalysis included dipstick pH, erythrocytes and leukocytes. microscopy for 
indinavir crystals and urine albumin/creatinine ratio. Servm creatinine and indinavir plasma 
concentrations were measured and urological symptoms were retrieved from medical 
records. Presence of urinary tract infection was excluded. 
Results: 184 patients undef'Nent at least one urinalysis, 35% of whom had leukocyturia (ie. 
>75 ce!IS/J.tl) at any time during the study period. Leukocyturia coincided with mild albumin 
loss. erythrocyturia and crystalluria. Thirty-two of 134 {24%) patients with two or more 
assessments had persistent leukocyturia (ie. ~2 occasions). Risk factors were indinavir plasma 
concentration above 9 mg/L urine pH above 5.7 and crystaJJuria. Persistent leukocyturia 
was associated with a gradual loss of renal function, but was not associated with urological 
symptoms. 
Conclusion: Leukocyturia is a frequent finding whkh ·,s associated with a loss of renal 
function independently of urological symptoms. Patients should be monitored for renal 
function during indinav·lr treatment. lndinavk plasma concentraf1ons, urine pH and indinavir 
crystalluria are associated with persistent leukocyturia. 
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Introduction 
The HJV-protease inhibitor indinavir is widely used in the treatment of HlV-infection. As 
prolonged viral suppression can now be achieved by chronic treatment with highly active 
antiretroviral treatment [HAART), long-term adverse effects become of increasing concern. 
lndinavir may cause symptoms of nephrolithiasis through the formation of indinavir 
crystals, particularly in urine with a high pH {1-5). However, damage to the tubular 
epithelium may also occur without symptoms. This sub-clinical phase can be followed by 
symptomatic renal injury (6]. There have been several reports of renal failure (7-10), renal 
atrophy (11, 12), interstitial nephritis (6, 13-15) and papillary necrosis (16) following the use of 
indinavir. 
we performed a prospective cohort study among patients on indinavir to 
systematically screen for sub-clinical signs of nephrotoxicity with the objective to estimate 
the prevalence of mild and non-symptomatic urine abnormalities as indicator of mild renal 
injury (17-19). Furthermore, we determined risk factors for persistent leukocyturia and 
changes in renal function. 
Patients and methods 
Setting 
Between August 1, 1998 and September 1, 2000 the outpatient clinics of the Erasmus 
Medical Centre Rotterdam (Erasmus MC), the University Medical Centre Nijmegen and the 
Walcheren Hospital in Vlissingen in the Netherlands carried out an indinavir nephrotoxicity 
monitoring program, which was approved of by the Institutional Review Board. Patients 
treated with an indinavir containing antiretroviral regimen were monitored on their three-
monthly visits to the outpatient clinic. 
For the present analysis, our cohort comprised all patients 18 years and older in the 
monitoring program (both prevalent and incident users of indinavir). Cohort members were 
followed from the moment of inclusion in the monitoring program until the end of the study 
period, one visit after discontinuation of indinavir, departure from the clinic or death, 
whichever event occurred first. 
Laboratory assessments 
We assessed midstream urinary pH, presence of leukocytes, erythrocytes, crystals and 
bacteria in urine, proteinuria as a marker of tubular damage {urine albumin and urine 
creatinine concentration ratio] as well as serum creatinine levels and indinavir plasma 
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concentrations. Assessment of urinary pH, presence of leukocytes, erythrocytes and 
bacteria was done by means of a dipstick analysis (Combur-Test M, Roche 
DiagnosticsGmbH, Mannheim, Germany). Presence of leukocytes, erythrocytes and 
bacteria was confirmed by light microscopy. Urine light microscopy using a polarisation filter 
was performed to identify the presence of indinavir crystals. Urine samples were analysed 
with a maximum delay of two hours after voiding. 
Urine samples from five consecutive patients with qualitative signs of leukocyturia 
were used for leukocyte differentiation on cytospins. For this purpose fresh urine samples 
were centrifuged at 1400 rounds per minute (rpm) at 6°C for 10 minutes. The resulting pellet 
was washed twice in 500 ~L phosphate-buffer solution (PBS) with centrifugation steps in 
between. The final cell suspension was diluted to reach a cell density of 2*106 cells/ml. 
Cytospin filtration paper on a slide was humidified by adding 50 )..ll of 0.9% sodium chloride 
solution, which was rotated at 500 rpm for one minute. Subsequently, 50 J..LL cell suspension 
was added and the slide was rotated again at 50 rpm for ten minutes. Finally, slides were 
fixated and stained with the May-GrUnwald-Giemsa staining method after which an 
experienced laboratory technician performed cell differentiation. 
Creatinine clearance was estimated from serum creatinine using the equation of 
Cockcroft and Gault (20}. At one hour after the last ingestion of indinavir, seven ml of blood 
was sampled from an antecubital vein into a lithium heparin vacutainer, for estimation of 
the maximum indinavir plasma concentrations. lndinavir plasma concentrations were 
determined at the un-Iversity Hospital in Nijmegen, the Netherlands according to a prev·1ously 
validated high performance liquid chromatography assay (21 }. The maximal plasma 
indinavir concentration for each patient was used for data analysis. 
Additional data collection 
Baseline data regarding serum creatinine levels and weight prior to the start of indinavir and 
details on height, indinavir treatment, concomitant medication, HIV-1 RNA CD4 cell counts 
and urological symptoms during treatment were collected from the medical records. 
Urological symptoms included notes of renal colic, flank pain, the passing of a stone, dysuria 
and gross hematuria and were validated independently by three authors blinded to the 
presence of leukocyturia, indinavir dose frequency and indinavir plasma concentration. 
Symptoms were classified as either indicators of nephrolithiasis, such as the passing of a 
stone and flank pain with or without hematuria, or other associated urological symptoms not 
attributable to urinary tract infection. 
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Case definition 
Since we considered sterile leukocyturia as an indicator for mucosal damage in the urinary 
tract, this was the primary outcome of our study. We considered sterile leukocyturia to be 
present if the dipstick test showed more than 75 ceiiS/J.LL and urinary tract infection was 
absent. We further determined the presence of persistent sterile leukocyturia [persistent 
leukocyturia), defined as the presence of sterile leukocyturia on two or more occasions 
during the use of indinavir, since persistent rather than incidental mild renal injury is likely to 
hove more serious implications. 
For diagnosis of urinary tract infection we applied the CDC-definitions for 
nosocomial infections based on clinical symptoms, dipstick analysis and urine culture [22). 
Urine culture was performed if signs of bacteria were detected by dipstick or urine light 
microscopy or if there was suspicion of urinary tract infection. The results of urine cultures 
were judged by an experienced infectious diseases specialist. 
Secondary outcomes were erythrocyturia [ie. more than 60 erythrocytes/J..LL by 
dipstick analysis), crystalluria [more than two indinavir crystals per 40x magnified field), mild 
albumin loss [ie. albumin/creatinine> 3.5 mg/1-JmOI), urological symptoms and a decrease in 
renal function (ie. more than 45 [..Jmoi!L increase in serum creatinine since the start of 
indinavir]. 
Statistical analyses 
To describe the prevalence of leukocyturia and other urological abnormalities over time we 
first categorized all measurements into 12-week assessments thereby ignoring extra 
intermediate assessments [which may have been triggered by abnormal findings at routine 
monitoring). Proportions and 95%-confidence intervals [95%CI] were calculated based on a 
binomial distribution. The six-month hazard of leukocyturia among incident users of indinavir 
was calculated by means of Kaplan-Meier survival analysis. Associations between the 
presence of leukocyturia and other urine abnormalities were tested with a Chi-square test or 
Asher's exact test for categorical variables and the Mann-Whitney U test for continuous non-
normally distributed variables in a cross-sectional analysis of the first assessment of prevalent 
indinavir users. 
In a second step, we calculated the prevalence of persistent leukocyturia among 
patients who had two or more urine assessments during the use of indinavir. Potential risk 
factors for persistent leukocyturia were identified through univariate and multi-variate risk 
ratio analysis. Results were expressed as relative risks (RR) with 95%CI. In the subpopulation of 
patients with two or more urine assessments we also compared renal function {serum 
creatinine and creatinine clearance) during follow-up between patients with and without 
persistent leukocyturia by means of General Linear Model for repeated measurements 
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adjusted for baseline values. For all analyses statistical significance was accepted at a two-
sided p-value lower than 0.05. 
Results 
During the monitoring period, we included 184 adult patients with a median age of 39 years 
of whom 80% were male. Patients were predominantly prevalent users of indinavir (n=161, 
88%), who had been using indinavir for a median of 67 (inter quartile range [IQR]: 12-109] 
weeks prior to entry in the monitoring program (Table 1). The overall median follow-up while 
being monitored was 48 (IQR: 24-72) weeks. Patients who were monitored from the start of 
indinavir use [incident users) had a median follow-up of 39 (14-64) weeks. During follow-up, 
we obtained a total of 622 urine samples with a median of three analyses [IQR: 1-4) per 
patient. 
Table 1 Characteristics of patients included in the indinavir nephrotoxicity monitoring program (n=184) 
Characteristic at the first assessment 
Age (years) 
Male 
Leon body mass (kg) [n=168] 
CDC-C classification [n=164] 
Hepatitis C infection [n=76] 
Concomitant use of Co-trimoxozole 
Prevalent use of indinovir 
Weeks on indinovir (prevalent users] 
CD4 cell count [n=140] 
HIV-1 RNA< 500 copies/ml fn=84l 
IQR~ inter quartile range 
39 
148 
72 
66 
11 
43 
161 
67 
330 
46 
[lOR: 34-48) 
[80%) 
[lOR: 65-77) 
[40%) 
[14%) 
[23%) 
[88%) 
[lOR: 12-1 09) 
[lOR: 170-508) 
[55%) 
During follow-up 64 {35%, 95%CI: 28-42) patients had sterile leukocyturia in at least one urine 
specimen. Eight of 23 (35%, 95%CI: 16-54] incident indinavir users presented with sterile 
leukocyturia with a six-month cumulative hazard of 0.31 (95%CI: 0.20-0.36). The prevalence 
of crystalluria was highest at the start of the monitoring program [Figure 1). Erythrocyturia 
and urological symptoms were constant at a prevalence of approximately 1 0% of patients 
every three months. We did not observe any seasonal variation in the prevalence of 
symptoms. 
Cross-sectional analysis of the first assessment of prevalent indinavir users showed 
that sterile leukocyturia {n=19, 20%) was associated with erythrocyturia (p=0.043) and mild 
albumin loss [p=0.008) but not with crystalluria (p=0.393) or urological symptoms [p=0.905) 
(Figure 2). Presence of Jeukocyturia coincided with greater increases in serum creatinine 
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Figure 1 Urine abnormalities and urological symptoms during 
follow-up over calendar time 
from baseline (p=0.008). leukocyturia was the least prevalent (4%) among patients using 
indinavir 400 mg with ritonavir 400 mg bid (n=25), whereas the prevalence during other 
indinavir regimens (800 mg tid, n=89; 800 mg with 100 mg ritonavir bid, n=30; other, n=l6) 
ranged from 20% to 30%. Urinary pH did not differ between samples with and without 
leukocyturia [p=0.740). 
Persistent sterile Jeukocyturia 
A total of 134 patients provided two or more urine samples during use of indinavir and 
thereby defined the subpopulation for the assessment of abnormalities associated with 
sterile leukocyturia and with persistent sterile leukocyturia (persistent leukocyturia). Reasons 
for not having two urine samples were omitting sampling during outpatient clinic visits 
(n=20), discontinuation of indinavir (n=l6), late study entrance (n=8) and lost to follow-up 
(n=6). Apart from an under-representation of incident indinavir users (9% vs 22%) and 
patients with CDC-C stage of HIV-infection (35% vs 58%) in those with two or more visits 
versus those with one visit, both groups did not differ. 
During follow-up 56 (42%, 95%0:34-50) patients with two or more visits ever 
presented with sterile leukocyturia. Persistent sterile leukocyturia was observed in 32 (24%, 
95%CI: 17-31) patients, 10 (31%) of whom were newly identified (ie. leukocyturia was absent 
at cohort entry) during follow-up. leukocyte differentiation {n=5) showed that leukocyturia 
consisted predominantly of neutrophils (76%) and a small proportion of eosinophils {3%). 
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Figure 2 Urine abnormalities associated with leukocyturia (n=19) in a cross-sectional 
analysis of the first urine assessment among prevalent users of indinavir (n=l61). 
Small bars indicate standard errors. 
Thirteen (41%) of 32 patients with persistent Jeukocyturia also presented with symptoms of 
nephrolithiasis (n=8) or other urological symptoms (n=5), which was not significantly different 
from patients without persistent Jeukocyturia (RR=l.5, 95%CI: 0.7-3.1 ]. Three patients 
discontinued indinavir because of urological symptoms. 
Risk factors for persistent leukocyturia 
As potential risk factors for persistent leukocyturia we identified high plasma indinavir 
concentrations as well as urine pH and crystalluria (Table 2). The median plasma indinavir 
concentration one hour after indinavir ingestion was 7.3 {IQR: 4.2-9.6, n=90). Patients with 
concentrations above 9 mg/L had a 2.6-fold increased risk for persistent leukocyturia 
compared to patients with concentrations lower than or equal to 9 mg/L. Patients with an 
average urine pH value above the cohort median of 5.7 (lOR: 5.3-6.1) had a 3.1-fold 
increased risk for persistent leukocyturia and patients with crystalluria (n=39, 29%) had a 2.4-
fold increased risk (Table 2). These factors remained independent predictors upon 
multivariate analysis modelling. 
Age, gender, lean body mass, CDC-C stage of HIV-infection, hepatitis C infection, 
the use of concom"1tant co-tr·1moxazole, prevalent indinavir use at cohort entry, f1me on 
indinavir at cohort entry, CD4 cell count and HIV-1 RNA and were not associated with 
persistent leukocyturia. 
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Table 2 Potential risk factors for persistent sterile leukocyturia among patients who hod at least two 
assessments in the indinavir nephrotoxicity monitoring program (n=134) 
Parameter 
N [%)/ 
Median (IQR) 
RR (95% Cl)' 
Univariate 
Median plasma indinavir 
concentration {mg/L)'f' 7.3 (IQR: 4.2-9.6) 1.1 
>6mg/Lvs~6mg/L 55 (60) 1.4 
> 7 mg/l vs .$. 7 mg/l 50 (55) 1.8 
>Smg/Lvs~Smg/L 41 (45) 2.1 
> 9 mg/l vs .$. 9 mg/l 29 (32) 2.6 
Urine pH> 5.7 vs.::: 5.7 mg/L.;. 66 (49) 3.1 
lndinavir crystalluria vs no crystalluria 39 (29) 2.4 
lQR~ inter quartile range; RR relative risk; Cl- confidence interval; 
[0.98-1.2) 
(0.6-3.4) 
(0.7-4.3) 
(0.9-5.1 I 
(1.1-5.9) 
(1.4-6.9) 
[1.2-4.9) 
calculated by means of Cox-regression analysis with a fixed follow-up time 
Multivariate# 
2.3 
3.4 
2.3 
(1.01-5.5) 
(1.3-8.7) 
(0.99-5.5) 
# plasma indinavir concentration above or below 9 mg/L, urine pH and crystalluria included into the 
model 
'¥ maximum value measured at one hour after ingestion (n=90) 
.;. mean dipstick pH value per patient over all assessments during follow-up (median= 5.7] 
The one patient with persistent leukocyturia who switched to 400 mg indinavir with 400 mg 
ritonavir twice daily and five of six patients who stopped indinavir experienced resolution of 
leukocyturia within three months. Persistent leukocyturia did not resolve in the four patients 
who switched to 800 mg indinavir with 100 mg indinavir. 
Renal function in patients with persistent leukocyturia 
Patients with persistent leukocyturia showed a statistically significant increase in serum 
creatinine during follow-up compared to patients without persistent leukocyturia [Figure 3, 
p=0.027). The creatinine clearance rate reduced accordingly. A quarter [26%) of patients 
with persistent leukocyturia had an increase of more than 45 ~moi/L in serum creatinine 
since the start of indinavir (range: 47 to 7 6 j.tmoi/L). Creatinine concentrations did not differ 
between patients with or without urological symptoms and men or women. Serum 
creatinine concentrations did not normalise within three months after discontinuation of 
indinavir. 
Discussion 
In this prospective cohort study of patients on indinavir we observed a high rate of 
leukocyturia associated with mild albuminuria, indinavir crystalluria and micro-hematuria. 
Persistent leukocyturia as represented by persistent presence of leukocyturia, was observed 
in almost 25% of patients, most of whom were prevalent users of indinavir at the start of our 
monitoring program. Even though persistent leukocyturia remained sub-clinical, it was 
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Figure 3 Course of mean serum creatinine (s-creatinine) and mean creatinine clearance during 
indinavir (IDV) treatment (n=l34) for patients with (n=32. square marks) and patients 
without (triangle marks) persistent sterile leukocyturia. Bars represent 95%-confidence 
intervals.IDV= indinavir 
accompanied by a gradual loss of renal function. an observation, which has been 
described before (17). 
As with urological symptoms, persistent leukocyturia was associated with high 
indinavir plasma concentrations (23). The risk of persistent leukocyturia was increased at 
plasma concentrations of 9 mg/L or higher at one hour after indinavir ingestion. It was our 
aim to estimate the maximum plasma concentration {Cmax) for each patient by drawing 
blood samples one hour after ingestion. It is. however. possible that we hence 
underestimated the Cmax among patients who took ritonavir concomitantly (24-26}. 
especially among those taking 800 mg bid indinavir with 100 mg bid ritonavir. 
The risk of persistent leukocyturia was also increased at a urine pH above 5.7, which may be 
related to the poor solubility of indinavir at high pH values (5). A high urine pH might be 
caused by a high pH of the glomerular filtrate in the proximal renal tubuli as can be seen 
with tubular dysfunction. but it might be caused by dietary influences in the distal tubuli as 
well. 
We observed an association between the detection of indinavir crystalluria and 
persistent leukocyturia, which is in line with the assumption that indinavir crystals are part of 
the patho-physiological mechanism underlying leukocyturia (1. 2, 17, 18, 27). The assessment 
of indinavir crystals in urine samples should, however, be regarded with caution since 
crystals might be formed in standing urine in the bladder or canister (28). Moreover, the high 
prevalence of crystalluria at the start of the monitoring program suggests the presence of 
bias regarding assessment of crystalluria. Overestimation of crystalluria at the beginning 
might have occurred due to initial diagnostic suspicion by laboratory technicians or by 
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longer lag periods be1ween voiding and urine analysis in the beginning. On the other hand, 
underestimation of crystalluria at the end might have occurred due to decreased alertness. 
Persistent leukocyturia occurred independently of factors such as gender, hepatitis 
C and concomitant use of co-trimoxazole, which have previously been reported to be 
associated with urological symptoms (3, 19, 29-34). 
It is not known if continued renal injury as indicated by persistent leukocyturia will 
eventually lead to severe renal damage. So far, none of the patients with persistent 
leukocyturia in our population developed severe renal failure during follow-up. However, on 
the basis of our data we cannot exclude the risk of irreversible renal damage after 
prolonged exposure. 
Since our study was based on a monitoring program that did not apply exclusion 
criteria there are several limitations. The most important limitation is the low number of 
incident indinavir users who were followed from the start of therapy. This implied that we 
could not estimate the incidence of and lag time for persistent leukocyturia. It also implied 
the absence of baseline measurements before the start of indinavir. However, in absence of 
the baseline rate of leukocyturia, the positive de-challenge after discontinuation of indinavir 
at least pointed towards a causal relation be1ween indinavir and leukocyturia. Since we 
had many prevalent users of indinavir. there was a potential selection of patients who are 
able to tolerate indinavir. Such a bias might have caused an underestimation of the actual 
prevalence and effects on renal function by depletion of susceptibles. 
In conclusion, we observed a high prevalence of indinavir associated (persistent) 
leukocyturia. Leukocyturia was not always accompanied by urological symptoms. This sub-
clinical nephrotoxicity is of clinical relevance given the reduction in renal function, which we 
observed. It emphasizes the need for systematic monitoring of renal function during the use 
of indinavir. The long-term consequences are not known at present. but should be 
monitored by regular assessment of renal function and imaging procedures. Alternatively, 
there should be studies on the efficacy and effectiveness of regimens with lower indinavir 
plasma concentrations since increasing hydration alone may not protect against 
leukocyturia. 
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Persistent sterile leukocyturia is associated 
with impaired renal function in HIV-1 infected 
children treated with indinavir 
Chapter 2.6 
Abstract 
Background: Prolonged administration of indinavir is associated with the occurrence of a 
variety of renal complications in adults. These well documented s"1de effects have restricted 
the use of this potent protease inhibitor in children. 
Design: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 HIV-
1 infected children treated with indinavir. 
Methods: Urinary pH, albumin, creatinine, the presence of erythrocytes, leukocytes, 
bacteria, and crystals, and culture were analyzed every 3 months for 96 weeks. Serum 
creatinine levels were routinely determined at the same time points. Steady state 
pharmacokinetics of indinavir were done at week 4 after the initiation of indinavir. 
Results: The cumulative incidence of persistent sterile leukocyturia {':::::75 cells/M.l in at least 2 
consecutive visits) after 96 weeks was 53%. Persistent sterile leukocyturia was frequently 
associated with a mild increase in the urine albumin/creatinine ratio and by microscopic 
hematuria. The cumulative incidence of serum creatinine levels more than 50% above 
normal was 33% after 96 weeks. Children with persistent sterile leukocyturia more frequently 
had serum creatinine levels of 50% above normal {p=0.02) than those children without 
persistent sterile leukocyturia. In children younger than 5.6 years, persistent sterile 
leukocyturia was significantly more frequent(p= 0.05) than in older children. A higher 
cumulative incidence of persistent leukocyturia was found in children with an AUC > 19 
(mg/L'h) or a peak serum level of indinavir > 12 (mg/L) (p:Q.05 and p:0.02, respectively). In 4 
children indinavir was discontinued because of nephrotoxicity. Subsequently, the serum 
creatinine levels decreased, the urine albumin/creatinine ratios returned to zero and the 
leukocyturia disappeared within 3 months. 
Conclusion: Children treated with indinavir have a high cumulative incidence of persistent 
sterile leukocyturia. Children with persistent sterile leukocyturia more frequently had an 
increase in serum creatinine levels of more than 50% above normal. Younger children have 
an additional risk for renal complications. The impairment of the renal function in these 
children occurred in the absence of clinical symptoms of nephrolithiasis. lndinavir-
associated nephrotoxicity must be monitored closely, especially in children with risk factors 
such as persistent sterile leukocyturia, age <5.6 years, an AUC of indinavir > 19 {mg/L *h), and 
a Cmax >12(mg/L). 
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Introduction 
lndinavir is a potent HIV-protease inhibitor that has been used successfully in adults in 
combination with nucleoside reverse transcriptase inhibitors to suppress infections by HJV-1. 
Discontinuation of the antiretroviral therapy rapidly results in virologic rebound, decreased 
immune function, and the redevelopment of AIDS-defining illness. Thus, antiretroviral drugs 
such as indinavir need to be continued for many years. This necessitates a careful 
surveillance for long-term toxicity of the medication. 
The experience with the administration of indinavir to HIV-1-infected children has 
been limited because of the absence of a pediatric formulation and the well-documented 
side-effects of the drug on the upper and lower urinary tract in adults. lndinavir is 
metabolized by the liver, but approximately 20% of a single oral dose is excreted 
unchanged in the urine. [1) PH dependent crystallization of indinavir in renal tubuli may 
cause renal symptoms such as kidney stones, flank pain {even without evident stone 
formation), interstitial nephritis, elevation of the serum creatinine, dysuria and asymptomatic 
urine abnormalities such as hematuria, leukocyturia and crystalluria. indinavir crystals may 
illicit an inflammatory response in the tubules, leading to sterile leukocyturia and renal 
insufficiency. {2-7) To minimize renal side effects of indinavir, an increased fluid intake is 
advised. (8) 
The incidence of indinavir associated nephrolithiasis in adults varies from 4 to 43%. 
[2, 9] Renal complications [including nephrolithiasis) from indinavir are found in 0 to 80% {1 0-
15] and nephrolithiasis in 0 to 20% {10, 12-15) of children who have been treated with this 
drug. 
Renal and urologic symptoms of indinavir crystals have been correlated with the 
serum levels of indinavir. [16) In children, sufficiently high area under the plasma-
concentration curves {AUCs) for indinavir are required to achieve trough levels (13, 17) 
associated with an optimal virologic response. (18-20] The risk of nephrotoxicity in children 
might therefore be higher than in adults. 
In contrast to symptomatic nephrolithiasis, other renal complications such as 
leukocyturia, microscopic hematuria, and crystalluria usually do not lead to a decision to 
discontinue indinavir, although an association betvveen recurrent severe leukocyturia and 
renal damage by indinavir-induced crystalluria has been reported in adults. [6, 21) 
Currently it is unknown whether and when these asymptomatic signs of renal 
damage lead to renal complications and long-term renal damage. This prospective study 
was performed to monitor renal and urinary complications in a cohort of 30 HIV-1-infected 
children treated with indinavir. We hypothesized that indinavir-related nephrotoxicity might 
83 
Chapter 2.6 
occur more frequently in children than in adults due to the higher risk for cellular damage to 
the still developing renal system. 
Methods 
In 1997 a prospective, open, uncontrolled, multicenter study was initiated to evaluate the 
clinicaL immunologic and virologic response to combination therapy consisting of indinavir, 
zidovudine, and Jamivudine in HIV-1-infected children (15). Children >3 months of age and 
one of the following 2 items: a decreased CD4+ T-ceJI count (<1 year: <1750/mm3, 1-2 years: 
<1 OOO/mm3, 3-6 years: <750/mm3, >6 years: <500/mm3) or a HIV-1 RNA load >5000 copiesjml 
were included. The follow-up period was 96 weeks after the initiation of indinavir. Two years 
after the initiation of this multicenter study a separate study was started in one of the 
participating centers to analyze additional urinalysis parameters with a follow-up period of 
96weeks. 
The Ethics Committee of the University Hospital Rotterdam approved the study. 
Patients and their caretakers provided written informed consent. 
Laboratory parameters 
The routinely analyzed laboratory parameters of the children included dipstick analysis 
(RapignostrP total screen L Behring Diagnostics Inc. Westwood, USA) for urinary pH (at urine 
pH values below 5 solubility of indinavir ·Increases (22}), erythrocytes, leukocytes and 
bacteria at baseline {before the use of indinavir) and every three months thereafter. Routine 
biochemistry tests included serum creatinine. Steady state pharmacokinetics of indinavir 
(400 mg/m2 every 8 hours} were determined at week 4 after the inHiation of indinavir. This 
procedure was repeated when a dosage adjustment of indinavir was necessary to 
normalize the area under the curve-concentration (AUC) curve to adult values (20 mg/l *h, 
range 10-30 mg/L'h). (17) 
Demographic parameters, indinavir start date and stop date, indinavir dosing 
regimens, urinary tract symptoms, concomitant treatment, HIV-1 RNA, and CD4+ T-cell 
counts were recorded on structured data collection forms. Nephrolithiasis related symptoms 
included renal colic, flank pain, the passing of a stone, and gross hematuria. 
Additional laboratory tests were performed in children included in one center, from 
March 1999 onwards. Urinary pH was measured by means of calibrated electrode 
technique. Urine albumin and creatinine were measured to calculate the albumin to 
creatinine ratio as an indicator of renal damage. Urine light microscopy for presence of 
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indinavir crystals under a polarized filter was perfomed and urine cultures were performed in 
patients with a positive dipstick test or microscopy for bacteria. 
Sterile leukocyturia is considered to be caused by damage of renal tubuli. 
Therefore we considered this the principal endpoint this study. Leukocyturia was defined by 
the presence of a dipstick test with more than 75 cells/J.LL. Persistent sterile leukocyturia was 
present when leukocyturia with negative urine cultures was found at at least two 
consecutive visits, after the start of indinavir. In children with more than 150 leukocyteS/J.LLat 
at least two visits and a negative urine culture a renal ultrasound was performed. 
Analysis 
Cumulative incidences of persistent leukocyturia and serum creatinine more than 50% 
above age and sex specific normal values (23) were calculated with Kaplan-Meier analysis. 
The influences of pharmacokinetic factors were determined with the logrank test. The 
relation between the occurrence of persistent leukocyturia and an increased creatinine 
and between persistent leukocyturia and nephrolithiasis related symptoms were analyzed 
using the Fisher's exact test. In order to describe urine abnormailties associated with 
leukocyturia, we performed a cross-sectional analysis 12 weeks after the start of the 
measurement of the additional urinalysis. 
Results 
Thirly HIV-1-infected children were enrolled between April 1997 and April 2000. Fifteen 
children were available for additional analyses between March 1999 and March 2001. The 
other 15 children were not available for additional analyses for various reasons: enrollment in 
a center different from that where the additional analyses were performed (n=8), 
discontinuation of indinavir (n=6: 5 children because of virological failure and one because 
of nephrotoxicity) and age> 18 years (n=l). Baseline characteristics of the children are 
presented in Table 1. 
A good clinical, immunologic and virologic response was observed in all children 
who were treated with indinavir. Most of the children needed 600 mg/m2 of indinavir every 8 
hours to obtain an AUC of indinavir between 10 and 30 mg/L"'h. The median (IQR) AUC was 
19 (14-28) mg/L'h with a median {IQR) peak level of 9 (6-12) mg/L. Baseline and follow-up 
serum creatinine and urinalysis data were available from 30 children in whom indinavir was 
initiated. 
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Table 1 Patient Characteristics 
Characteristic 
Age(y) 
Male 
Body mass index (kg/m2] 
HIV-1 RNA (copies/ml) 
CD4 cells (ceiiS/J.LL) 
lndinavir regimen 400 mg/m2 tid 
500 mg/m2 tid 
600 mg/m2 tid 
~700 mg/m2 tid 
500/l 00 mg/m2 bid* 
Serum creatinine (J.Lmoi/L) 
Urine leukocytes> 75 cells/J.LL 
erythrocytes> 60 cells/fll 
"'indinavir/ritonavir; IQR interquartile range 
Median (range) 
N (%) 
Median [IQR) 
Median (IQR) 
Median (IQR) 
N (%) 
N [%) 
N (%) 
N (%) 
N (%) 
Median (IQR) 
N (%) 
5.6 
15 
16 
127.500 
610 
8 
11 
7 
4 
24 
0 
(2.4-9.9) 
(50) 
(14-17) 
(18.400-661.000) 
(230-880) 
(27) 
(37) 
(23) 
(13) 
(19-38) 
10) 
The cumulative incidence of persistent sterile leukocyturia (2:2 times 275 cells/microliter) 
Eleven out of thirty (37%) children developed persistent sterile leukocyturia {tvvo times or 
more 275 leukocyteS/J.tl). The cumulative incidence after 96 weeks was 53% with a mean 
time to leukocyturia of 74 weeks {95% confidence ·Interval: 61-87 weeks) of combination 
therapy containing indinavir (Figure lA). 
The influence of age and sex on the cumulative incidence of persistent sterile 
leukocyturia was determined. Children were divided into tvvo groups: younger and older 
than the median age of 5.6 years. Rgure 1 B shows that children younger than 5.6 years had 
a significantly higher cumulative incidence of persistent sterile leukocyturia than children 
older than 5.6 years (p=0.05]. Sex did not influence the incidence of leukocyturia. 
The cumulative incidence of a change of serum creatinine more than 50% above age and 
sex specific normal values 
Six (20%) of 30 children had a change of serum creatinine more than 50% above age and 
sex spedfic normal values. The cumulative incidence after 96 weeks was 33% with a mean 
time to creatinine increase of 90 weeks (95% confidence interval: 82-98 weeks) of 
combination therapy containing indinavir. (Figure 1 C) 
Relation between persistent sterile leukocyturia and an increase of serum creatinine 
One (5%) of the 19 children without persistent sterile Jeukocyturia had a change in serum 
creatinine more than 50% above age and sex specific normal values, whereas 5 (45%) of 11 
children with persistent sterile leukocyturia had a change in serum creatinine more than 50% 
above age and sex specific normal values {p=0.02]. The median (JQR) time to a creatinine 
increase among paf1ents with leukocyturia was 24 (0-48) weeks. 
86 
lndJnovJr nephrotoxicity Jn children 
Figure 1A Figure 18 
,,0 ,,0 
·' ·' 
I ·' I ,6 1)"0.05 
~ .• 
·' * ·' 
-~ ~ ~ 
i ~ "----' 
' 
' " " ·' ' 
, i-------- -+---- .... 
~ ~ 
----+-----· 
5 0,0 t 0.0 
" " " " " 
n 
" 
00 
"' " " " " 
00 
" " 
, 
"' 
Wooks ~fler start of IDV Waaks oftar smrt of IDV 
Figure 1C Figure 10 
1,0 1,0 
·' ·' 
" t i 
" ·' ' ·' 
" 
~ 
:~ i ~ A i ·' I 
·' " 
> , 
' 
' ' " "5 0.0 6 0,0 
" " "' " " " " 
00 100 
" " " " 
00 
" " 
, 
"' 
Wooks after start of IDV Wooks oftor ~tart of IDV 
Figure 1E Figure 1A: Cumulative incidence of persistent 
1,0 sterile leukocyturia 
Figure 1 S: Cumulative incidence of persistent 
sterile leukocyturia in children < 5.6 
·' years {dotted line) and in children 
-~ >5_6 years 
~ Figure 1C: Cumulative incidence of children j ·' ]r'0.Q1 with creatinine increase > 50% 
.• above age and sex specific normal 
* 
A values -~ t,; 
----' 
Figure 1 D: Cumulative incidence of persistent 
., 
sterile leukocyturio in children with 
" 
" 
-' ~--- -+---- +---- .... AUC of indinavir S:19 (dotted line) 
' ~ I t----' or> 19 (mg/L *h) 0,0 Figure 1 E: Cumulative incidence of persistent 
" " "' " " 
n 
" " 
100 sterile leukocyturio in children with 
Cmox :::::;12 (dotted line) or >12 
Wool<$ oftor start of IDV [mg/L) 
87 
Chapter 2.6 
Relation between persistent sterile leukocyturia and pharmacokinetic parameters 
Children with an AUCo. of indinavir higher than the median AUC of 19 (mg/L'h) had a 
significantly higher cumulative incidence of persistent sterile leukocyturia compared with 
those with an AUC ,:19 (mg/L'h) (p=0.05). After 96 weeks 8 (67%) of the 12 children with an 
AUC>l9 (mg/L'h) had persistent sterile leukocyturia. in contrast with 2 (13%) of 16 of the 
children with an AUC<19 {mg/L *h). The cumulative incidences were 79% and 19%, 
respectively after 96 weeks. (Figure 1 D) Having a maximum concentration (Cmax) of 
indinavir of 12 (mg/L) was significantly {p=0.02) associated with the presence of persistent 
sterile leukocyturia. (Figure I E). Five of the 21 (24%) children with a Cmax <12 (mg/L) had 
persistent sterile leukocyturia, whereas in 5 of 7 (71 %) children with a Cmax 212 (mg!L) this 
abnormality was observed. No relation was found between Cmin and the presence of 
persistent sterile Jeukocyturia, between age and AUC of indinavir and betvveen age and 
Cmax. 
Relation between persistent sterile leukocyturia and nephrofithiasis related symptoms 
Four {19%) of the 21 children without persistent sterile leukocyturia presented with urological 
symptoms, whereas 7 {78%) of 9 children with persistent sterile leukocyturia hod symptoms 
during the follow-up time (p=0.003). 
Hematuria 
Persistent hematuria {22x 260 cells/!-ll) was not detected in any child. 
In addition to the standard analyses performed in the 30 children, urine creatinine, urine 
albumin, quantitative pH measurements and crystalluria were analysed in 15 children. At the 
time of the start of the additional analyses, these children were using indinavir for a median 
of 75 weeks (interquartile range (lOR): 8-77 weeks). 
A cross-sectional analysis at week 12 after the start of the initiation of additional 
analysis showed that in these children (median time on indinavir (lOR): 87 (20-89) weeks) 33% 
of the patients had a change of serum creatinine more than 50% above age and sex 
specific normal values. In four of these 5 patients an albumin/creatinine ratio 2 3.5 g/mmol 
was observed. In two of these patients indinavir was discontinued because of nephrolithiasis 
on renal ultrasound. 
Fourty-three% of the patients had leukocyturia, 21% had microscopic hematuria, 
54% had crystalluria and 29% had an albumin/creatinine ratio 2 3.5 g/mmol. Urine cultures 
were all negative for bacteria. 
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Figure 2 Urinary abnormalities associated with leukocyturia (cross-
sectional week 12) in 15 children included in cohort B 
In Figure 2 urine abnormalities associated with leukocyturia at week 12 are presented. An 
increase of serum creatinine levels of more than 50% above age and sex specific normal 
values, an albumin/creatinine ratio ;?:: 3.5 g/mmol and hematuria were observed more 
frequently in children with leukocyturia. The median (lQR] albumin/creatinine ratio of 
children with and without persistent leukocyturia was 0.7 (0.6-2.5) and 2.8 (1.2-1 0.6) 
respectively. In contrast indinavir crystalluria was not detected more frequently in children 
with leukocyturia. The presence of symptoms, urinary pH>5, and the presence of crystalluria 
were not associated with persistent sterile leukocyturia. 
Symptoms of nephrotoxicity after discontinuation of indinavir because of nephrotoxicity 
In 4of the 15 children indinavir was discontinued because of nephrotoxic symptoms [n=2} or 
nephrolithiasis on renal ultrasound (n=2}. In these children serum creatinine (J..lmOI/1) levels 
decreased from a median (lQR) of 54 (49-75) at the last observation during the use of 
indinavir to 39 [28-42) 12 weeks after discontinuation of indinavir (p=0.07). The 
albumin/creatinine ratio decreased from 16 (8-44) to 0.7 (0.4-2.1) g/mmol (p=0.07). 
Leukocyturia disappeared within 3 months after the discontinuation of indinavir. Figure 3 
shows the serum creatinine levels and the albumin/creatinine ratios of the four children that 
discontinued indinavir because of nephrotoxicity. Urine albumin/creatinine ratio increases 
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during the use of indinovir and afer discontinuation of indinavir in 4 
children. 
preceded serum creatinine increases and may therefore be an early marker of renal 
impairment. 
In three other children that discontinued indinavir for other reasons (virologic failure, 
n:::::2, and because of the poor taste of indinavir, n=l) serum creatinine levels did not 
decrease, whereas the albumin/creatinine ratio showed a decrease from 3.94 (0.51-11.2} to 
0 g/mmol (p~O.I 0). 
Discussion 
We here present the first study to monitor nephrotoxicity in HIV-1 infected children with a 
prolonged treatment with indinavir. We hypothesized that indinavir related nephrotoxicity 
might occur more frequently in children than in adults due to the higher risk for cellular 
damage to the still developing renal system. 
In our study a cumulative incidence of persistent sterile leukocyturia (;:::2x ;::: 75 
celiS/lJ.L) of 53% was observed after 96 weeks. This persistent sterile leukocyturia was 
frequently accompanied by a mild increase of the urine albumin/creatinine ratio and 
microscopic hematuria. The cumulative incidence of an increase in serum creatinine levels 
more than 50% above normal was 35% after 96 weeks. Children with persistent sterile 
leukocyturia more frequently hod an increase of serum creatinine levels of more than 50% 
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above normal {p=0.02). This suggests that persistent sterile leukocyturia is an early indication 
for the development of renal damage. 
Recently Gagnon et al. found a significant reduction in the renal function of 3 
adults with recurrent severe leukocyturia. Our data confirm the observations in adults of 
Gagnon et al., that reduction of renal function is associated with recurrent severe 
leukocyturia. but not with isolated hematuria or crystalluria. {21) Renal damage resulting in 
leukocyturia and an increased creatinine may be a result of irritation of the tubular 
epithelium. This is supported by the pathologic finding of tubulointerstitial nephritis in patients 
on therapy with indinavir. (4, 24, 25) 
The prevalence of persistent leukocyturia in adults screened on the same 
nephrotoxicity monitoring program was 22% (personal communication), which is 
substantially lower than we observed in children. One might hypothesize that indinavir 
crystals more easily congest in the small tubuli of young children which may lead to a higher 
incidence of nephrolithiasis. The more frequent presence of persistent sterile leukocyturia in 
younger children confirms this observation. However. nephrolithiasis was only diagnosed by 
renal ultrasound in two asymptomatic children with persistent sterile leukocyturia (26]. Renal 
ultrasounds of the other children with persistent leukocyturia showed no nephrolithiasis. Since 
it is well documented that the occurrence of indinavir nephrolithiasis increases with a poor 
hydration status and high environmental temperatures (27), the Dutch climate with relatively 
moderate temperatures may contribute to a lower incidence of nephrolithiasis in our 
patients. Persistent leukocyturia might have been prevented by an increased fluid intake. 
Since it is more difficult to achieve a large fluid intake in young children, a relatively small 
fluid intake in younger children may be the cause of the more frequent occurrence of 
persistent sterile leukocyturia in children younger than 5.6 years (cumulative incidence after 
96 weeks: 78%). 
We did not observe an association between indinavir crystalluria and leukocyturia. 
Since indinavir crystals can develop in the urine canister (28]. it is possible that crystalluria 
reflects the time lapse between urine collection and urinalysis. 
We observed a higher cumulative incidence of persistent leukocyturia in children 
with an AUC0-8 of indinavir of >19 {mg/L"'h) and in children with a peak level of indinavir 
higher than 12 (mg/L). This is in accordance with previous publications on the relation 
between levels of indinavir and urological complications in adults. An AUC of indinavir less 
than 20 (mg/L*h] is associated with virological failure (17). This observation complicates the 
treatment of HIV-1-infected children with indinavir: to achieve optimal virologic suppression 
an AUC higher than 20 (mg/L*h) is required, but to avoid persistent leukocyturia an AUC less 
than 19 [mg/L 'h) is needed. 
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These observations suggest that indinavir may be less useful in the treatment of HIV-
1-infected children. However. indinavir is a very potent protease inhibitor which in 
combination with nucleoside analogues gives an excellent long-term clinical, virologic and 
immunologic response in adults and in children. (15, 29, 30) We therefore propose to monitor 
nephrotoxicity very closely in children treated with indinavir and change therapy only in the 
case of overt signs of renal impairment. In this respect it is reassuring that the signs of renal 
impairment are reversible after discontinuation of indinavir. Serum creatinine levels 
decreased in the 4 children with signs of nephrotoxicity who discontinued indinavir. The urine 
albumin/creatinine ratio retumed to zero in all patients. It still remains unclear whether renal 
impairment is reversible in all stages of damage or that a chronic renal insufficiency will 
develop above a critical level of cellular damage. 
Conclusion 
Prolonged therapy with indinavir is associated with a high risk for persistent sterile 
leukocyturia in children especially in those younger than 5.6 years. The presence of sterile 
leukocyturia is associated with a significant increase in serum creatinine levels. A high AUC 
(>19 (mg/L'h)) and high peak levels (>12 (mg/L) of indinavir are associated with the 
occurrence of leukocyturia. Therapeutic drug monitoring of indinavir serum levels ·Is 
therefore essential to estimate the risk of nephrotoxicity. Children with risk factors for the 
development of nephrotoxicity such as on age <5.6 years, AUC of indinavir > 19 (mg/L *h), 
Cmax > 12 (mg/L)) should be monitored routinely by means of urinalysis and analys·ls of 
serum creatinine levels. 
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Chapter 3.1 
lipodystrophy and buffalo hump during 
treatment with HIV-protease inhibitors 
ChapterS.! 
Abstract 
Many patients who are using HIV-protease inhibitors, gradually develop generalized 
lipodystrophy. The observed syndrome can be defined by peripheral fat wasting, central 
fat accumulation, hyperlipidaemia and insulin resistance. Typically the subcutaneous fatty 
tissue disappears resulting in prominent zygomata, veins and muscles and thinning of 
extremities and buttocks. In contrast, patients may accumulate visceral fat resulting in 
abdominal complaints and abdominal distension. In addition to abdominal fat 
accumulation. there have been reports on the occurrence of a dorso-cervical fat pad, the 
so called buffalo hump. To date it ·Is not clear whether this effect is part of the central fat 
accumulation seen with lipodystrophy an whether it is associated with exposure to a HIV-
protease inhibitor. The pathogenesis and prognosis of lipodystrophy and buffalo hump are 
still unknown. Recognition is essential for adequate follow-up and possible treatment. In this 
paper we present three patients with typical signs of lipodystrophy with and without buffalo 
hump. 
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Introduction 
The introduction of the HIV-protease inhibitors, saquinavir, indinavir en ritonavir, preluded a 
new era for the treatment of HIV-infection. In combination with two reverse transcriptase 
inhibitors HIV-protease inhibitors can induce a strong reduction in plasma HlV-RNA and an 
increase in the number of CD4 cells {1 -5}. The new developments caused a reduction in 
AIDS-related morbidity and mortality (6-9). Knowledge regarding the long-term effectiveness 
and the adverse effects was. however, scanty. Since the registration of H!V-protease 
inhibitors in 1996 a number of new adverse effects have been observed, including HlV-
protease inhibitor associated diabetes mellitus and increased risk of haemorrhages for 
haemophiliacs (10, 11). 
Recently it was noted that many patients treated with HlV-protease inhibitors 
develop an abnormal fat distribution. referred to as lipodystrophy [12-14). The peripheral 
(subcutaneous] fat disappears leading to thinning of the extremities and buttocks and 
prominence of zygoma and vascular drawing without muscle weakness or significant 
weight loss. As a result the patient acquires a pseudo-cachexic appearance. On the other 
hand, central (visceral) fat accumulates as shown by Dual Energy X-ray Absorptiometry 
(DEXA) and Computer Tomography-scanning (CT) (13). The overall body fat mass hardly 
changes. In addition. a dorsa-cervical fat pad, or "buffalo hump" and hypertrophy of the 
breasts may occur (15, 16}. The "buffalo hump" might, however. be a separate 
phenomenon as it is observed among HlV-patients who are not using HlV-protease inhibitors 
(17). 
The dramatic body shape changes may have significant psychosocial 
consequences for patients and negatively affect adherence. With the below case histories 
and images we would like to draw attention to the clinical picture of this suspected adverse 
effect of H!V-protease inhibitors. 
Patient 1 
The first case concerned a 36-year old homosexual man, known with HIV-infection since 
1992 and known with AIDS based on Pneumocystis carini pneumonia. At the end of 1996, 
triple therapy with stavudine (D4T. 40 mg bid), didanosine (ddl, 400 mg qd) and ritonavir 
(600 mg bid} was instigated. During treatment, the patient complained of diarrhoea 
especially after food consumption. abdominal pain and occasionally abdominal distension, 
which was attributed to ddl intake. During a regular clinic visit approximately one year and 
a half after starting triple therapy, a recently developed change in appearance was noted, 
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comprising prominent zygoma, apparent muscle and vascularity on the extremities and 
abdomen due to generalised subcutaneous fat toss, in absence of overtly increased 
abdominal girth [figure 1). Based on these signs a diagnosis of lipodystrophy was made. 
Weight had decreased from 74 kg prior to starting triple therapy to 70 kg, of which 
the largest part happened during the past three months. During treatment serum 
triglycerides had been elevated [1.93 to 5.84 mmoi/L, normal 0.5-1.7 mmoi/L) with a 
maximum of 9.9 mmoi/L one month prior to diagnosing lipodystrophy. Serum cholesterol was 
slightly elevated [6.7 mmoi/L, normal < 6.5 mmoi/L}. During treatment serum glucose 
dropped regularly [3.4 mmoi/L), whereas plasma C-peptide was elevated [2.10 nmoi/L, 
normal 0.22-0.83 nmoi/L) at the last assessment, consistent with insulin resistance. There were 
no abnormalities of plasma cortisol, steroid hormone binding globulin, luteinizing hormone, 
follicle-stimulating hormone, estradiol, testosterone and free testosterone at the moment of 
establishing the diagnosis lipodystrophy. The CD4 cell count increased from 220/mm3 prior to 
therapy to 71 O/mm3 one year and a half later. The viral load at these moments was 66,000 
copies/mL and less than 80 copies/mL {NASBA-Nuclisens Organon] respectively. The patient 
did not experience any HIV-related events during treatment and treatment was not 
modified. Upon patient request treatment with nandrolone {200 mg intramusculariy/2 
weeks) was started in April 1998. By September 1998 weight had increased to 74.5 kg, but 
despite a slight improvement of the facial symptoms, prominent nasolabial folds persisted. 
Patient 2 
The second case concerned a 35-year old woman, known to be HIV-infected since 1987, 
who contracted HIV through heterosexual contact. HIV-infection progressed 
asymptomaf1cally and treatment with a combination of D4T [40 mg bid), 3TC [150 mg bid) 
and indinavir [800 mg tid] was started in January 1997. In April 1998, 15 months after the start 
of this treatment presence of a "buffalo hump" was noted during a routine clinic visit [Figure 
2). 
Thinned extremities, increased abdominal girth and prominent zygoma were 
observed as well on the basis of which the diagnosis lipodystrophy was made. In retrospect, 
signs started to develop approximately nine months after treatment instigof1on. We"1ght 
increased from 64.6 kg to 67.4 kg during treatment. The CD4 cell count increased from 
220/mm' to 370/mm' and plasma HIV-RNA declined from Ill ,000 copies/mL to below 500 
copies/ml {Amplicor HIV-1 monitor, Roche, Basel] within seven months. Plasma triglycerides 
appeared to be elevated [7.08 mmoi/L, normal < 2.0 mmoi/L) and serum HDL-cholesterol 
were reduced {0.74 mmoi/L normal > 1.1 mmoi/L]. Secondary diabetes mellitus was 
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diagnosed (glucose 15.1 mmoi/L). Cortisol levels had not been determined. During 
treatment HIV-related events were not encountered. One month after diagnosing 
lipodystrophy, indinavir was replaced by nevirapine, a non-nucleoside reverse transcriptase 
inhibitor, four months after which facial symptoms had improved but not disappeared. High 
serum triglycerides (3.87 mmoi/L) and low HDL persisted (1.35 mmoi/L) and high serum 
cholesterol was measured (6.7 mmoi/L normal ::;; 5.0 mmoi/L), whereas glucose 
concentrations had normalised. 
Figure 1 Prominent vascular drawing. typical for lipodystrophy during HIV-protease inhibitor treatment 
Figure 2 "Buffalo hump" during long-term use of an HIV-protease inhibitor 
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Patient 3 
The third case concerned a 59-year old woman with a known heterosexually transmitted 
HIV-infectian since 1989 which had progressed to AIDS because of wasting (CD4 cell count 
of less than 10 cells/mm3). She was treated with saquinavir (600 mg tid), AZT (100 mg tid] and 
ddl (125 mg bid) from May 1996 until April 1997 and subsequently with D4T (40 mg bid), 3TC 
(150 mg bid) and indinavir (800 mg tid). During the latter regimen plasma HIV-RNA dropped 
below 500 copies/ml (Amplicor HlV-1 monitor, Roche, Basel) and CD4 cells rose to a 
maximum of 90/mm3 • Weight initially increased from 64 kg to 66 kg, but subsequently 
dropped to 62 kg. Because of abdominal pain, diarrhoea, nausea and vomiting, urological 
symptoms coinciding with elevated plasma indinavir concentrations, indinavir dosing was 
reduced to 600 mg tid. In April 1998, "buffalo hump" with concomitant thinned extremities 
and a strongly increased abdominal girth were noted upon which the diagnosis 
lipodystrophy was made (figure 3). According to the patients' account these body shape 
changes already existed for some time. During triple therapy no abnormalities in serum 
glucose were observed. lndinavir was replaced by nevirapine but improvement of the 
lipodystrophy syndrome has not been recorded to date. 
Figure 3 Central adipos·rras during the use of an HIV-protease inhibitor. 
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Discussion 
Notwithstanding the uncertainties regarding the pathogenesis of lipodystrophy, there is little 
doubt about a causal relation with the current antiretroviral treatment, which typically 
contains an HIV-protease inhibitor. This is supported by the high prevalence of this otherwise 
rare condition among users of HIV-protease inhibitors, indinavir, saquinavir and ritonavir (14). 
Little is known about the risk of lipodystrophy during use of the newest HIV-protease inhibitor, 
nelfinavir. It is unclear as to whether lipodystrophy is caused by HIV-protease inhibitors 
directly or by an interaction with other factors. 
An association betvveen lipodystrophy and CD4 cell count, plasma HIV-RNA load, 
family history of diabetes mellitus, liver function disturbances, serum cortisol, testosteron, sex-
hormone binding globuline, prolactine, C3 and TN F-a was denied (12, 14, 15). Similarly to the 
above case histories, there was, however, an association with triglycerides (elevated), insulin 
(elevated), insulin resistance, C-peptide (elevated} and with the duration of HIV-protease 
inhibitor containing treatment (14). So far, it is not known if HIV-protease inhibitor 
discontinuation or replacement by a non-nucleoside analogue reverse transcriptase 
inhibitor has a favourable effect on the course of lipodystrophy. Some patients attempt to 
improve their appearance by using anabolic steroids, but the effect of such interventions is 
uncertain. Adequate treatment strategies for lipodystrophy remain to be determined. 
As hyperlipidemia, abdominal adipositas and diabetes mellitus predispose to 
premature development of cardiovascular diseases, patients with lipodystrophy probably 
are at an increased risk for these conditions (18, 19}. Treated HIV-infected patients with 
cardiovascular diseases have already been described (20-24). Assessment of serum lipids 
and glucose, therefore, is useful and may facilitate early intervention. It is possible and 
recommended to treat hyperlipidemia as is customary with other patients (25). Other 
complications, which might occur in association with lipodystrophy are osteoporosis and 
liversteatosis (26, 27). 
A possible explanation for lipodystrophy might be a recently recognised homology 
between HIV-protease and cytoplasmatic retinoic-acid binding protein type 1 (CRABP-1) en 
lipoprotein-receptor-related protein {LRP) (28]. HIV-protease inhibitors could potentially bind 
to these proteins and hence stimulate apoptosis of peripheral adipocytes and disturb 
triglyceride uptake leading to an excess of circulating triglycerides. Triglycerides are 
subsequently stored in central adipocytes (intra-abdominal, dorsa-cervical and mammae] 
leading to insulin resistance with secondary diabetes mellitus type 2. Another in vitro study, 
on the other hand, suggested that HIV-protease inhibitors do in fact stimulate adipogenesis 
(29). 
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The number of patients developing abnormalities of the lipid metabolism is 
unknown, but a small cross-sectional study observed a prevalence of 60% {13). In order to 
determine the incidence, prospective research is needed. Hopefully, research on the 
pathogenesis will soon provide more insight into prognosis and possible treatment strategies. 
Research on the natural course of lipodystrophy, with and without treatment modifications, 
and the risks of cardiovascular diseases, liver steatosis and osteoporosis is equally important. 
As children are now being treated with HIV-protease inhibitor combination therapy as well, 
potential disturbances in fat metabolism, which may manifest in a different way, should be 
traced. In order to study lipodystrophy and its complications more adequately objective 
assessment tools such as serum lipid spectrum, glucose concentrations, anthropometry and 
pictures should be applied. Since relevant baseline parameters regarding body 
composition are usually not available, prospective research is necessary. 
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Risk of lipodystrophy is highest after 
prolonged exposure to stavudine containing 
antiretroviral treatment. 
The ATHENA cohort. 
Chapter3.2 
Abstract 
Background: Epidemiological studies on the incidence rate of lipodystrophy among HIV-
infected patients treated with antiretroviral agents and on risk factors are scanty. 
Objective: To estimate the incidence of clinically evident npodystrophy and to identify risk 
factors within the Dutch HIV-infected patient population. 
Methods: All antiretroviral treatment naTve patients from the nation wide ATHENA cohort in 
the Netherlands were included upon starting antiretroviral treatment and followed until a 
clinical diagnosis of lipodystrophy, death or end of study period (December 2000]. 
Cumulative exposure to individual antiretroviral agents and their combinations, 
immunological and virological response and body mass index (BMI) were calculated. 
Results: 1952 patients were included of whom 261 developed lipodystrophy. The incidence 
rate of lipodystrophy was 6.2 per 1 00 person years with a four-year cumulative incidence of 
25%. Older age, female gender, higher BMJ and superior immunological and virological 
response were associated with an increased risk of npodystrophy. Patients who had used 
stavudine had the highest risk of lipodystrophy. lndinavir was identified as a risk factor as 
well, but appeared to play a minor role compared to stavudine. The lowest risk was 
observed with zidovudine/lamivudine regimens especially if combined with nevirapine. 
Conclusion Antiretroviral treatment including stavudine, treatment response, age and 
female gender are associated with an increased risk of lipodystrophy. To reduce the risk of 
lipodystrophy, regimens with zidovudine and lamivudine may be preferred. 
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Introduction 
The lipodystrophy syndrome is a widely recognized adverse effect of antiretroviral treatment 
(1-3), although consensus on an adequate definition of the syndrome has not been reached 
yet. It is generally accepted that the lipodystrophy syndrome comprises changes in body fat 
distribution consisting of subcutaneous fat loss with or without central fat accumulation (1, 4, 
5). These phenotypic changes are often accompanied by hyperlipidemia and disturbances 
in glucose metabolism (6). The patho-physiological processes underlying these signs and 
symptoms, however, are incompletely understood. 
Previous studies and case reports have attributed the lipodystrophy syndrome to 
HIV-protease inhibitors alone [in particular indinavir) (3, 4, 7-16), to nucleoside analogue 
reverse transcriptase inhibitors [stavudine in particular] [8, 16-19) and to immune 
reconstitution and metabolic stress relieve effects (19, 20]. Most of the studies, however, had 
important limitations because of either cross-sectional designs or small patient numbers not 
allowing adequate analysis of individual antiretroviral agents and specific combinations of 
antiretroviral agents. High prevalences (1 0-80%) {8, 12, 21, 22), potential cardio-vascular risks 
(23) and uncertainty about the reversibility of the syndrome prompt further research into the 
patho-physiological pathway and risk factors (24, 25). 
In the present study we examined risk factors for the lipodystrophy syndrome in the 
antiretroviral treatment na"ive subset of the ATHENA cohort, with particular emphasis on 
individual antiretroviral agents and combinations of antiretroviral agents. 
Patients and methods 
Setting 
The present study was performed in the ATHENA cohort of treated HIV-infected patients in 
the Netherlands. Patients were included in the ATHENA cohori if their treatment at least 
included an HIV-protease inhibitor, a non-nucleoside reverse transcriptase inhibitor or one of 
the newer nucleoside analogue reverse transcriptase inhibitors such as lamivudine and 
stavudine, and gave written informed consent. All22 Dutch hospitals providing treatment to 
HIV-infected patients participate in the ATHENA project which effectively started in May 
1998. At the time of this analysis 3377 patients had entered the ATHENA cohort representing 
about 75% of the estimated treated HIV-infected patient population in the Netherlands. 
Patients are followed at approximately three-monthly intervals (26). Data for the 
ATHENA project are collected from the medical records on standardised forms by trained 
research nurses and treating physicians. This is done retrospectively for the period prior to 
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consent and prospectively thereafter and continues to date. The resulting database 
contains information on gender, age, route of HIV-transmission, height and weight. Start and 
stop dates as well as dose frequency of any antiretroviral medication and prophylactic 
treatment against opportunistic infections, reasons for stopping such treatments, date of 
onset and resolution of HIV-related diseases, CD4-ceJJ counts, plasma HIV-1 RNA load and 
abnormal laboratory values are all recorded in a standardised manner. Information on 
adverse events in the ATHENA database comprises all events, which lead to a change in 
antiretroviral treatment and a number of pre-specified adverse events, among which 
lipodystrophy. No distinction, however, is made regarding the presence of fat accumulation 
and/or lipoatrophy. In addition, physicians are requested to report all remarkable clinical 
events and laboratory abnormalities. On site data monitoring takes place at regular 
intervals on 1 0% of completed study forms. In addition, central data verification through 
automated database consistency checks is performed, the resulting queries of which are 
resolved by local research nurses and physicians. For the present analysis, we used data, 
whkh had been monitored and verified before December 2000. The study period lasted 
from July 1, 1996 until the date of lost data extraction on December 15, 2000. 
Cohort definition 
For the purpose of our analysis, patients had to have used at least one of the newly 
available antiretroviral agents {ie. abacovir, adefovir, omprenavir, combivir, delavirdine, 
efovirenz. indinavir, lamivudine, lopinavir, loviride, nelfinovir, nevirapine, ritonavir, saquinavir 
and stovudine) after July 1, 1996. Cohort entry was defined as the date of first intake of one 
of these antiretrovirol agents. Patients who hod used any ontiretroviral agent before cohort 
entry or before July 1, 1996 were excluded in order to generate a cohort of ontiretroviral 
naTve patients and limit the effect of survival bias. In addition, we excluded all patients for 
whom treatment dates were missing, who had a diagnosis of lipodystrophy before cohort 
entry or for whom there was no follow-up available. Follow-up lasted from the date of 
cohort entry until the occurrence of lipodystrophy, last ATHENA update or death, whichever 
came first. 
Exposure definition 
As the main risk factor for lipodystrophy, we considered the type of antiretroviral agents 
used and cumulative exposure time to individual antiretroviral agents and combinations. 
Since lipodystrophy ·rs probably not an on/off phenomenon we assumed an induction plus 
latency period of more than six months and therefore accepted exposure to antiretroviral 
agents or regimens if the cumulative time on a certain agent or regimen exceeded six 
months. The analysis of antiretroviral treatment combinations was limited to all regimens 
110 
Risk factors for lipodystrophy 
including zidovudine and lamivudine {AZT/3TC-based regimens), stavudine and lamivudine 
(d4T/3TC-based regimens), zidovudine and didanosine (AZT/DDI-based regimens) or 
stavudine and didanosine (d4T/DDI-based regimens). 
In addition, we examined age, gender, calculated body mass index {kg/mZ), 
change in weight over the last six months, baseline CD4 cell count, change in CD4 cell 
count and HJV-1 RNA load as potential risk factors for lipodystrophy. 
Outcome 
Although there is no global consensus on the definifton of the lipodystrophy syndrome HIV-
specialized physicians are mostly able to easily recognize the more severe syndrome, which 
comprises overt loss of subcutaneous fat and/or central fat accumulation irrespective of 
metabolic changes. Therefore, we confined the outcome to a clinical diagnosis of 
lipodystrophy as made by the treating physician. No differentiation was made between the 
various forms of lipodystrophy, such as lipoatrophy, fat accumulation or a mixed syndrome. 
The date of onset of first symptoms as reported by the physicians was defined as the index 
date. 
Analysis 
Incidence rates of lipodystrophy were calculated by dividing the total number of cases of 
lipodystrophy by the total amount of follow-up time or by the total cumulative exposure 
time to specific antiretroviral regimens, irrespective of the agents used at diagnosis of 
lipodystrophy. Ninety-five percent confidence intervals (95%CI} were estimated assuming a 
normal distribution. The cumulative incidence of lipodystrophy was estimated by means of 
Kaplan-Meier survival analysis. In order to examine the effect of calendar time, we stratified 
for calendar time by calculating cumulative incidences per calendar year among persons 
commencing treatment in that calendar year. 
Factors associated with lipodystrophy were analyzed by means of univariate and 
multivariate Cox-regression analysis. In order to adjust for calendar time and differences 
between hospitals, all analyses were stratified for the period of cohort entry and hospital, 
the results of which were presented as pooled relative risks with 95%CI. The influence of 
partially retrospective data collection was examined. Factors that could alter the risk of 
lipodystrophy over time, such as exposure to individual antiretroviral agents or specific 
combinations, and change in body mass index, weight and CD4 cell counts were entered 
into the model as ftme dependent co-var·tates. 
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Results 
At the time of this analysis, the ATHENA population comprised 3377 eligible patients. For our 
study, we excluded 137 4 patients because of previous treatment with antiretroviral agents, 
47 patients because of missing treatment dates, two patients because of a diagnosis of 
lipodystrophy before cohort entry and two because of missing follow-up. The final study 
cohort consisted of 1952 patients, who entered the study cohort between July 1, 1996 and 
September 30. 2000. The median date of cohort entry was October, 28 1997 (Inter Quartile 
Range [IQR]: Feb 28, 1997-Nov 4, 1998). 
The baseline characteristics of the study cohort are summarized in table 1. In brief, 
15% was female, the median age was 37 years, the median weight was 70 kg, the median 
HIV-1 RNA load was 4.971og copies/ml, and the median CD4 cell count was 230 cells/mm3. 
The most frequently used antiretroviral treatment combination at cohort entry was 
zidovudine combined with lamivudine and indinavir. 
Table 1 Baseline characteristics of the study cohort comprising HIV-infected patients who started their 
first antiretroviral regimen (n=l952) 
Characteristic at cohort entry N (%) 
Age 37 [32-45] 
Female gender 293 [IS) 
CDC-C disease 502 [26] 
HIV-transmission [n=1806] Homosexual 1207 (67] 
Heterosexual 452 (25] 
Intra-venous drug use 103 (6) 
Other 44 (2) 
Weight (kg) [n=1748] 70 [63-79] 
BMI (kg/m2) [n=1712] 22 (20-25] 
CD4 baseline (cells/ml) [n=1478] 236 [90-380] 
Log HIV-1 RNA (copies/ml) [n=1708] 5.0 [4.5-5.4] 
PI upon cohort entry 1602 (82) 
First antiretroviral regimen AZT/3TC/IDV 330 (17) 
AZT /3TC/RTV 223 (11) 
AZT/3TC/N FV 203 (10) 
AZT/3TC/SQV 157 (8) 
d4T/3TC/IDV 112 (6) 
AZT/3TC/NVP 105 (5) 
d4T /3TC/SQV /RTV 89 (5) 
Other <I> 733 38 
ARV- antiretroviral medication; CDC-C- Centers for Disease Control and Prevention disease 
classification for HIV class C; PI= HIV-protease inhibitor 
AZT= zidovudine; 3TC= lamivudine; d4T= stavudine; IDV= indinavir; SQV= saquinavir; RTV= ritonavir; NFV= 
nelfinavir; SQV/RTV= SQV combined with RTV; NVP= nevirapine; NNRTI= non-nucleoside analogue 
reverse transcriptase inhibitor 
<I> Comprises 97 different antiretroviral treatments 
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Incidence rates of lipodystrophy 
The total follow-up time of the study cohort was 4208 person years with a median follow-up 
of 2.2 years (inter quartile range [lQR[: 1.3-3.2). During this period, 261 cases of lipodystrophy 
were identified. Other reasons for end of follow-up (right censoring) other than last data 
retrieval were death (n=84) and loss to follow-up {n=4). The incidence density of 
lipodystrophy accumulated to 6.2 per I 00 person years (95%Cl: 5.5-6.9) with a one-year 
cumulative incidence of 2.7% {95%CI: 1.9-3.5), a two-year cumulative incidence of 12.1% 
(95%Cl: 10.5-13.8) and a three-year cumulative incidence of 18.2% (95%Cl: 16.0-20.4). The 
four-year cumulative incidence of lipodystrophy was 24.8% (95%CI: 20.1-29.3} (Figure 1 }. 
Over calendar time, the one-year cumulative incidence of lipodystrophy increased 
from 1.7% (95%Cl: 0.0-4.5) in 1997 to 1.8% (95%Cl: 0.0-3.6) in 1998 and 2.5% (95%Cl: 0.0-5.3) in 
1999. The two-year cumulative incidence increased from 2.0% (95%CI: 0.4-3.7} for patients 
starting in 1996 to 11.4% (95%Cl: 8.2-14.6) for patients starting in 1997 and 11.7% (95%Cl: 7.3-
16.1) for patients starting in 1998. 
Lipodystrophy occurred most frequently among patients who had been exposed 
to stavudine and was least frequent among patients exposed to zidovudine irrespective of 
the other antiretroviral agents used during follow-up {Figure 2 upper panel}. A relatively high 
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Figure 1 The cumulative incidence of lipodystrophy in a population of newly treated HIV-infected 
patients {n=1952). 
Pole gray lines indicate the one-year. two-year. three-year and four-year cumulative 
incidence respectively. 
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incidence was observed among patients exposed to combinations with nevirapine or 
ritonavir. However. since treatment switches and clustering of antiretroviral treatment 
combinations are expected to have occurred, the results concerning individual drugs 
cannot be interpreted adequately in isolation. 
Patients used a median of iwo {IQR: 1-3) antiretroviral treatment combinations 
during follow-up. lndinavir combined with zidovudine and lamivudine was the most 
frequently used combination (Table 2). Comparing patients who had used stavudine-based 
regimens during follow-up with patients who had used zidovudine based regimens showed 
that the rates of lipodystrophy were consistently higher among patients who had been 
exposed to stavudine (Figure 21ower panel}. Among the HIV-protease inhibitors the highest 
incidence rate was observed for patients who had used the ritonavir saquinavir 
combination. 
Table 2 Cumulative exposure to antiretroviral treatment regimens during follow-up of a cohort of 
previously antiretroviral treatment na"ive patients (n=l952] 
Antiretroviral regimen AZT/3TC d4T/3TC AZT/DDI d4T/DDI 
based based based based 
Months of use of Months 13524 6790 672 1039 
IDV Months 4948 1934 231 368 
SQV Months 2344 715 354 121 
RTV Months 2373 913 41 258 
NFV Months 877 520 17 91 
SQV/RTV Months 1374 703 0 62 
SQV/NFV Months 680 877 22 90 
IDV/RTV Months 57 449 0 2 
IDV800/RTV100 Months 240 239 6 7 
IOV400/RTV400 Months 94 0 0 0 
NVP Months 142 120 0 0 
No with > 6 months exposure* N 804 439 39 58 
IDV N 281 127 14 22 
SQV N 151 46 20 5 
RTV N 131 52 2 14 
NFV N 107 58 0 4 
SQV/RTV N 40 62 2 4 
SQV/NFV N 4 34 0 0 
IDV/RTV N 16 20 1 0 
IDV800/RTV1 00 N 6 6 0 0 
IDV400/RTV400 N 10 10 0 0 
NVP N 63 39 6 7 
AZT- zidovudine; 3TC-Iomivudine; d4T- stavudine: DOl- didonosine; IDV- indinovir: SQV saquinovir; 
RTV= ritonavir; NFV= nelfinavir; SQV /RTV= SQV combined with RTV; IDV /RTV= IDV combined with RTV; 
IDV800/RTV100= IDV 800 mg combined with RTV 100 mg; IDV400/RTV400= iDV 400 mg comb"1ned with 
RTV 400 mg; NVP= neviropine 
The sum of individual agents may be higher than the total due to combined use or switching 
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Figure 2 Incidence rates and 95%-confidence intervals of lipodystrophy for individual antiretroviral 
agents (upper panel) and for combinations of antiretroviral agents (lower panel) among 
previously untreated antiretroviral treatment patients (n=l952) 
3TC= lamivudine: AZT= zidovudine: d4T= stavudine: DOl= didanosine; IDV= indinavir; 
IDV/RTV= IDV with RTV; IDV800/RTV100= IDV 800 mg with RTV 100 mg; IDV400/RTV400= IDV 
400 mg with RTV 400 mg; NFV= nelfinavir; NVP= nevirapine; RTV= ritonavir: SQV= saquinavir: 
SQV /RTV= SQV with RTV 
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Risk factors for lipodystrophy 
The risk of lipodystrophy increased with older age, female gender, higher body mass index, 
more weight loss and better immunological and virological response [Table 3). HlV CDC-
disease classification and route of HIV-transmission as well as starting with an H!V-protease 
inhibitor-sparing regimen were not associated with lipodystrophy. Also, no influence of 
retrospective data collection was observed. 
Considering individual antiretroviral agents irrespective of other antiretroviral agents 
used, the highest risk of lipodystrophy was observed with stavudine and indinavir, whereas 
the lowest risk was observed with zidovudine and nevirapine [Table 3}. After adjustment for 
all other associated factors, stavudine was the only agent with an increased risk for 
lipodystrophy, whereas nevirapine was associated with a significantly lower risk. 
Table 3 Risk factors for development of clinically evident lipodystrophy (n=261) among patients 
receiving antiretrovirol treatment (n=1952] 
Variable [cases for whom data ore 
available if less than 261] 
Age (per 10 years] 
Female gender 
BMI cohort entry> 22 kg/m2 [n=242] 
On dote of diagnosis 
BMI > 22 kg/m2 [n=196] 
Weight change¥ (kg) [n=107] 
CD4 ·Increase [n=172] 
<=20% 
20-100% 
>100% 
Log HIV-1 RNA (per c/ml lower) [n=222] 
HIV-1 RNA~ 500 c/ml 
per month exposure to• 
Value cases 
[n=261) 
univariate 
N 
Median 
40 
62 
155 
148 
-0.92 
29 
50 
93 
2.6 
209 
[%) 
lOR 
[34-46) 
(24) 
(64) 
RR 
1.3 
2.0 
1.6 
(76) 1.4 
[-2.6-1.5) 1.1 
(17) 
(29) 
(54) 
[1.9-2.6] 
(94) 
1 
1.0 
1.6 
1.2 
1.7 
[95%CI) 
(1.1-1.4) 
(1.5·2.7) 
(1.2-2.0) 
(1.02-2.0) 
(1.01-1.1) 
(0.6-1.6) 
(1.04-2.4) 
(0.99-1.3) 
(1.1-2.6) 
multivariate<!> 
RR 
1.3 
1.7 
2.4 
1.0 
1 
1.0 
1.6 
2.0 
[95%CI) 
(0.97-1.6) 
(0.9-3.3) 
(1.3-4.3) 
[0.96-1.1 I 
(0.5-2.1) 
[0.8-3.2) 
(0.6-6.4) 
regimens containing AZT 138 (53) 0.95 (0.94-0.97) 1.0 (0.97-1.1) 
regimens containing DOl 35 (13} 1.0 (0.98-1.03) 
regimenscontoiningd4T 180 (69) 1.1 (1.1-1.1) 1.1 {1.04-1.2) 
regimens containing 3TC 231 (85} 1.0 (0.99-1.02) 
regimens containing IDV 131 (50) 1.2 (1.01-1.03) 1.0 (0.96-1.03) 
regimens containing SQV 110 (42) 1.0 (0.99-1.02) 
regimens containing RTV 134 (51} 1.0 (0.98-1.01) 
regimens containing NFV 43 (16) 1.0 (0.98-1.04) 
regimens containing NVP 31 1121 0.95 (0.9-0.98) 0.8 (0.7-0.97) 
3TC lomivudine; AZT zidovudine; BMI~ body moss index (weight/height2); Cl- confidence interval; d4T= 
stovudine; DOl= didonosine; IDV= indinovir; NFV= nelfinavir; NVP= neviropine; PI= HIV-proteose inhibitor; 
RR= relative risk; RTV= ritonovir; SQV= saquinavir 
<l> Includes variables that were associated with lipodystrophy according to the univariate analysis (bold 
prints]. Excludes variables that were strongly associated with another variable in the analysis (BMl at 
index date, log HIV-1 RNA). 
¥ Change over six months preceding diagnosis of lipodystrophy 
• exposure groups ore not mutually exclusive as patients may have used multiple antiretroviral agents 
either sequentially or in combination 
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Antiretrovira/ treatment combinations 
Since the use of antiretroviral agents was expected to be clustered, we also considered 
commonly used antiretroviral treatment combinations as opposed to individual agents. This 
analysis showed a significantly higher risk of lipodystrophy for all combinations with stavudine 
(Table 4). The confidence intervals of those regimens did not overlap with the confidence 
intervals for combinations with zidovudine and lamivudine, implying statistically significant 
different risks of lipodystrophy. 
Table 4 Association between antiretrovirol treatment combinations and development of clinically 
evident lipodystrophy (n=261) among patients receiving ontiretroviral treatment (n=1952) 
> 6 months exposure vs. no exposure Per month exposure 
Used regimen<l> Cases Univariate multivariate.;. Cases Univariate multivariate.;. 
RR (95%CII RR (95%CII RR (95%CII RR (95%CII 
AlT/JTC combined wlfh 
IDV 45 0.8 (0.6-1.1 I 65 0.99 (0.98-1.011 
SQV 21 0.6 (OA-1.01 I 26 0.97 (0.9·1.00) 1.0 (0.95-1.1 1 
RTV 14 0.4 (0.3·0.7) 1.1 (0.3-3.81 30 0.96 (0.9-0.99) 1.0 (0.9-1.1 I 
NFV 7 0.5 (0.2-1.21 13 0.96 (0.9-1.021 
SQV/RTV 9 0.7 (0.3-1.31 14 0.96 (0.9-1.011 
SQV/NFV 0 1 
IDV/RTV 2 0.7 (0.2-2.71 11 0.96 (0.9-1.11 
IDV800/RTV1 00 1 3 1.03 (0.9-1.21 
IDV400/RTV400 1 7 0.9 (0.7-1.1 I 
NVP 3 0.2 (0.1-0.5}¥ Not assessable 13 0.9 (0.8-0.9) 0.7 (0.5-1.1 I 
D4T/3TC combined with 
IDV 47 3.0 (2.2-4.1) 3.0 (1.6-5.8) 61 1.1 (1.04-1.1) 1.1 (1.01-1.1) 
SQV 17 2.1 (1.3-3.5) 7.7 (2.0-29. 9) 20 1.04 (1.01·1.1) 1.05 (0.96-1.21 
RTV 13 1.2 (0.7-2.11\i 16 1.01 (0.98-1.11 
NFV 14 2.3 (1.3-4.1) 2.7 (0.9-9.2) 20 1.1 (1.02-1.1) 1.1 (0.98-1.21 
SQV/RTV 23 2.0 (1.3-3.2) 2.9 (1.3-6.7) 31 1.1 (1.02·1.1) 1.1 (1.03-1.2) 
SQV/NFV 9 1.5 (0.8-2.91 9 1.02 (0.97-1.1 I 
IDV/RTV 5 3.6 (1.3-9.5) 2.8 (0.2-32.61 6 1.1 (1.01-1.2) 1.1 (0.9-1.41 
IDV800/RTV1 00 1 3 
IDV400/RTV400 2 2.5 (0.6-10.61 3 1.1 (0.91-1.31 
NVP 13 1.5 (0.9-2.71 17 1.02 (0.98-1.1 I 
D4T/DDI combined with 
IDV 8 2.2 (1.1-4.5) 3.8 (1.1-13.6) 11 1.03 (0.99-1.1) 1.1 (0.99-1.11 
SQV 2 1.7 (0.4-7.01 3 1.1 (0.99-1.1 I 
RTV 5 1.7 (0.7-4.21 7 1.03 (0.99-1.1 I 
NFV 1 5 1.1 (0.96-1.21 
SQV/RTV 2 3.1 (0.8-12.81 6 1.1 (1.03-1.1 I 
SQV/NFV 1 1 
AZT= zidovudine; 3TC-lomivudine; d4T- stovudine; DDI= didonosine; IDV- indinovir; SQV- saquinovir; 
RTV= ritonovir; NFV= nelfinovir: SQV /RTV= SQV combined with RTV; IDV /RTV= IDV combined with RTV; 
IDV800/RTV100= lDV 800 mg combined with RTV 100 mg; 1DV400/RTV400= lDV 400 mg combined with 
RTV 400 mg; NVP= neviropine 
<I> exposure groups ore not mutually exclusive as patients may hove sequentially used multiple 
ontiretrovirol treatment combinations 
" 
statistically significant difference from IDV /d4T/3TC 
'¥ statistically significant difference from IDV /AZT/3TC 
+ adjusted for age, gender. bmi at baseline, change in weight over post six months, cd4 cell increase, 
HIV~ 1 RNA detectobility and treatment combinations that were associated with lipodystrophy in the 
univariate analysis (bold prints) 
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Distinguishing cumulative exposure to antiretroviral agents into mutually exclusive exposure 
groups allowed for the direct comparison of different agents and combinations. We hence 
compared, for example, patients who only used stavudine and never used zidovudine with 
patients who only used zidovudine but never used stavudine. This analysis showed that 
saquinavir, ritonavir and nevirapine tended to have a lower risk of lipodystrophy than 
indinavir (Table 5). 
TableS Association between mutually exclusive antiretroviral treatment combinations and 
development of clinically evident lipodystrophy (n=261) among previously ontiretrovirol 
treatment noTve patients (n=l952) 
> 6 months exposure vs. no 
exposure¢ cases 
Univariate 
RR (95%CII 
Exclusively used one of the following key components 
JOY 69 reference 
SQV 11 0.4 (0.2-0.8) 
RTV 13 0.4 (0.2-0.7) 
NFV 8 0.6 (0.3-1.41 
NVP 2 0.3 (0.1-1.11 
None 6 0.9 (0.4-2.0) 
Multiple or< 6 months use 152 0.8 (0.6-1.05) 
Exclusively used one of the following backbones 
AZT 74 reference 
D4T 128 3.8 (2.8-5.1) 
AZT and d4T 21 1.8 (1.04-3.1) 
Neither AZT nor d4T 5 1.6 (0.6-4.4) 
< 6 months use of AZT and or d4T 33 1.9 (1.3~2.8) 
Exclusively used one of the following regimens"¥ 
AZT/3TC/IDV 28 reference 
AZT/3TC/SQV 12 1.1 (0.5-2.1 I 
AZT/3TC/RlV 7 0.5 (0.2-1.2) 
AZT/3TC/NFV 1 0.3 (0.03-2.0) 
AZT/3TC/SQV/R1V 3 0.9 (0.3-3.21 
d4T/3TC/IDV 32 4.6 (2.7-7.71 
d4T/3TC/SQV 5 3.4 (1.3-9.0) 
d4T/3TC/RlV 4 1.4 (0.5-4.1) 
d4T/3TC/NFV 7 4.3 (1.7-11.31 
d4T/3TC/IDV400/R1Y400 1 3.9 (0.5-33.71 
d4T/3TC/SQV /NFV 7 2.6 (1.1-6.1 I 
d4T/3TC/SQV /RlV 7 2.2 (0.9-5.2) 
d4T/3TC/NVP 7 1.1 (0.3-4.7) 
multivariate.;. 
RR (95%CI) 
reference 
1.0 (0.2-4.6) 
0.3 (0.1-1.4) 
0.4 (0.1-2.2) 
0.6 
reference 
5.4 
2.8 
1.6 
1.7 
(0.3-1.041 
(2.6-11.5) 
(0.7-10.71 
(0.2-13.71 
(0.6-4.7) 
reference 
1.4 (0.2-8.01 
0.6 (0.1-5.41 
4.3 (1.3-13.81 
90.2 (3.2-2527.1 I 
1.2 (0.1-11.8) 
8.1 (1.2-54.9) 
2.7 (0.7-10.91 
3.6 (0.7-17.41 
d4T/DDI/IDV 9 2.3 (1.1-5.0) 1.8 (0.4-8.7) 
other¥ 32 1.7 [1.03-2.91 2.1 (0.6-7.4) 
AZT- zidovudine; 3TC lomivudine; d4T- stovudine; 001- didonoslne; IOV ind1novir, SQV saquinovir; 
RTV= ritonovir; NFV= nelfinovir; SQV/RTV= SQV combined with RTV; IOV/RTV= IDV combined with RTV; 
IDV800/RTV100= IDV 800 mg combined with RTV 100 mg; JDV400/RTV400= IDV 400 mg combined with 
RTV 400 mg: NVP= nevirapine 
q, Patients contribute only to one category of the key components and backbones during follow-up 
+ Adjusted for age, gender, bmi at baseline, change in weight over past six months, cd4 cell increase 
and HIV-1 RNA detectability, key components and backbone 
'¥ There were insufficient data to analyse combinations of AZT/3TC with IDV/RTV, SQV/NFV and NVP, 
d4T/3TC with IOV800/RTV100 and d4T/ddl combinations with SQV and RTV. These regimens ore not 
included in the 'other' group. The 'other' group contains patients who switched regimens, who used 
regimens not included in this list or used regimens for less than 6 months. Multivariate results ore not 
adjusted for keycomponent and backbone. 
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Comparing patients who had used stavudine for more than six months with patients who 
had only used zidovudine showed that the risk was highest after exposure to stavudine. 
Direct comparison of treatment combinations showed that compared to regimens 
containing AZT, 3TC and IDV, regimens containing d4T and 3TC had the highest risk of 
lipodystrophy. In the multivariate analysis, the observed risk was especially high for d4T, 3TC 
combinations with saquinavir, nelfinavir and indinavir, but confidence intervals were 
extreemly high due to the low number of patients. 
Discussion 
In this population based prospective cohort study of incident users of antiretroviral 
treatment. we observed an incidence rate of clinically evident lipodystrophy of 6.2 per 1 00 
person years of treatment. Within four years after starting treatment comprising a wide 
range of regimens, 25% of patients had developed lipodystrophy. 
The risk of lipodystrophy increased with older age, female gender, high body mass 
index and good immunological and virological response. The results showed a clear 
association between the prolonged use of any combination with stavudine and 
lipodystrophy. The lowest risk of lipodystrophy was observed with zidovudine and lamivudine 
containing regimens, especially if combined with nevirapine. lndinavir appeared to play a 
minor role compared to stovudine. 
Only few cohort studies on incident users of antiretroviral treatment and 
lipodystrophy have been reported so far. Studies with prevalent cases hove been reported 
but these are highly susceptible to bias. Prevalences of lipodystrophy have been reported 
but vary widely from 49% to 83% {8, 12, 21, 22, 27) since time on treatment is not always 
taken into account. Figures on incidence rates of lipodystrophy are scanty (7, 17). Martinez 
et-al reported an incidence rate of 11.7 per 100 person years (7), whereas Van der Yolk et-
al reported a cumulative incidence of 17% over two years (17). Differences may be 
explained by differences in patient populations and assessment of lipodystrophy. 
Despite the inconsistencies between studies, other studies also reported that the risk 
of lipodystrophy increased with older age and was highest in women [7, 8, 19, 27]. In 
addition, most studies agree on a role of antiretroviral treatment in the development of 
lipodystrophy {7, 8, 18, 19, 27), but not necessarily on the type of antiretroviral agents 
involved. Many studies reported on individual antiretroviral agents without accounting for 
the potential risk of clustering between certain agents (7, 18}. The sample size of our study 
was large enough to extensively analyse both individual antiretroviral cgents and 
antiretroviral treatment combinations. We there-rare believe our results convincingly show 
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that among the antiretroviral agents studied, stavudine is the most important independent 
risk factor for lipodystrophy. lndinavir also acted as an independent risk factor, but the 
effect was less pronounced than with stovudine. The fact that the results were adjusted for 
immunological and virological response argues against speculations that lipodystrophy is a 
pure immune recovery effect or metabolic stress relieve effect, although interaction 
between these effects and treatment effects cannot be excluded (19). The association 
between weight loss in the last six months and lipodystrophy might reflect increased 
recognition of lipodystrophy among patients with weight Joss. 
An important limitation of our study is the lock of objective measurements of 
lipodystrophy and discrimination between lipoatrophy and fat accumulation, and the 
absence of on accepted definition of the lipodystrophy syndrome. The recently presented 
validated algorithm, including results from DEXA scans, anthropometric measurements and 
laboratory assessments (28) could not be applied to the ATHENA cohort. It has, however, 
been reported previously that there is 98% concordance between patient self-report and 
physical examination (21). The amount of misclassification of lipodystrophy may therefore 
have been small. Furthermore, we have no reason to bel"leve that misclossification of the 
outcome, if any, was differential especially since we stratified for hospital and calendar 
time. Importantly, our results are consistent with other studies, which did identify on 
association between the use of stavudine and lipo-atrophy and the use of indinavir and fat-
accumulation (16, 18, 19, 27), even though we did not differentiate between various types 
of lipodystrophy. Finally, our data produced similar relative risks for gender and age as 
previous studies, suggesting little influence of our case definition on the actual associations. 
In 1996 the cumulative incidence of lipodystrophy was lower than later in calendar 
time, which probably is the result of underreporting or under-recognition bias shortly after 
the introduction of the new ontiretroviral agents when lipodystrophy was not even known. 
Subsequent awareness may have led to delayed reporting of early cases of lipodystrophy. 
This might hove caused an underestimation of the actual incidence rate of lipodystrophy. 
Since we did anticipate a calendar time effect we dealt with this in the analyses of risk 
factors by stratification for calendar time. In doing so, the analyses effectively compared 
cases of lipodystrophy with non-cases who started the first antiretrovirol regimen within a 
three month window of the case and had the same length of follow-up. Thus calendar time 
is unlikely to hove disturbed our results. 
In conclusion, in this previously antiretroviral treatment naTve patient population 
clinically evident lipodystrophy occurred at a rate of 6.2 cases per 1 000 years of follow-up. 
Aport from older age, female gender, high body mass index, and good immunological and 
virological response, exposure to stavudine and to a lesser extent exposure to indinovir were 
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independent risk factors for lipodystrophy. Patients exposed to zidovudine and lamivudine-
containing regimens, combined with nevirapine in particular, had the lowest risk of 
lipodystrophy. The risk of developing lipodystrophy with the use of other regimens including 
other non-nucleoside reverse transcriptase inhibitors, such as efavirenz, boosted HIV 
protease inhibitor combinations, regimens solely composed of nucleoside analogues, or 
nucleoside-sparing regimens remains to be determined. 
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Substituting nevirapine for HIV-protease inhibitors 
Short report 
Many patients fail Highly Active Anti-Retroviral Therapy (HAART) because of poor 
compliance, which is a consequence of the complexity of the dosing regimens, the large 
volumes of pills to be taken and the side effects associated with the use of protease 
inhibitors {Pis}. The most commonly reported side effects of Pis include nausea, vomiting, 
diarrhoea, urological complaints and lipodystrophy {1, 2). Several studies have shown that 
'step down- strategies' as an easier maintenance therapy fail to preserve viral suppression 
(3-5). 
Nevirapine {NVP) has demonstrated anti-HIV-1 efficacy with a less complex dosing 
regimen and a more favourable safety profile than Pis in antiretroviral therapy naTve 
patients (6]. Rash seems the most important side effect. In view of its favourable efficacy 
and safety profile, substituting NVP for PI might be a good alternative as maintenance 
therapy after PI induction treatment. 
To investigate this strategy, we retrospectively reviewed data on all patients whose 
PI containing regimen was switched to a NVP containing regimen because of PI-intolerance 
(reasons listed in Table 1) between July 1997 and September 1998. All patients had HlV-1 
RNA levels below the detection limit {<500 copies/ml, Roche Amplicor) at the time of 
switch. Of 300 patients on HAART in our institute, 41 (14%) patients {29 men and 12 women] 
had changed therapy. Their mean age was 41 ± 10 years and of them twelve (29%) had 
CDC C3 disease classification. As part of their first HAART-regimen, 18 patients used indinavir, 
13 ritonavir, seven a ritonavir-saquinavir combination and three used saquinavir. Viral loads 
had decreased from a mean of 4.97±0.52 log copies/ml to undetectable levels within a 
mean of 17± 17 weeks (range 3-91) after start of HAART. The average C04 cell count had 
increased by approximately 200 cells/ml at the time of switch. Before changing to NVP, 
eight patients tried another Pl. 
Table 1 shows reasons for PI discontinuation, treatment duration and subsequent 
virological, immunological and clinical outcomes. Following the switch to NVP, gastro-
intestinal complaints improved considerably in 22 out of 26 patients. Although lipodystrophy 
improved in some patients according to the patient's self report, body appearance 
remained abnormal in all six during a median follow-up period of 24 (range 15-45) weeks. 
Urological complaints subsided. Glucose regulation improved in the two hyperglycaemic 
patients. Four patients [1 0%} developed a rash on NVP treatment. Two patients discontinued 
NVP within four weeks because of side effects, one because of rash and one because of 
persistent nausea and vomiting. HIV-1 RNA remained undetectable in all patients who 
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continued NVP treatment but two, who experienced an increase to 1340 copies/ml and 
18700 copies/ml after 56 and 15 weeks of NVP treatment, respectively. 
Tobie 1 Reasons for stopping PI and effects of changing to NVP 
Assessment N-41 End of PI treatment On NVP treatment 
Main reason for switch 
Gastro-intestinal complaints N [%) 26 [63) 4 [10) 
Lipodystrophy N [%) 6 [15) 6 [15) 
Urological complaints N [%) 2 [5) 0 [0) 
Hyperglycaemia N [%) 2 [5) 2 [5) 
Patient request N [%) 3 [7) 
Unknown N [%) 2 [5) 
Weeks of therapy Mean (SO) 49 [31) 36 [19) 
Median (range) 47 [5-102) 30 [8--,37) 
CD4 count (cells/ml) N 32 38 
Mean {SO) 439 [227) 518 [265)# 
Median {range) 435 [90-900) 440 (70-1230) 
HIV·1 RNA (copies/ml) N 41 39 
N<500 % 41 100 37 95 
# Wilcoxon signed ranks test for paired samples {CD4 count at end of PI treatment versus last CD4 cell 
count during NVP treatment, n=29): p<O.OOl 
In this case-study, we show that switching from a PI to a NVP containing anti-HIV-1 regimen 
dimin·1shed most s·rde effects w·rthout loss of viral suppression in 37 of 39 patients during a 
median follow-up period of 30 weeks {range 8-87). We suggest that NVP in combination with 
two NRTis has potential as a long-term maintenance treatment after successful induction 
therapy with a PI containing regimen. The favourable risk profile and the less complex 
treatment regimen should enhance adherence and promote long-term effecfrveness, 
which is an emerging issue in anti-HIV-1 treatment to date. It seems worthwhile to further 
investigate the role of NVP as part of a maintenance therapy in a controlled setting and 
with ultra-sensitive HIV-1 RNA measurement techniques. 
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low risk of treatment failure one year after 
substituting nevirapine for human 
immunodeficiency virus (HIV)-protease inhibitors 
among HIV-infected patients with viral 
suppression. 
The ATHENA cohort. 
Chapter4.2 
Abstract 
Information on the risk of treatment failure after switching from human immunodeficiency 
virus (HIV)-protease inhibitors [PI) to nevirapine (NVP) while having successful viral 
suppression is scanty. We compared the one-year risk of treatment failure betvveen patients 
switching from the first PI-containing antiretroviral regimen to NVP (NVP-groupJ and patients 
switching to second-line PI (PI-group) in the ATHENA-cohort (n=2470) while HIV-1 RNA was 
<500 copies/ml. Treatment failure was defined as HIV-1 RNA tvvice >500 or once > 10,000 
copies/ml or treatment discontinuation for any reason. 
There were 446 eligible patients, 125 and 321 patients in the NVP-group and PI-group 
respectively. Adjusted for other risk factors, the NVP-group had a five-fold (95%CI:O.I-0.4) 
lower risk of treatment failure than the PI-group, predominantly because of lower 
discontinuation rates. In presence of successful viral suppression switching to NVP as 
opposed to second-line Pis was superior with regarding the likelihood of maintaining the 
same treatment. 
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Introduction 
Treatment of human immunodeficiency virus (HIV)-1 infection with Highly Active 
Antiretroviral Therapy (HAART) containing an HIV-protease inhibitor (PI) may be troubled by 
large quantities of capsules, stringent intake schedules, food restrictions, drug-drug 
interactions and numerous adverse drug reactions (1, 2) . These factors may interfere with 
long-term adherence and therefore lead to premature viral rebound and the selection of 
resistant viral variants. Various strategies for maintenance treatment have proven to be 
ineffective in a number of studies [3-5) . Moreover, the benefits of switching between Pis are 
limited, possibly due to the presence of class specific problems (6) . 
Nevirapine (NVP) is a non-nucleoside analogue reverse transcriptase inhibitor 
(NNRTI) that has demonstrated potent anti-HIV efficacy in combination with two nucleoside 
analogue reverse transcriptase inhibitors (NRTis] {7, 8] . Combination therapy of NVP with 
two NRTis is relatively easy and has shown few adverse effects, although potentially serious 
rashes and liver toxicity have been reported (8) . 
Patients who have been treated successfully with a PI-containing HAART regimen 
may benefit from the less complex treatment regimen with NVP, which should help improve 
long-term adherence, and thereby the chance of sustained antiviral efficacy. This 
hypothesis has been subject of a number of studies so far, most of which lacked a 
comparison arm, studied small patient numbers or had a short follow-up period (9-12) . As a 
consequence the information regarding the effectiveness and safety of NVP for patients 
with viral suppression is insufficient so far. 
In order to gain more insight into the consequences of substituting NVP for Pis 
during viral suppression under everyday circumstances, we conducted an observational 
cohort analysis within the Dutch nationwide ATHENA cohort of patients treated for their HIV-
infection. In this cohort with detailed data on HIV-treatment and treatment outcome we 
determined the one-year risk of treatment failure after switching from Pis to NVP as opposed 
to switching to a second-line PI regimen {PitoN study cohort]. 
Materials and methods 
Setting 
We conducted our study within the ATHENA cohort, which is a nationwide observational 
cohort in the Netherlands. The ATHENA cohort includes HIV-infected patients who are 
treated with one or more of the new antiretroviral drugs that became available in the 
Netherlands in July 1996 and thereafter [ie. all Pis, all NNRTis and the newer NRTls such as 
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lamivudine and stavudine). The source population comprises HIV-infected patients in follow-
up at the 22 hospitals that provide treatment to HIV-infected patients in the Netherlands 
and willing to give written informed consent. The ATHENA project has been approved by the 
local Ethics Committees of all centres. 
According to the national guidelines for HIV-treatment in the Netherlands. patients 
are seen at approximately three-monthly intervals for regular follow-up (13) . Data for the 
ATHENA cohort are collected on standardised forms. retrospectively from medical records 
until patient entry into the cohort, and prospectively thereafter by trained research nurses 
and treating physicians. The resulting ATHENA database. which is updated approximately 
every six months, contains information on gender. age, hospital. height and weight. Start 
and stop dates as well as dose frequency of every antiretroviral medication and 
prophylactic treatment against opportunistic infections, primary reason for stopping such 
treatments as classified by the treating physician. dates of onset and resolution of HIV-
related diseases. CD4 cell counts. plasma HIV-1 RNA load and abnormal laboratory values 
are recorded. Information on adverse events comprises all events that lead to a change in 
antiretroviral treatment and a number of pre-specified adverse events such as neuropathy, 
lipodystrophy and hepatitis. Available data on plasma HIV-1 RNA result from three different 
quantitative assays. Amplicor (Roche Diagnostics, Branchburg. NJ, USA), NucliSens 
[Organon Teknika, Boxtel, Nederland) or Quantiplex (Chiron Diagnostics Corporation, East 
Walpole, MA. USA). At the time of data extraction for the analysis in March 2000 data were 
available for 2470 patients. 
PitoN study cohort 
The source population for our study involved all patients in the ATHENA database using a PI-
containing first antiretroviral regimen during the study period. The study period ran from 1 
May 1997, when the compassionate use program for NVP became effective, until March 
2000. Patients entered the PitoN study cohort upon switching the PI component of the first-
line antiretroviral regimen (HAART 1) while HIV-1 RNA was below 500 copies/ml. Changes of 
ritonavir (RTV) formulation were not considered as a switch because of a nation-wide 
change to a new formulation. Any other change of the PI component, including dose 
frequency change other than standard initial dose escalations. addition or removal of a PI 
and change of saquinavir (SQV) formulation, was considered as a switch. The date of 
cohort entry was defined as the start date of the second HAART regimen (HAART 2}. We 
excluded all patients for whom we did not have an HIV-1 RNA assessment within at least 
three months prior to the start of HAART 2 or who interrupted treatment for more than seven 
days in order to ensure the presence of viral suppression at the start of HAART 2. The resulting 
PitoN study cohort was divided into two treatment groups based on the use of NVP or Pis in 
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HAART 2. Switches to other NNRTis, such as efavirenz, were not studied separately in this 
study since NVP was the only registered NNRTl in the Netherlands at the time of this analysis. 
Switches to triple NRTI-regimens were not studied either as the primary interest of our study 
was to compare switching to NVP with switching between Pis. 
Outcome 
The primary endpoint of the study was the proportion of patients experiencing treatment 
failure within one year after switching to HAART 2. Treatment failure was defined as either 
virological failure or discontinuation of HAART 2 for any reason. Virological failure was 
defined as plasma HIV-1 RNA levels above 500 copies/ml on two consecutive 
measurements or a single plasma HIV-1 RNA assessment of more than 10,000 copies/mL. 
Discontinuation of HAART 2 was defined as either another treatment switch according to 
the above description, discontinuation of HAART 2 or death. Notably switching NRTis only 
was not considered as a treatment switch. 
As secondary endpoints we studied time to treatment failure, the effect of 
substituting NYP versus substituting a new HIV-protease inhibitor and versus other types of 
switch, the effect of the most common switches at the level of individual antiretroviral 
agents, the course of CD4 cell counts and the occurrence of clinical adverse events. 
Follow-up for the study lasted from the date of study entrance until the completion of one 
year, last update of data collection or treatment failure, whichever occurred first. 
Co-variates 
As potential determinants of treatment failure and potential confounding factors we 
considered demographic factors, such as age, gender, country of birth, route of HlV-
transmission and CDC-disease classification at the time of switch (14) . In addition, we 
considered treatment history prior to HAART 1 (categorised as either naive or experienced 
to NRTis), duration of HAART 1, duration of viral suppression prior to switch (defined as the last 
uninterrupted period of HIV-1 RNA below 500 copies/ml), prior history of virological rebound 
{defined as HIV-1 RNA at least once above 500 copies/ml after suppression below 500 
copies/mL), CD4 cell count at the time of switch, type of antiretrovirals used in HAART 1 and 
2, calendar time (expressed as months since start study period) and the reason for switch. 
Reasons for switch were categorised by the treating physician as: intolerance, patient 
request, failure (the latter in the context of the ATHENA study being defined as either 
increase in viral load, decrease in CD4 cell count or disease progression), pharmacological 
indication, other with specification and unknown. 
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Analysis 
Differences in baseline characteristics between the PI-group and NVP-group were tested by 
means of the Pearson's Chi-square test or Fisher's exact test for categorical variables. The 
Student's t-test was used for continuous variables unless non-normally distributed in which 
case we used the Mann-Whitney-U test. The one-year hazard for treatment failure was 
estimated by means of Kaplan Meier survival analysis. Crude comparisons regarding the risk 
of treatment failure between the HAART 2 groups were made both with the log-rank test 
and univariate Cox-regression analysis. Risk factors for treatment failure were identified by 
means of univariate and subsequent multivariate Cox-regression analysis. The multivariate 
model included all factors from the univariate analysis that were associated with treatment 
failure at a p-value of <0.1. Time to failure was calculated from the date of cohort entry to 
the first date of HIV-1 RNA above 500 copies/ml or discontinuation of HAART 2, whichever 
occurred first. Results were expressed as % of patients or relative risk (RR) with 95%-
confidence intervals (95%CI}. The course of CD4 cell counts until treatment failure or end of 
follow-up was analysed by means of a General Linear Model (GLM) for repeated 
measurements adjusted for the baseline CD4 cell count. The presence and resolution of 
adverse events was described. 
Statistical significance was accepted at a two-sided p-value of 0.05. Ali analyses 
were performed with SPSS statistical package for w·1ndows version 8.0. 
Results 
Cohort 
The source population in the ATHENA database consisted of 2434 paf1ents who ever used a 
PI before March 2000. Of these, 1716 patients were ineligible for our study cohort because 
ot an NNRTI in HAART 1 (n=126), conf1nuation of HAART I (n=738), HIV-1 RNA above 500 
copies/ml (n=637) and change of HAART I before 1 May 1997 (n=215), We further excluded 
those with more than seven days between HAART 1 and HAART 2 (n=510) and absence of a 
baseline HIV-1 RNA measurement (n=129}, resulting in a final cohort of 446 patients. 
The final study cohort consisted of 125 (28%) patients for whom Pis were replaced 
by NVP (NVP-group) and 321 (72%) patients who had a change of the PI component (PI-
group, Table 1 }. The most common switches included switches from SOV hard gel capsule 
(hgc) to SQVhgc combined w·1th RTV, from one indinavir (IDV) dose frequency to another 
IDV dose frequency (n=42, 9%), from RTV, SQVhgc combined with RTV or from IDV to NVP 
(n=42, 9%) and from IDV or RTV to nelfinavir (Table 2), 
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Table 1 Type of treatment change of the first human immunodeficiency virus (HlV]-protease inhibitor 
containing antiretroviral treatment in presence of viral suppression 
Treatment changea 
NVP-group 
Changed PI into NVP 
PI-group 
Changed to another type of PI 
Removed one PI, maintaining one of two Pis 
Added one PI 
Changed SQV formulation 
Changed dosage and/or dose frequency 
Total 
NVP- nevirapine; PI- HIV-protease inhibitor; SQV- saquinavir 
N 
125 
117 
7 
99 
22 
76 
446 
(%] 
(28.0) 
(26.2) 
(1.6) 
(22.2] 
(4.9] 
(17.0) 
100 
Table 2 The most common substitutions for the first human immunodeficiency virus {HlV)-protease 
inhibitor in presence of viral suppression 
HIV-protease inhibitor I NNRn component 
HAART 1 HAART2 N (%) 
SQVhgc SQVhgc/RTV 53 (12) 
IDV IDV 42 (9) 
RTV NVP 42 (9] 
SQVhgc/RTV NYP 34 (8) 
IDV NYP 25 (6) 
IDV NFV 25 (6) 
RTV NFV 21 (5) 
IDV IDV/RTV 20 (4] 
RTV SQVhgc/RTV 19 (4) 
Other 165 37 
HAART- highly active antiretrovirol therapy; IDV= indinavir; NFV- nelfinovir; NVP- neviropine; RTV= 
ritonovir; SQVhgc= soquinovir hard gel capsule 
Patient characteristics at the time of switch of HAART 1 (baseline] are presented in table 3. 
The NVP-group was more often antiretroviral treatment-naive prior to HAART 1, had longer 
successful viral suppression prior to switch, more often had a concomitant change in NRTis, 
switched later in calendar time and more often had intolerance and patient request as 
reasons for switch than the PI-group. furthermore, the NVP-group used more stavudine (d4T) 
and less didanosine (ddl] in HAART 1 than the PI-group, and the NVP-group more often had 
RTV and SQV combined with RTV but less SQV in HAART 1. 
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Table3 Patient characteristics of the PitoN study cohort (n= 446) 
Switch to P-
Characteristic N [%) NVP [n-125) PI [n-321 jb volueo 
Age Median (IQR) 40 [35-48) 39 [33-46) Ns 
Gender Mole 110 [88.0) 264 [82.) Ns Female 15 [12.0) 57 [17.8) 
Country of birth Netherlands 83 [66.9) 233 [73.7) Ns Other 41 [33.1) 83 [26.3) 
Route of tronsm·1ssion MSM 80 [67.8) 204 [67.3) 
intravenous drug use 3 [2.5) 20 [6.6) Ns 
Other 35 [29.7) 79 [26.1) 
CDC-classification c 30 [24.0) 78 [24.3) Ns A orB 95 [76.0) 243 [75.7) 
Naive start HAART 1 Yes 97 [77.6) 189 [58.9) 
<0.001 No 28 [22.4) 132 [41.1 I 
weeks on HAART 1 Median (IQR) 66 [38-92) 64 [30-87) Ns 
Weeks <=500 copies/mL Median (IQR) 47 [21-82) 37 [15-66) 0.008 
Prior virological failure Yes 17 [14.7) 61 [22.4) Ns No 99 [85.3) 211 [77.6) 
CD4 at switch (cells/~L) Median {IQR) 440 [300-600) 420 [300-600) Ns 
NRns changed Yes 32 [25.6) 36 [11.2) <0.001 
No 93 [74.4) 285 [88.8) 
Months since 1 May 1997] Median (IQR] 20 [16-23) 14 [10-18) <0.001 
Reason for switch HAART 1 Intolerance 62 [49.6) 89 [27.7) 
Patient request 38 [30.4) 66 [20.6) 
Pharmacological indication 3 [2.4) 36 [112) 
<0.001 Foilured 3 [2.4) 15 [4.7) 
Othero 11 [8.8) 83 [25.8) 
Unknown 8 [6.4) 32 [10.0) 
HIV-protease inhibitor before NFV 5 [4.0) 6 [1.9) 
switch IDV 25 [20.0) 104 [32.4) 
SQVhgc 10 [8.0) 77 [24.0) 
SQVsgc 2 [1.6) 2 [0.6) 
RTV 42 [33.6) 66 [20.6) 
<0.001 IDV/RTV 6 [4.8) 2 [0.6) 
SQVhgc/NFV 1 [0.8) 14 [4.4) 
SQVsgc/NFV 0 [0) 10 [3.1) 
SQVhgc/RTV 34 [27.2) 38 [11.8) 
other 0 [0) 2 [0.6) 
NRTis before switch AZT/3TC 60 [48.0) 151 [47.0) 
D4T/3TC 44 [35.2) 117 [36.4) 
d4T 10 [8.0) 9 [2.8) 
AZT/ddl 2 [1.6) 14 [4.4) 0.042 
d4T/ddl 2 [1.6) 12 [3.7) 
other 3 [2.4) 15 [4.7) 
none 4 {3.2) 3 {0.9) 
3TC-Iamivudine; AZT- zidovudine; d4T- stovudine: ddC= zolcitobine: ddl- didonosine: HAART- H·1ghly 
Antiretrovirol Therapy; IDV= indinovir; IQR= Inter Quartile Range; MSM= men having sex with men; NFV= 
nelfinavir; NRTI= nucleoside analogue reverse tronscriptase inhibitor; NVP= neviropine; PI= HIV-protease 
inhibitor: RTV= ritonovir; SQVhgc= soquinovir hard gel capsule: SQVsgc= SQV soft gel capsule 
0 Pearson Chi-square or fisher's exact test for categorical variables and Monn-Whitney-U for 
continuous variables; Ns: p>O.OS 
b PI-group consisted of nelfinovir {22%), indinovir {20%), soquinavir hard gel capsule (4%), soquinovir 
soft gel capsule {3%), ritonovir (3%), indinovir/ritonovir (9%),soquinovir hard gel copsule/nelfinovir 
(1 %), soquinovir soft gel copsule/nelfinovir (7%), soquinovir hard gel copsule/ritonavir (30%), 
saquinovir soft gel copsule/ritonovir (1%), other (2%) 
c Percentages of treatment group HAART 2 
d Failure wh.lle HIV-1 RNA<SOO copies/mL ne. low CD4 cell count and/or clinical progression and/or 
HIV-1 RNA detectable with ultra sensitive HIV-1 RNA assay]. 
e Including convenience (7% resp.12%), protocol directed {2% resp.9%) and other {0% resp.4%). 
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Figure 1 Cumulative hazard of treatment failure after substituting the first human 
immunodeficiency virus (HlV)-protease inhibitor (PI) 
Patients who had switched to a second-line HIV-protease inhibitor (PI-group) 
under successful viral suppression (solid line) had a significantly higher risk of 
treatment failure (virological failure or treatment discontinuation) than patients, 
who hod switched to nevirapine (NVP--group] under the same circumstances 
(dotted line) (log-rank p<O.OOl). 
Treatment failure 
Within one year after changing HAART 1, 187 (42%) patients experienced treatment failure 
{Figure 1 ). The one-year cumulative hazard of treatment failure was 0.2 (95%CI: 0.1-0.2) and 
0.8 (95%CI: 0.7-0.9) for the NVP-group and PI-group respectively. resulting in a RR of 0.2 
(95%CI: 0.1-0.3) for the NVP-group versus the PI-group (Table 4). The median time to 
treatment failure within the first year after switch was 22 (IQR: 5-35) and 17 (IQR: 9-30) weeks 
for the NVP-group and PI-group, respectively. 
Regarding the causes of treatment failure, 27 (6%) patients failed because of 
virological failure, including 11 patients with more than 10,000 HIV-1 RNA copies/ml.ln total, 
160 (36%} patients failed because of discontinuation of HAART 2. We observed significantly 
fewer treatment discontinuations [crude RR: 0.2, 95%CI: 0.1-0.3) and a trend toward less 
virological failure (crude RR: 0.4, 95%CI: 0.2-1.2) in the NVP-group as compared to the PI-
group (Table 4]. For both groups the primary reason for HAART 2 discontinuation was 
intolerance (50% and 48% of the discontinuations in the NVP-group and PI-group 
respectively). These included two deaths in the NVP-group. One male patient with a history 
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of cardiac disease died at the age of 69 because of heart failure. The cause of death of the 
other patient could not be retrieved as neither HIV-related events nor adverse events had 
been reported for this 41-year old man. 
Other characteristics associated with treatment failure were: intra-venous drug use 
as route of HIV-transmission, antiretroviral treatment experience before HAART 1, d4T/ddl in 
HAART 1 or HAART 2, shorter duration of viral suppression before switch, absence of a 
change in NRT!s and switch later in calendar time. The use of RTV or a RTV /SQV combination 
in HAART 1 was associated with less treatment failure on the subsequent regimen. Many of 
the above factors were not equally distributed across the NVP-group and PI-group at 
baseline. After adjustment for all of these factors, including the reason for switch HAART 1 in 
a multivariate analysis, substitution of NVP for Pis relative to other changes of the PI-
component remained, however, associated with a lower risk of treatment failure with an 
adjusted RR of 0.3 (95%CI: 0.1-0.5) (Table 4). 
Restricting the outcome to virological failure and switches due to intolerance with 
right censoring of the other switches, produced similar results as analyses with the primary 
outcome (Table 4). Separating virological failure and treatment switches, however, 
indicated that differences between the NVP-group and PI-group were mainly attributable 
to treatment discontinuations as the risk of virological failure was not significantly different 
between the NVP-group and PI-group in the multivariate analysis. Stratification for NRTl 
experience prior to HAART 1 showed that the favourable effect of NVP was more 
pronounced among NRTI treatment naive patients. The adjusted RRs of treatment failure 
were relatively constant when comparing the NVP-group to individual types of switch {ie. 
change to another type of PI, continuation of one of two Pis, addition of one PL change of 
SQV formulation and change of dose and/or frequency), ranging from 0.1 (95%CI: 0.03-0.2) 
to 0.3 (95%CI: 0.1-0.6). 
Similar to the univariate analysis, the lowest risk of treatment failure was observed 
after switches from RlY to NVP (adjusted RR: 0.2, 95%CI: 0.1-0.6) when compared to 
switching from SQVhgc to SQVhgc with RlY (the most frequent switch) (Table 4). The highest 
risk was observed after switches from IDV to IDV with RlY (adjusted RR: 3.6, 95%CI: 1.6-82). 
Among patients who used IOV in HAART 1, switching to NVP was associated with a 
5-fold lower risk of treatment failure than switching to another PI-containing regimen 
{adjusted RR: 0.2, 95%CI:0.04-0.6). Similar results were found for patients coming from a 
regimen with RlY (adjusted RR: 0.2, 95%CI: 0.03-0.9) or a regimen of SQVhgc with RlY 
(adjusted RR: 0.1, 95%CI: 0.01-0.7). 
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Table 4 The relative risks of treatment failure within one year after substituting the first human 
immunodeficiency virus (HIV]-protease inhibitor 
NVP-group versus PI-group 
Overall 
ART experienced patients 
ART naive patients 
Outcome HMRT 2b 
Virological failure+ Treatment switch due 
to intolerance 
Virological failure 
Treatment switch for any reason 
NVP-group versus 
Changing to another type of PI 
Removing one PI 
Adding one PI 
Changing SQV formulation 
Changing the PI dose frequency 
Most common switches 
Crude 
RR 
0.2 
0.4 
0.1 
0.2 
0.4 
0.2 
0.2 
0.1 
0.2 
0.2 
0.2 
Adjusted0 
95%CI RR 95%CI 
{0.1-0.3) 0.2 {0.1-0.4) 
{0.2-0.8) 0.3 {0.1-0.96) 
{0.1-0.3) 0.1 {0.1-0.3) 
{0.1-0.4) 0.3 {0.1-0.6) 
{0.2-1.2) 0.8 {0.2-3.0) 
{0.1-0.3) 0.2 {0.1-0.3) 
{0.1-0.4) 0.3 {0.1-0.6) 
{0.04-0.3) Too few 
{0.1-0.3) 0.1 {0.03-0.2) 
{0.1-0.4) O.lC {0.02-0.4) 
{0.1-0.4) 0.1 {0.05-0.4) 
SQVhgc to SQVhgc/RTV 1 Reference Reference 
IDV to new dose frequency IDV 1.2 (0.7-2.1) 0.9c (0.4-2.0) 
RTV to NVP 0.1 {0.05-0.4) 0.2' {0.1-0.6) 
SQVhgc/RTV to NVP 0.2 (0.1-0.6) 0.4c (0.1-1.5) 
IDV to NVP 0.3 (0.1-0.8) 0.3c (0.1-0.98) 
IDV to NFV 0.8 {0.4-1.7) 0.7° {0.3-1.7) 
RTVto NFV 0.4 {0.2-1.03) 0.40 {0.1-1.2) 
IDV to IDV/RTV 2.2 {1.2-4.1) 3.6° {1.6-8.2) 
RTV to SQVhgc/RTV 1.9 {1.00-3.7) 2.4° {1.03-5.6) 
Other 0.9 (0.6-1.5) 1.2c (0.6-2.4) 
95%CI- 95% confidence interval; HAART Highly Antiretroviral Therapy; IDV indinavir; NFV nelfinavir; 
NVP= nevirapine; PI= HIV-protease inhibitor; RR= relative risk; RTV= ritonavir; SQVhgc= saquinavir hard gel 
capsule 
a Adjusted for route of HIV-transmission, type of Pis in HMRT l, nucleoside analogue reverse 
transcriptase inhibitors (NRTis) in HMRT 1 and HMRT 2, duration of viral suppression before HMRT 2, 
change in NRTis yes or no, time of switch, reason for switch and either adjusted or stratified for 
treatment experience prior to HAART 1 
b Calculated with right censoring of the alternative outcome(s) 
c Adjusted for all variables mentioned in note a except for type of PI in HMRT 1 
Adverse events 
Before switching to HAART 2 adverse events had been reported for 91 (73%] patients in the 
NVP-group and 207 (65%) in the PI-group (p~0.094). After switch respectively 43 (47%) and 96 
(46%) patients in the NVP-group and PI-group failed to achieve resolution of these events or 
died within the available follow-up period. For 19 (21%) patients in the NVP-group and 38 
(18%] patients in the PI-group part of the events resolved. Twenty-nine (32%] patients in the 
NVP-group and 73 (35%] patients in the PI-group had complete resolution of all events. The 
most frequently reported new adverse event after switching was lipodystrophy as 
diagnosed by the treating physician. occurring among 13% and 11% of patients in the NVP-
group and PI-group respectively. Only 2 (2%) patients in the NVP-group and 5 (2%) in the PI-
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group experienced dermatological adverse effects. There were no reports of toxic {non-
viral} hepatitis or severe rash on NVP leading to discontinuation of NVP. 
Immunology 
CD4 cell counts continued to increase in both groups after start of HAART 2 {Figure 2). No 
statistically significant difference in C04 cell counts was observed between the NVP-group 
and PI-group at any time point {GLM for repeated measurements, p=0.088). 
Figure 2 
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Course of CD4 cell counts after substituting the first human immunodeficiency virus (HIV)-
protease inhibitor (PI) 
No d"tfference in CD4 cell counts was observed between patients who switched to a 
second-line HIV-protease inhibitor (PI-group, solid line] and patients who switched to 
nevirapine (NVP, dotted line] while having successful viral suppression (General Linear 
Model for repeated measurements: p>0.05). Mean CD4 cell counts (lines) and 95%-
confidence intervals (bars) ore plotted. 
Discussion 
In this study under everyday circumstances it was observed that substituting NVP for Pis 
during viral suppression was three-fold more likely to result in sustained virus suppression and 
maintenance of the new treatment regimen than substituting for any alternative PI or PI 
combination. This was found after adjustment for the imbalance in other determinants of 
treatment failure (ie. the route of HIV-transmission, type of antiretrovirals used in HAART 1 and 
HAART 2, concomitant changes of NRTis, duration of viral suppression prior to switch, and 
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calendar time of switch] and reasons for switch. The differences were most pronounced 
among patients who were fully treatment-naive before their first PI and were mainly 
attributable to the lower number of treatment discontinuations on NVP. 
By using the database derived from the ATHENA project we were able to 
substantiate previous findings in a larger cohort of patients with a more substantial follow-up 
period (9-12). The available data allowed us to compare switching to NVP with switching to 
second-line Pis in a multivariate analysis including multiple predictors of treatment failure. 
Moreover. this cohort allowed us to explore different types of switch within the class of Pis, 
including switches at the level of individual antiretroviral agents, which indicated that 
switching to NYP was superior to all types of PI switches included in this study. For adequate 
analysis of the effects on virological failure, probably a larger sample size is necessary as the 
rate of virological failure was generally low. 
With respect to adverse events the NVP-group and PI-group appeared equally 
successful in resolving events, although there were two deaths in the NVP-group. We were 
unable to exclude NVP as the cause of one of these deaths. No other ser"1ous adverse 
effects, such as severe hepatitis or skin rash leading to treatment discontinuation had been 
reported. The incidence of skin rashes in the NVP-group was 2%, whereas we anticipated 
see skin rashes in at least 5% of patients in this group (7, 8). The absence of severe skin 
reactions and severe clinically overt liver toxicity to NVP (15-17) might point at a potentially 
lower risk of these events among patients with viral suppression than among patients with 
high viral loads as has been speculated before (18). On the other hand potential 
underreporting in the ATHENA project may be responsible for the low incidences of skin 
rashes and hepatitis observed in our study. 
Our study was not primarily aimed at assessing the differences in adverse events 
after switch. Nevertheless, despite the comparable number of adverse events in both 
groups, the number of discontinuations in the NVP-group was significantly lower, suggesting 
relatively better tolerance of NVP-based second-line regimens. On the basis of the available 
data on the ATHENA cohort it was not possible to examine improvement of lipodystrophy as 
described elsewhere {19). 
Possible limitations of observational studies concern potential bias and 
confounding. Since we did not have data on the actual severity of adverse effects, we 
cannot exclude the effect of confounding due to the absence or presence of a simpler 
alternative [or a new class of antiretrovirals) to the regimen on which intolerance is 
experienced. The observed difference in the rate of treatment discontinuations might 
partially reflect different switching behaviour in both treatment groups. If this bias indeed 
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plays a role, the results imply that the presence of an alternative in addition to the presence 
of adverse effects is a risk factor for treatment switches. 
We aimed to create a homogeneous study cohort with respect to the reasons for 
changing therapy by limiting the cohort to patients with viral suppression at the time of 
switch. As a result, the reasons for changing to a certain regimen were assumed to be 
unrelated to the risk of treatment failure. Yet there were important differences between 
patients who substituted NVP for Pis and patients who switched to a second-line Pl. For 
example, the proportion of patients treated with NRTis prior to starting the first PI was lower in 
the NVP-group. NVP probably is prescribed less frequently to NRTI-experienced patients 
since they have a potential for viral resistance to NRTls as a result of which they are less likely 
to have a sustained virological response to NVP (20-22}. Furthermore, the duration of the first 
PI-containing regimen was longer and the type of antiretrovirals used in the first regimen was 
different. The risk profile for virological failure of patients who substituted NVP for Pis therefore 
seemed more favourable. We were. however, able to adjust for those factors that were 
associated with both the treatment group and treatment failure and for the reason for 
treatment switch in a multivariate analysis. 
F1nally, we compared switch"1ng to NVP with a variety of switches between Pis. The 
types of switch used as a reference included switching to another type of PI, switching to a 
dual PI regimen or switching from dual to a single PI regimen, changing SQV formulation 
and changing the PI dose frequency. The resulting treatment regimens were believed to be 
effective in earlier documented studies [23-28}. However, in order to exclude the potential 
negative influence of any of these switches, we also compared switching to NVP with each 
single type of switch and individual type of Pl. These sub-analyses did show similar results 
across all types of switch. 
In conclusion, this study showed that under everyday circumstances, second-line 
Pis had a poorer performance than NVP with respect to tolerability in particular, as reflected 
in a higher rate of treatment discontinuations. For patients who have achieved viral 
suppression on the first HAART regimen, replacing Pis by NVP appears to be safe in terms of 
treatment endurance and therefore may improve the likelihood of long-term adherence 
and viral suppression. Further studies are needed to explore the benefits of switching to 
other N N RTis such as efavirenz. 
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Determinants of recurrent toxicity-driven 
switches of highly active antiretroviral therapy. 
The ATHENA cohort. 
Chopter4.2 
Abstract 
Background: Toxicity is the most important reason for premature switching of highly active 
antiretroviral therapy [HAART). In order to optimise the benefit-risk ratio of HAART, guidelines 
for toxicity-management are needed. 
Objective: We conducted an observational cohort study to estimate the incidence and 
identify determinants of toxicity-driven switches on second-line HAART after having switched 
first-line HAART despite successful viral suppression. 
Methods: We selected all patients from the ATHENA-cohort (n=2470), who switched the 
initial HIV-protease inhibitor {PI) containing HAART while plasma HIV-1-RNA was :;; 500 
copies/ml {n=775). One-year cumulative incidences of subsequent toxicity-driven switches 
and adjusted relative risks {RR) for potential determinants were calculated. 
Results: The one-year cumulative incidence of toxicity-driven switches of the second 
regimen was 24% {95%CI:21-28), mostly because of gastro-intestinal toxicity and neuropathy. 
Those who had switched the first HAART due to toxicity, were at an increased risk of a 
recurrent toxicity-driven switch (RR:2.5, 95%CI:l.7-3.5). Switching from PI to nevirapine while 
continuing the other antiretrovirals was more protective against a subsequent switch 
because of further toxicity than changing to another PI-containing regimen {RR:0.2, 
95%CI:O.I-0.6). 
Conclusions: As for first-line HAARL toxicity remains responsible for the majority of switches 
during second-line HAART. Prior sw·ttching for toxicity increases the risk of having to switch the 
subsequent regimen for toxicity, but this risk is reduced when switching to nevirapine rather 
than to an alternative Pl. The latter should be taken into account when designing toxicity-
management guidelines. 
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Introduction 
The burden of toxicity resulting from highly active antiretroviral therapy (HAART) is of 
concem. as it constitutes a threat to sustained success of HIV treatment {1, 2). The high 
frequency of toxicily (3, 4) results in a high rate of treatment switches (5-7). In fact. 44-58% of 
switches on initial HAART regimens and 56% of switches on subsequent regimens have been 
attributed to toxicity, which makes toxicity the most important reason for premature 
switching of antiretroviral treatment (6, 8, 9). The impact of toxicity on the benefit-risk ratio of 
HIV treatment may become even more pronounced as sustained virological suppression 
becomes more feasible due to the availability of potent antiretroviral regimens (10-12). 
Obviously, risk factors for developing HAART-associated toxicity include the specific 
antiretroviral drugs used. {10). However, underlying conditions and patient characteristics, 
including pharmacokinetic parameters such as high drug absorption, low distribution 
volume and low metabolic clearance, may cause increased susceptibility to toxic effects of 
certain classes of drugs (13-16]. Accordingly, patients who switch first-line HIV-protease 
inhibitor {PI]-containing treatment because of toxicity are at an increased risk of a similar 
switch on a subsequent PI-containing regimen (8]. As yet there is no information to suggest 
that switching to another class of drugs can reduce this risk. In addition. information on the 
influence of other factors on the risk of recurrent toxicity-driven switches is scanty, despite 
the high incidence of such switches. 
We conducted the present study within the ATHENA cohort to estimate the 
incidence of treatment switches because of toxicity in a population of patients who had 
switched first-line PI-containing HAART despite successful viral suppression. In order to obtain 
more insight into toxicity-driven switches, we identified determinants of the renewed need to 
switch treatment. 
Patients and methods 
Setting 
The ATHENA-cohort is a multi-centre clinical cohort of HIV-infected individuals in the 
Netherlands, who are or have been treated with one or more antiretroviral medications that 
became generally available as of July 1996 (lamivudine, stavudine, the Pis and non-
nucleoside reverse transcriptase inhibitors]. All 22 Dutch hospitals that provide treatment to 
HIV-infected patients participate in this cohort study, with approval of their local ethical 
committees. Patient enrolment for which informed consent is obtained, effectively started 
in May 1998 and continues to date. 
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According to the national guidelines for HIV-treatment in the Netherrands, patients 
receiving antiretroviral treatment visit the outpatient clinic at approximately three-monthly 
intervals for regular follow-up (17]. Data for the ATHENA cohort are abstracted by treating 
physicians and trained research assistants from medical records onto standardised forms. 
This is done retrospectively for the period prior to having obtained participants' informed 
consent. and prospectively thereafter. The resulftng database contains anonymous 
information on patient characteristics (eg. age. gender, date of birth, date of death, height 
and weight), HIV-infection (eg. HIV-iype, HIV-related events, route of HIV-transmission, CD4-
ceiJ count and plasma HIV-1 RNA load}, detailed treatment data (eg. antiretroviral and 
prophylactic medications against opportunistic infections, dose frequencies, start and stop 
dates and reasons for treatment switch} and adverse events. Adverse events recorded 
include certain drug-associated events, which are pre-printed on the data collection forms 
{e.g. hepatitis, lipodystrophy, nephrolithiasis, neuropathy) and which are recorded at the 
discretion of the treating physician. In addition other events resulting in a treatment switch, 
as well as laboratory values outside pre-specified ranges are recorded. Reasons for 
treatment switch are categorised into mutually exclusive groups, consisting of toxicity 
(referring to the adverse event(s]), treatment failure {increase in viral load and/or decrease 
in CD4 cell count, and/or clinical disease progression], patient request. pharmacological 
indication, dose escalation, other (with specification} and unknown. Treating physicians are 
requested to indicate a single primary reason for the switch. 
Study cohort 
The source population for the present study comprised all-patients who started a first HAART 
regimen, consisting of at least one HIV-protease inhibitor (PI} and tvvo nucleoside analogue 
reverse transcriptase inhibitors (NRTis) or the combination of ritonavir and saquinavir, with or 
without stavudine as used in the Prometheus study {18}. The current study cohort "tncluded all 
patients from the source population who had a switch of their first PI-containing HAART 
regimen without having virological failure, in order to select a population of patients for 
whom toxicity was of a potential concem. To achieve this we excluded patients in whom 
plasma HIV-1 RNA at the time of treatment switch was above 500 copies/ml. In addition, we 
excluded patients for whom treatment data were missing, no information on a subsequent 
regimen was available, or whose treatment was interrupted for more than seven days, in 
order to reduce the chance of an increased viral load being present at the start of the 
second-line HAART regimen. 
The date of switch of the first HAART regimen was considered as the baseline date 
for the current cohort study. Switches were defined as any change in composition of the 
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regimen, dose adjustments other than the standard dose escalations (coded as dose 
escalation] or adjustments in frequency of administration of drugs. 
The primary outcome measure was a toxicity-driven switch, defined as a switch of 
the second-line regimen due to toxicity, as indicated by the treating physician. A secondary 
outcome measure was switch of the second regimen for reasons other than toxicity. Follow-
up lasted from the date of switch of the first HAART regimen until the date of switching the 
second regimen, the end of the one-year period, or the end of follow-up, whichever came 
first. A one-year period was chosen to ensure an equal follow-up time for various regimens. 
Statistical analysis 
The cumulative incidence of a switch, while on the second-line HAART regimen was 
estimated by means of Kaplan Meier survival analysis. The proportion of patients with HIV-1 
RNA > 500 copies/ml at the end of follow-up was calculated. Risk factors for toxicity-driven 
switches were analysed by means of univariate and multivariate Cox-regression analysis. 
Factors included into the analysis were: calendar time of switch. route of HIV-transmission. 
Centre for Disease Control and Prevention (CDC) classification of HIV-disease (classified as 
C and non-C) (19), antiretroviral treatment experience prior to the first HAART. duration of 
the first HAART. CD4-cell count at switch, reason for switch and the type of treatment switch. 
As proxies for underlying conditions or characteristics we included age, gender, nationality 
(classified as Dutch or non-Dutch), body mass index and lean body mass. All factors that 
were univariately associated with toxicity-driven switch at a p-value of 0.1 were included in 
the multivariate analysis. Subsequently we excluded variables from the multivariate analysis 
in a stepwise manner if the p-value was above 0.1. Results were expressed as relative risks 
(RR) with 95%-confidence intervals (95%Cl). 
All analyses were performed using SPSS® for Windows® version 9.01 as the statistical 
software package. 
Results 
Among the 2470 patients in the ATHENA database who were available for analysis, 2096 
(85%) used at least one PI with two NRTis or a Prometheus-trial regimen (18] as the first HAART 
regimen, and 1573 (75%) of these patients had ever switched this regimen. From the 
population of switchers we excluded 696 (45%) patients because of an H!V-1 RNA level 
above 500 copies/mL 9 (0.6%) patients because of missing treatment data, 41 (3%] patients 
because there was no information on a subsequent regimen, and 52 (3%] patients because 
of a treatment interruption of more than seven days. Thus. our final cohort consisted of 775 
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patients who entered the study be1ween June 1996 and December 1999. The baseline 
characteristics of the study cohort are summarized in Table 1. 
Table 1 Baseline characteristics of the study cohort of patients who switched a first PI-containing 
HAART regimen without having virological failure [n=775) 
Characteristic 
Gender 
Age 
Nationality 
Route of HIV-transmission 
CDC-C disease 
classification 
ARV na"ive at start first 
HAART 
Duration first HAART 
(months) 
CD4-cell count at 
change (xl 06/L) 
Reason for switch first 
HAARTc 
Type of switch 
NRTI unchanged 
NRTI changed 
Mole 
Female 
Median (IQR) 
Dutch 
Other 
MSM 
Other 
Yes 
No 
Yes 
No 
Median (IQR) 
Median {IQR) 
Toxicity 
Foilured 
Patient request 
Pharmacological indication 
Other (specified) 
Unknown 
Pl(s] to other Pl(s) 
Pl(s) to nevirapine 
Dose/frequency PI changed 
Other change of Pl(s) 
Pl{s) unchangedo 
Pl(s) to other Pl(s) 
Pl(s] to neviropine 
Dose/frequency PI changed 
Other change of Pl(s) 
Pl(s) unchanged 
Study cohort Toxicity-driven 
(n=77Sjo switch second 
HAART (n=142) 
N (%)' N (%)b 
659 [85) 113 [85) 
116 [15) 29 [15) 
40 [34-47) 39 [34-47) 
633 (86) 112 [85) 
101 [14) 20 [15) 
509 [66) 84 [59) 
266 [34) 58 [41) 
272 [35) 49 [34) 
503 [65) 93 [66) 
398 [51) 62 [44) 
377 [49) 80 (56) 
7.8 [3.4-15.9) 5.9 [3.0-14.7) 
365 [195-550) 370 [18Q-558) 
270 [35) 77 [54) 
51 [7) 7 [5) 
116 [15) 13 [9) 
92 [12) 14 [10) 
157 [20) 20 [14) 
89 [12) 11 [8) 
185 [24) 44 [31) 
89 [12) 4 [3) 
108 [14) 15 [11) 
32 [4) 9 [6) 
169 [22) 28 [20) 
40 [5) 10 [7) 
24 [3) 6 [4) 
13 [2) 1 [1) 
11 [1) 2 [1) 
104 [13) 23 [16) 
ARV antiretroviral: CDC-C CDC disease classification C; HAART highly active antiretroviral therapy; 
IQR= Inter Quartile Range; MSM= men having sex with men: NRTI= nucleoside analogue reverse 
transcriptase inhibitor: NNRTI= non-nucleoside analogue reverse transcriptose inhibitor; PI= HIV-protease 
inhibitor 
a Within one year 373 patients hod switched the second regimen, 142 of whom for toxicity reasons 
b Percentage of column total 
c A single reason for change had to be chosen from the following: toxicity, patient request, treatment 
failure (immunologicol,and/or virological,and/or or clinical], pharmacological indication, other (with 
specification] and unknown. 
d Patients may have switched because of failure while HIV-1 RNA was below 500 copies/ml 
e Includes dose frequency changes of NRTis and treatment interruptions shorter than 7 days 
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The median date of cohort entry, i.e. the date of having switched a first-line HAART regimen, 
was March 1998. The majority of patients were homosexual males of Dutch nationality with a 
median age of 40 years. Most patients had asymptomatic or mildly symptomatic HIV-
disease with a median CD4 cell count of 365 cells/mm3. Approximately half of the patients 
were antiretroviral treatment-experienced prior to initiating their first HAART. The most 
frequent reason for switching the first HAART regimen (with HIV-1 RNA :5 500 copies/ml) as 
indicated by the treating physician was toxicity and the most frequent type of treatment 
switch was replacement of Pis by another PI without changing the NRTis. The various Pis used 
in HAART reg·1mens are summar"1zed in table 2. The most common PI and NRTI-combinations 
in both the first and second regimens were indinavir with zidovudine and lamivudine {data 
not shown). The only NNRTI used in second-line regimens was nevirapine {n=122, Table 1). 
Table 2 Pis or NNRTls used in HAART regimens by patients who switched a first PI-containing HAART 
regimen without having virological failure (n=775) 
PI or NNRTI used First HAART Second HAART 
N (%) N (%) 
lOY 248 (32) 186 (24) 
RTV 182 [24) 84 (11) 
SOY 212 [27) 124 (16) 
NFV 18 (2) 66 (9) 
IDY/RTV 7 [1) 20 (3) 
SOY/RTV 84 [11) 114 (15) 
SOY /NFV 21 (3) 21 [3) 
NYP 0 (0) 113 [15) 
Other 3 (0.4) 13 [2) 
No PI or NNRTI 0 (0) 34 (4] 
IDV- indinavir; NFV= nelfinavir; NNRn- non-nucleoside analogue reverse transcriptase inhibitor; NVP= 
nevirapine; PI= HIV-protease inhibitor; RTV= ritonavir; SQV= saquinavir 
Incidence of toxicity-driven switches of the second HAART regimen 
Within one year 373 {48%) patients had a switch of the second regimen, with toxicity being 
the most common reason {n=142) rrables 1 and 3). Table 3 summarizes the ·lnddence of the 
different reasons for switching second-line HAART, as well as the detectability of HIV-1 RNA 
{below or above 500 copies/ml) at the end of follow-up. The one-year cumulative 
incidence of toxicity-driven switch on second-line HAART was 24% (95%CI: 21-28). The overall 
one-year cumulative incidence of switching a second-line HAART regimen was 53%, 
indicating that approximately half of the switches were attributable to toxicity. Switching 
treatment for toxicity usually did not coincide with virological failure. 
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Tobie 3 Reasons for switch of the second HAART regimen with one-year cumulative incidences and 
last HIV-1 RNA among patients who had switched the first HAART regimen without having 
virological failure (n=775) 
Reason for switch of the 
second HAART Total 
HIV-1 RNA at end of follow-up" 
Missing <500 >500 
copies/ml copies/mL 
Not switched 
Total switched 
Switched due toe: 
n 402 
N=373 
N (%) 
1 [OJ 
45 [12) 
N [%) N 
352 [88) 49 
259 [69) 69 
Toxkity no142 17 (12) 113 (80) 12 
Failure n=53 9 (17] 5 (9] 39 
Patient request n=40 3 (8) 30 (75] 7 
Pharmacological indication n=24 2 (8) 21 (88) 1 
Other no76 6 (8) 64 (84) 6 
Unknown n~33 8 (21 J 26 (68) 4 
95%Cl- 95%-confidence interval; HAART highly active antiretrovirol therapy 
(%) 
[12) 
(18) 
(8) 
(74) 
(18) 
(4) 
(8) 
111 I 
One-year 
cumulative 
incidenceb 
% (95%CIJ 
53 
24 
11 
8 
5 
14 
7 
(49-56) 
(21-28) 
(8-13) 
(5-10) 
(3-7) 
(11-17) 
[5-9) 
a Follow-up ended at last data delivery, end of one-year period or switch of the second regimen. 
whichever come first 
b Rgures have been estimated by means of Kaplan Meier survival analysis 
c Within one year 373 patients hod switched the second regimen due to various reasons. Physicians 
hove to indicate the primary reasons for switch as toxicity, patient request, treatment failure 
(immunological, virological or clinical). pharmacological, other (with specification) and unknown. 
In a sub-group analysis among patients who had switched the first HAART regimen due to 
toxicity {n=270), 77 (representing more than 1 0% of the current study cohort) subsequently 
had another toxicity-driven switch. The one-year cumulative incidence of such subsequent 
toxicity-driven switches was 37% {95%CI: 30-44), indicating a higher risk of switching for 
toxicity for patients who had previously changed treatment likewise as a result of toxicity 
compared to patients who had not [Figure 1). 
Factors associated with toxicity-driven switches of the second HAART regimen 
After univariate analysis and stepwise multivariate analysis, four factors were identified 
which were associated with toxicity-driven switching of second-line HAART (Table 4). First, we 
observed a risk reduction over calendar time. Second, women appeared to have a higher 
risk of toxicity-driven switches than men. Similarly, patients who switched the first HAART 
regimen due to toxicity relative to patients who switched due to other reasons had a 2.5-
fold increased risk {95%CI: 1.7-3.5) for toxicity-driven switch of the second regimen. Finally, 
among the various types of switch. switching from PI to nevirapine without changing the 
NRTis appeared to be protective against a subsequent switch for toxicity reasons (adjusted 
RR: 0.2. 95%CI: 0.1-0.6]. Conversely, switching from PI to nevirapine with a concomitant 
change of NRTis was not protective. Within the sub-group of patients who prev·1ously 
switched first HAART due to toxicity (Table 4, column 3], switching to neviropine without 
changing the NRTis was equally protective, whereas switching to nevirapine and 
concomitantly changing NRTis tended to increase the risk. 
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Figure 1 Probability of toxicity-driven switches of the second HAART regimen in relation to the reason for 
having switched the first HAART regimen 
Figure shows the probability of toxicity-driven switches of the second HAART regimen 
according to the reason for having switched the first HAART regimen. Patients who switched 
the first regimen due to toxicity {solid line) hod a higher probability than patients who switched 
the first regimen for other reasons [broken line). 
Table 4 Risk factors for toxicity-driven switch on the second HAART regimen for patients who hod 
switched the first HAART regimen without having virological failure [n=775) 
Risk factor Multivorioteo First HAART switched 
for toxicity (n=270) 
RRodj 95%CI RRodj 95%CI 
Calendar time of switching first HAART Per month 0.98 (0.9-0.99) 0.97 (0.9-1.0) 
Gender Mole 1 1 
Female 1.7 (1.1-2.6) 1.6 (0.9-3.0) 
Switch first HAART due to toxicity No 1 
Yes 2.5 (1.7-3.5) 
Type of switch 
NRTI unchanged Pl(s)tootherPI(s) 1 1 
Pl(s) to nevirapine 0.2 (0.1-0.6) 0.2 (0.1-0.8] 
Dose/frequency PI changed 0.8 (0.4-1.5) 1.1 [0.4-2.9) 
Other change of PI 1.4 (0.7-2.8) 1.4 (0.6-3.5) 
Pl(s) unchanged 0.8 (0.5--1.2) 1.0 (0.5--2.0) 
NRTI changed Pl(s) to other Pl(s) 0.9 (0.4-1.8) 0.9 (0.4--2.9) 
Pl(s] to neviropine 1.5 (0.6-3.7) 2.6 (0.9-7.3] 
Dose/frequency PI changed 0.3 (0.0-1.8) 0.4 (0.1-2.9) 
Other change of Pl(s) 0.8 (0.2-3.2) 1.4 (0.3-5.9) 
Pllsl unchanged 0.7 {0.4-1.2) 0.8 (0.4-1.51 
95%CI 95% confidence interval; ARV ontiretrovirol: freq. frequency; HAART- highly active 
antiretrovirol therapy; MSM= men having sex w·tth men: NRTI= nucleoside reverse tronscriptose inhibitor. 
NNRTI= non-nucleoside reverse tronscriptose inhibitor; PI= HIV-proteose inhibitor. RR= relative risk: RRodj= 
adjusted relative risk 
a Adjusted for all other variables in the table, which were all associated with switch of the second 
regimen due to toxicity at a p-volue of 0.1 in the univariate analysis 
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Body mass index and lean body mass as well as other baseline characteristics, such as 
nationality, route of HIV-transmission, antiretroviral treatment experience prior to first HAART 
and duration of first HAART did not significantly influence the incidence of toxicity-driven 
switch on the second regimen (data not shown). Stratification by hospitaL in order to 
explore whether results may have been influenced by being under the care of a specific 
treatment centre, did not alter the conclusions {data not shown). 
Types of toxicity leading to toxicity-driven switches 
Table 5 summarizes the different types of clinical toxicities, which were specified as the 
reason(s) for switching treatment. No significant difference in the distribution of toxicities was 
observed between initial and subsequent HAART regimens. For both the first and second 
regimen, the most common types of toxicity resulting in a treatment switch were gastro-
intestinal events and peripheral neuropathy. 
Table 5 Types of toxjcity leading to treatment switches on first- and second-line HAART regimens 
First HAART Second HAART Both first and second 
(n=270) (n=142) HAART {n=77) 
Event description° N {%]b N (%)' N [%)d 
Gastro-intestinal 100 (37) 53 (37J 19 [36J 
Peripheral neuropathy 34 (13J 17 (12) 6 [35) 
Hoematologicol 30 (11) 11 (8) 3 [27J 
Renal 18 (7J 10 (7J 3 (30J 
Malaise 18 (7) 9 (6J 1 [11J 
Lipodystrophy 14 (5J 6 (4J 0 (0) 
Hepatologicol 11 (4) 8 (6) 1 [13J 
Ear Nose and Throat 10 (4J 4 (3J 1 [25J 
Hyperlipidemia 8 (3) 2 (1) 0 [0) 
Musculo-skeletal 7 (3J 2 Ill 0 [OJ 
Dermatological 5 (2) 1 (1J 0 [OJ 
Pancreatitis 3 (1) 3 (2) 2 [67) 
Diabetes mellitus 1 (0.4) 1 (1) 1 (100) 
Miscellaneous 4 (2J 7 (5) 0 [OJ 
Missing 27 [10J 16 (11J 4 [25J 
Discontinuation due to H 4 [3J 1-J 
death 
HAART- highly active ontiretroviral therapy 
a Descriptions are based on the body-system in which the event occurred; patients may hove more 
than one event 
b Percentage of patients who switched first HAART due to toxicity {n= 270) 
c Percentage of patients who switched second HAART due to toxjcity (n= 142] 
d Percentage of patients who switched both first and second HAART due to this toxjcity {column 3] 
After having switched the first HAART due to gastro-intestinal toxicity (n=lOO), the one-year 
risk of a recurrent toxicity-driven switch due to gastro-intestinal toxicity was 26% (95%CI: 15-
37%), representing a 5.1 (95%CI:2.1-12.1) fold increased risk relative to patients who switched 
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the first HAART due to other toxicity reasons [n=170). Out of 100 patients who switched the 
first HAART for gastro-intestinal toxicity reasons, 22 patients switched to NVP without 
changing NRTis. Only one of those had a recurrent switch due to gastro-intestinal toxicity on 
the second regimen, suggesting a general improvement of gastro-intestinal toxicity among 
patients who switched to NVP. 
After having switched the first HAART due to neuropathy, the one-year risk of 
another toxicity-driven switch due to neuropathy on the second regimen was 21% (95%CI: 5-
37%) yielding a RR of 12.8 [95%CI: 3.2-51.3) compared to patients who switched the first 
regimen due to other toxicity reasons. The small number of patients did not allow a 
distinction be1ween the types of switch regarding the risk of neuropathy driven switches on 
the second regimen. 
Differentiating be1ween those who concomitantly changed NRTis during the first 
switch and those who did not resulted in relative risks for a recurrent switch due to 
neuropathy on the second regimen of 8.2 [95%CI: 1.5-45.1) and 19.2 [95%CI: 1.7-212.7) for 
these 1wo groups of patients respecf1vely. These results suggest that changing the NRTis 
along with Pis can reduce the risk of a neuropathy driven switch. The fact that recovery from 
neuropathy is a time consuming process might explain that the increased relative risk did 
not disappear. 
Discussion 
In this cohort study, more than half of the patients who switched initial treatment for reasons 
other than virological failure again switched treatment within one year. Toxicity accounted 
for approximately half of these second switches and mostly involved gastro-intestinal events 
and peripheral neuropathy. In line with previous reports, patients who switched a first HAART 
regimen for reasons of toxicity had a greater than 1wo-fold increased risk of a subsequent 
switch because of toxicity (8). This imp~es that a subgroup of patients may exist including at 
least 10% of all patients, who are particularly prone to the development of HAART-
associated toxicity. There was a slight reduction in risk of toxicity-driven switch over calendar 
time, which may reflect improved toxicity management as the experience of a physician 
evolves. 
The proportion of toxicity-driven switches has previously been reported to be high 
for both first-line (26% within one year) (5, 6) and second-line PI-containing HAART regimens 
(33% during a median of 483 days) (8). These findings however were based on the first 
regimen only and a relatively small single-centre patient population. In a much larger and 
multi-centre patient sample, we observed a 24% one-year cumulative incidence of 
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switching second-line regimens for toxicity. This figure may be slightly higher than for the 
entire population on second-line HAART, given that patients were selected who had a prior 
switch of treatment in the absence of virological failure, and therefore may have been at 
potentially higher risk of a subsequent toxicity-driven switch. However, selecting such a 
population allowed us to investigate various types of switch including switches betvveen 
classes of antiretrovirals, without the choice of subsequent regimens being influenced to 
any important extent by concerns of antiviral potency and cross-resistance betvveen drugs. 
An interesting observation was that switching to nevirapine, without concomitantly 
switching the NRTis, was associated with a five-fold lower risk of a subsequent toxicity-driven 
switch. The favourable effect of switching to nevirapine has been described before, albeit in 
small series of patients with a limited follow-up or a limited reference group {20-23). 
Unfortunately, we were not able to study the effect of switching to other NNRTis, such as 
efavirenz and delavirdine, since these drugs were not licensed in the Netherlands during the 
period covered by our current analysis. Remarkably, combining the switch to nevirapine 
with a change in concomitant NRTis, annihilated the advantageous effect of switching to 
nevirapine, possibly indicating the additional toxicity of the newly introduced NRTis. None of 
the other types of switch, including switching betvveen different Pis and changing NRTis at 
the same time, significantly influenced the risk of a subsequent toxicity-driven switch. 
No associations were found betvveen lean body mass or body mass index and the 
incidence of treatment switch for toxicity, suggesting little influence of distribution volume on 
toxicity risk for any of the drugs. Toxidty-driven switches occurred independently of patient 
nationality, which might suggest that cultural differences do not play a major role, but this 
association needs further substantiation. Women seemed to be more susceptible to toxicity. 
This may be attributable to sex-dependent pharmacokinetics or adherence leading to 
higher plasma concentrations of Pis in particular {24). Alternatively, women may be more 
sensitive to toxicity or report toxicity more easily than men, resulting in a reporting bias. 
Since this was an observational cohort study, results may have been confounded. 
For example, as guidelines for switching primarily focus on virological failure rather than 
toxicity [12, 17, 25), the decision to switch and how to switch was dependent of the treating 
physicians. They were also asked to indicate the primary reason for switching. As a 
consequence the observed effects for the type of switch might in fact have been 
confounded by physician's preference. However, stratification by hospital did not alter the 
results, which to some extent reduces the likelihood of physician confounding. As we were 
able to adjust for the potential confounding effects of other determinants for toxicity-driven 
switches, the effect of residual confounding is assumed to be minimal. 
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Risk factors for intolerance driven switches 
In conclusion, toxicity continues to be a cause of major concern in the treatment of 
HIV-1 infection. It was deerned responsible for the majority of recurrent treatment switches 
among patients who had initially switched first-line HAART while having reasonable virus 
suppression, particularly among patients who had also switched their first-line HAART for 
toxicity. Switching to nevirapine rather than to an alternative PL without concomitantly 
switching the NRTis, was associated with a significantly lower risk of again having to switch 
the new regimen for toxicity, even in patients with prior toxicity. These findings may provide 
guidelines for how to minimize the risk of renewed toxicity when managing patients with 
toxicity during PI-based HAART. 
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General Discussion 
Chapter 5 
The overall objective of this thesis was to provide more insight into the risk of adverse effects 
during treatment with HIV-protease inhibitors under everyday circumstances. Within the 
scope of this objective the incidence of renal complications of the HIV-protease inhibitor 
indinavir were studied as well as the risk factors and consequences. Also, the incidence of 
and risk factors for dnically diagnosed lipodystrophy, an alleged adverse effect of HIV-
protease inhibitor treatment, were examined. In addition, we investigated whether 
switching to an HIV-protease inhibitor-sparing regimen might be favorable in terms of 
regimen consistency and viral suppression. Finally, we evaluated the impact of treatment 
intolerance on treatment continuity. 
In this chapter, the main findings and limitations of the thesis will be discussed and 
the results will be put into perspective. First however, relevant developments in the five 
years following the introduction of the HIV-protease inhibitors are described. 
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Five-years of experience with HIV -protease inhibitor treatment 
In July 1996, the HIV-protease inhibitors were introduced to the Dutch market at an 
unprecedented speed. Therefore, extensive research on safety and effectiveness had to be 
done in the post-marketing setting. Typical problems of HIV-protease inhibitor treatment, 
which were expected to jeopardise treatment success included complex treatment 
schedules, drug interactions via cytochrome P450 (1-3) and abundance of adverse effects 
(4-6). 
Treatment success 
Notwithstanding the anticipated problems, the new antiretroviral treatment modalities 
involving HIV-protease inhibitors turned HIV-infection into a manageable chronic condition 
as illustrated by a dramatic decrease in HIV-related morbidity and mortality (7-9). Similar 
trends were observed in the Dutch treated HlV-infected population described in the final 
ATHENA report (10). As there is, however, no prospect of eradication of HIV with currently 
available an.tiretroviral agents. treatment needs to be life-lon.g (11-16). In fact, HIV-infection 
continues to be a potentially life-threatening condition as disease progression can occur 
rapidly if treatment is sub-optimal or plasma drug concentrations are sub-therapeutic (17-
19). 
Changes in treatment schedules 
Waning adherence is a known problem for chronic treatments (20-22). A sub-analysis within 
the ATHENA cohort showed that only half of the patients fully adhere to treatment 
instructions (23). Until the arrival of easier treatment regimens, professional support tailored 
to the individual patients' needs is probably the best safeguard against poor adherence 
(24). 
Most changes within the currently available treatment modalities have been 
directed at treatment simplification and toxicity reduction. An important development 
regarding treatment simplification has been the use of the cytochrome P450 dependence 
of H!V-protease inhibitor clearance for pharmocokinetic manipulation of plasma drug levels, 
such as the boosting of indinavir or saquinavir plasma levels by ritonavir (25-35). Hence, 
regular treatment schedules can be given twice daily instead of three times daily and many 
food restrictions can be dropped. 
The arrival of non-nucleoside analogue reverse transcriptase inhibitors. like 
nevirapine and efavirenz, in 1997 provided further means for treatment simplification (36, 
37). These agents exert strong antiretroviral activity (38, 39) but generally have longer half-
lives than HIV-protease inhibitors allowing for twice daily or even once daily dosing. 
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Interactions between HIV-protease inhibitors and concomitant drugs 
A high impact of drug interactions with HIV-protease inhibitor treatment was expected 
because of the involvement of the cytochrome P450 system in the metabolism of HIV-
protease inhibitors (L 4, 40, 41). Tabulated lists of potentially hazardous combinations and 
contra-indicated medications often based on theoretical interactions were developed to 
assist treating physicians in choosing the right treatment combinations. 
In due course, however, the importance of interactions decreased with the 
reduced need for concomitant treatment (9). Moreover, growing expertise with HIV-
protease inhibitor plasma concentration measurements facilitated the 'safe' use of 
concomitant therapies in which the cytochrome P450 system might play a role. 
Adverse effects reported dun"ng the use of H/V-protease inhibitors 
Regarding the safety of HJV-protease inhibitors, a Jorge number of published case-reports 
about adverse effects illustrated some of the risks involved in using HIV-protease inhibitors 
(Table). Several observational studies showed a major impact of adverse effects on 
treatment continuity [42-46). 
A safety issue, which received much attention in the literature, was renal 
complications of indinavir treatment. Pre-registration studies had recognized nephrolithiasis 
as a characteristic adverse effect of indinavir {47, 48), but the severity and frequency of the 
complications appeared to be different under everyday circumstances (49-52). 
Probably the most important finding during post-marketing of HIV-protease 
inhibitors was the lipodystrophy syndrome and its associated disorders, such as 
cardiovascular complications {53, 54]. Clinical trials had failed to identify this adverse effect 
despite its high prevalence. This was at variance with the perception of experts at the 
introduction in July 1996, when many had the opinion that all adverse reactions of HIV-
protease inhibitors were already known, and illustrates the importance of post-marketing 
surveillance. 
A likely explanation for the fact that lipodystrophy was not detected in clinical trials 
is its gradual onset and relatively long induction and latency period. Although lipodystrophy 
showed a clear temporal association with the introduction of HIV-protease inhibitors, a 
definite causal link has not yet been established. 
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Table Adverse effects of HIV-protease inhibitors reported in case reports and case series in the literature 
Category 
Musculo-skeletal 
Breasts 
Fat metabolism 
Metabolic 
Cardiovascular 
Coagulation 
Urological 
Renal 
Hepatotoxicity 
Hypersensitivity 
Immune 
reconstitution 
Nails 
Pancreatitis 
Miscellaneous Pis 
adverse effects descriptions 
Acute monoarthritis, arthalgia+cryoglobulinemio 
Osteonecrosis, osteoporosis, pathological fractures 
Frozen shoulder 
Breast hypertrophy, gynaecomostia 
Buffalo hump 
Adipose tissue hypertrophy, lipemia retinalis, 
lipodystrophy, lipomatosis, protease paunch, pseudo 
Cushing's disease, striae, subcutaneous lipomas 
Diabetes or glucose abnormalities, hypertriglyceremia, 
hypercholesterolemia, ketoacidosis, mitochondrial and 
peroxisomal dysfunction 
Angiolipamotosis, bradycardia, coronary artery disease, 
intestinal infarction, myocardial infarction, sudden 
cardiac death, other vascular complications 
Haemolysis, haemorrhage, platelet dysfunction, 
thrombocytopenia 
Crystalluria, urolithios and nephrolithiasis, interstitial 
nephritis, renal atrophy 
acute renal failure, anuria 
anoxic hepatic necrosis, toxic hepatitis, portal vein 
thrombosis 
rash, Stevens-Johnson syndrome, urticaria 
Exacerbation viral hepatitis, MAC infection activation, 
progressive mu!lifocal leukoencephalopathy 
Ingrown toenails, paronychia 
Acute pancreatitis 
Alopecia, Groves' disease, carpal tunnel syndrome, 
hyperaestesio, iron overload, panniculitis, respiratory 
failure, uveitis, vifritis 
suspected antiretroviral drugs involved 
indinavir, HIV-protease inhibitors 
HIV-prolease inhibitors, saquinavir, 
indinavir+lamivudine+stavudine 
indinavir, indinavir+lamivudine+stavudine 
indinavir, HIV-protease inhibitors, HIV-protease 
inhibitors+stavudine, indinavir, saquinavir 
HIV-protease inhibitors 
HIV-protease inhibitors, indinavir, ritonavir 
HlV-protease inhibitors, nelflnovir, indinovir, 
ritonavir, saquinavir 
indinavir, nelfinavir, HIV-protease inhibitors, 
ritonavir 
indinavir, amprenavir, HIV-protease inhibitors, 
ritonavir, nelfinavir, saquinavir 
lndinavir 
indinavir, ritonavir, ritonavir+saquinavir 
indinavir, ritonavir+saquinavir, 
ritonovir+zidovudine, ritonavir 
HIV-protease inhibitors, indinavir, nelfinovir 
HIV-proteose inhibitors, 
indinavir+lomivudine+stovudine, indinavir, 
ritonavir+lamivudine+sfovudine 
indinovir, lamivudine 
nelfinovir, ritonavir 
HIV-protease inhibitors 
Relevant co- references 
factor 
hepatitis c 
Warfarin 
CMV 
(79, 80) 
(81-85) 
(86-88) 
(89-95) 
(96, 97) 
(53, 69, 70. 72, 
73, 98-108) 
(109-121) 
(122-133) 
(I 34-146) 
(55-59, 63, 147-
168) 
(60-62, 64, 65, 
169-175) 
(176-183) 
(184-190) 
(191-197) 
(198-202) 
(203-205) 
(206-214) 
Ga\octorrhoea+hyperprolactinaemio m•- tHY-protease inhibif_9rs, nevirapine {215) 
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Category adverse effects descriptions 
Cheilitis, focal mycobacterial lymphadenitis, hair loss, 
mood changes, leucocytoclostic vasculitis, 
maculopapular eruption, porphyria, uveitis 
suspected anliretroviral drugs involved 
lndinavir 
Neuropathy, normalisation von Wil!ebrond, oesophagitis Nelfinavir 
Herpes Zoster, hypermenorrhea, maculopapular Rilonavir 
eruption, myasthenia gravis 
Relevant co- references 
factor 
{216-222) 
{223-225) 
{226-229) 
Gout Ritonavir+didanosine (230) 
Mucosal Kaposi's sarcoma, renin-angiotensin inhibition Rilonavir+saquinavir Overdose (231, 232) 
Acute paranoid reaction, photosensitivity saquinavir (233, 234) 
ddl= didonosine; IDV"' indinovir; NFV::: nelfinavir; NVP= neviropine; PI::: HIV-protease inihibitor; RTV= ritonavir; SQV::: saquinavir 
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Main findings of this thesis 
lndinovir associated renal complications (chapter 2) 
Renal complications form an important treatment-limiting effect of indinavir (47). Apart from 
causing treatment switches. forms of renal injury, such as interstitial nephritis [55-57), renal 
atrophy (58, 59), renal failure (60-66) or. as described in this thesis (chapter 2.1 ). papillary 
necrosis {67) may have serious consequences (chapter 2.1). The onset of indinavir 
nephrotoxicity can be insidious particularly in children. Two out of five children, treated with 
indinavir at the Sophia children's hospital in Rotterdam and presenting with persistent 
leukocyturio without overt symptoms, appeared to have congested kidneys associated with 
renal cortex atrophy on ultrasound (68). Leukocyturia disappeared and renal structures 
recovered rapidly upon indinavir withdrawal. 
The first nephrotoxicity study (chapter 2.2) involved a small case series of patients 
with urological complaints from the Erasmus university Medical Centre. Plasma indinavir 
concentrations of patients with complaints were on overage 2.6-fold higher than plasma 
indinovir concentrations of patients without complaints from the University Hospital 
Nijmegen. Hence, it was suggested that indinovir-ossocioted urological complaints are 
associated with high indinavir plasma concentrations 
The second study [chapter 2.3} describes a population-based cohort study carried 
out within the ATHENA cohort. which confirmed that urological symptoms ore specific for 
indinavir. The incidence of urological symptoms (renal colic, flank pain, gross hematuria. 
renal failure, nephritis) among indinavir using patients was 8.3% within the first year of 
treatment. which is tvvice as high as reported in clinical trials (47). Risk factors for urological 
symptoms during indinovir treatment were: viral suppression (indicative of adequate or high 
indinovir plasma concentrations), low lean body mass (indicative of small distribution 
volume), indinovir dosing regimen of !:: 1000 mg bid [indicative of high Cmax), and high 
environmental temperatures (proxy for reduced urine output due to excessive sweating). 
These results ore consistent with a concentration dependent solubility problem of indinavir 
causing indinovir crystal formation [Figure 1). 
The third study (chapter 2.4} had an experimental design and was conducted to 
obtain more insight into the solubility problem underlying indinavir-associoted renal 
complications. The renal sites at which indinovir solubility is exceeded and crystals may arise 
was determined by simulating the normal physiological conditions in the renal system in in 
vitro crystallisation experiments (Figure 2). 
The risk of indinavir crystallisation appeared highest under the conditions 
encountered in the loop of Henle. Assuming absence of re-absorption and active secretion 
of indinavir in proximal tubuli. indinavir crystals might already occur in the loop of Henle at 
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plasma concentrations of 8 mg/L which is the average Cmax reached with indinavir 
regimens of 800 mg tid. As the conditions in the loop of Henle are not substantially 
influenced by water intake, increasing water intake (ie. diluting urine) as recommended for 
patients with ind"inavir nephrotoxicity, might be insufficient, in particular for patients with high 
indinavir plasma concentrations. Therefore, beyond the present recommendations, plasma 
concentration-guided dose adjustment is worth considering in the future. 
We performed prospective systematic monitoring of renal parameters to study the 
prevalence of renal abnormalities among adults {chapter 2.5) and children (chapter 2.6) 
treated with indinavir. These studies demonstrated that indinavir nephrotoxicity can have an 
insidious onset and may develop into sub-clinical renal failure. In the adult population, who 
had been using indinavir for more than a year, the prevalence of nephrotoxicity presenting 
as sub-clinical persistent sterile leukocyturia was 25%. The cumulative incidence of persistent 
leukocyturia in children was 53% in approximately three years. Leukocyturia was associated 
with high plasma indinavir concentrations, which confirms the findings of our previous 
studies. Urine supersaturation may cause indinavir crystal formation and a subsequent 
inflammatory reaction. Although leukocyturia disappeared instantly upon indinavir 
discontinuation, the long-term risks of persistent leukocyturia during indinavir continuation 
are unknown at present. 
The lipodystrophy syndrome (chapter 3} 
Lipodystrophy is both a remarkable and disturbing adverse effect of antiretroviral treatment, 
which was unknown at the time of licensing the HIV-protease inhibitors (chapter 3.1 )- The 
syndrome was initially attributed to HJV-protease inhibitors in particular (54, 69-73) owing to 
the temporal associaf1on between HIV-protease inhibitor introduction and development of 
lipodystrophy. Later studies, however, added stavudine as a potential causal agent (74) or 
even attributed the effect on fat distribution to alleviation of metabolic stress. A 
complicating factor for studies on causes of lipodystrophy, is the long induction and latency 
period during which patients may have received multiple treatment regimens. 
Because of its alleged but unproven association with HIV-protease inhibitors, we 
performed a retrospective cohort study within the ATHENA cohort (chapter 3.2). This study 
aimed to identify risk factors for lipodystrophy, taking into consideration treatment regimens 
and changes of regimens. Stavudine-containing HAART regimens rather than indinavir-
containing regimens were identified as the most important risk factor for lipodystrophy. 
Factors such as age, gender, baseline body mass index and immunological and virological 
response also appeared to play a role. Among the HJV-protease inhibitors, indinavir 
appeared to be most evidently associated with lipodystrophy, but HIV-protease inhibitors in 
general seemed to play a minor role. In conclusion, the data do not confirm a major role for 
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HIV-protease inhibitors in the development of lipodystrophy and allocate a more important 
role for the nucleoside-analogue reverse transcriptase inhibitor, stavudine. These data 
provide new clues for underlying (multi-factorial) causes of lipodystrophy and could help to 
direct further (prospective] research both in vivo and in vitro. 
Adverse effects and treatment switches (chapter 4) 
Inadequate adherence to antiretroviral treatment regimens is a cause of concern. Apart 
from the risk of waning motivation after long-term treatment, complex schedules, large 
quantity of pills, diet restn"ctions and bothersome or hazardous adverse effects continuously 
jeopardise adherence to HAART. Efforts to find suitable treatment regimens tailored to 
individual patients' needs or regimens with generally more favourable properties should 
help to improve adherence and treatment success. Unlike for virological failure {75-77), 
guidelines on strategies for other reasons for switching are absent. We examined the impact 
of switches performed in daily practice on treatment continuity and the impact of 
intolerance-driven switches on treatment continuity. 
Antiretroviral regimens with non-nucleoside analogue reverse transcriptase 
inhibitors such as nevirapine and efavirenz, are relatively simple and exert few adverse 
effects despite strong anti-HIY activity. These agents might offer a solution for the problems 
encountered with HIY-protease inhibitors. 
An initial case series from the Erasmus universtity Medical Centre indicated that 
patients who switched to a nevirapine-containing regimen while having a low HIV-1 RNA 
{<500 copies/ml) were able to maintain viral suppression with less adverse effects {chapter 
4.1). 
Subsequently, we compared the incidence of treatment discontinuation and 
virological failure between persons who switched either to nevirapine or to a second-line 
HIV-protease inhibitor despite viral suppression in the ATHENA cohort {chapter 4.2). This study 
failed to show a lower rate of adverse effects, but did show a 5-fold lower risk of having a 
further switch or having virological failure in the nevirapine group. Switches to non-
nucleoside analogue reverse transcriptase inhibitors were therefore beneficial for treatment 
continuity_ 
In the last study (chapter 4.3], we aimed to identify risk factors for toxicity-driven 
switches within the ATHENA cohort. The most frequent reason for switching HAART appeared 
to be gastro-intestinal complaints, such as nausea, vomiting, diarrhoea, and neuropathy 
whereas lipodystrophy rarely caused treatment switches. In this cohort study we showed 
that toxicity-driven treatment switches in daily practice often fail to resolve the problems 
and are soon followed by a further toxicity-driven switch. Switching to another class of 
169 
Chapter 5 
antiretrovirals. such as nevirapine was. however, associated with less further toxicity-driven 
switches and therefore seems worth considering for toxicity management. 
Methodological considerations 
The studies in this thesis were performed predominantly with prospective observational data. 
The advantages and disadvantages of observational studies are well recognised. 
Observational studies are often relatively cheap and tell us more about the actual use of 
drugs than clinical trials. Observational studies with ongoing data collection can provide 
quick clues to acute health care issues. Studies performed with observational data. 
however, have to deal with complex validity issues such as bias and confounding. 
In observational studies with exposure and disease registries. information bias is less 
likely since the research objective was not known at the time of registry. The original purpose 
of the registry and conditions for entering the registry, however. may be a source of 
selection bias. Moreover, the Iorge amount of data is usually achieved at the cost of detail. 
due to which it may be impossible to adjust completely for confounding factors. It can be 
extremely difficult to adjust for confounding by indication since the choice of treatment is 
not random and the underlying reason for giving a certain regimen is usually not registered. 
The limitations of each individual study in this thesis have been addressed in the 
discussion sections of the study reports. Here we describe potential general shortcomings 
pertaining to the chosen study settings. 
The ATHENA cohort 
The ATHENA cohort formed the source population for most of our studies. The ATHENA 
project aimed to recru.lt all patients starting on one of the new antketrov"1ral agents, 
including the HIV-protease inhibitors, non-nucleoside analogue reverse transcriptase 
inhibitors and nucleoside analogue reverse transcriptase inhibitors. Extensive informof1on on 
antiretroviral treatment details, CD4 cell count and HIV-RNA load was collected as well as 
details on adverse effects leading to antiretrovirol treatment changes or included in a list of 
special adverse effects. 
The purpose of the ATHENA project was to determine the implicaf1ons of 
introducing the new antiretroviral agents in July 1996 for the course of HIV-infection, public 
health and HIV/AIDS health care as well as the costs and economic benefits. In addition, 
the resulting database would serve as a source for several other. more specific studies. In 
order to judge the generalizobility and validity of results derived from the ATHENA cohort, 
the representativeness of the cohort and bias and confounding inherent to the design and 
set up of the ATHENA project and observational nature of the registry are discussed below. 
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Validity and generalizability of patient selection 
By the end of the year 2000, 3377 patients had been enrolled into the ATHENA cohort. They 
represented approximately 70-80% of the treated Dutch H!V-infected population 
(Monitoring of Human Immunodeficiency Virus Type l [H!V-1) Infection in the Netherlands) 
(10). The selected population may not be entirely representative of the Dutch H!V-infected 
patient population, since patients had to give written informed consent in order to be 
included. This might have caused selection toward relatively healthy patients, who were 
able to read and understand the Dutch or English language and willing to sign consent 
forms. Apart from limitations in generalizability, omission of certain patient types will lead to 
selection bias only if it is done differentially for both treatment regimens and outcomes. 
Validity and generaHzability concerns pertaining to method of data collection 
The quality of information on antiretroviral treatment and disease progression is likely to be 
high as these data are generally recorded very precisely in the medical records. The quality 
of information on adverse effects, however, may be a potential source of misclassification 
since case definitions for the diagnoses (special adverse effects) on the ATHENA data 
collection sheet are absent. 
Physicians may fail to record cases that do not fully comply with the listed 
diagnosis, but prompting of specific diagnoses may also lead to over-reporting. As a 
consequence some inaccuracy has to be taken into account for incidence and 
prevalence rate estimates of such outcomes. Furthermore, ambiguous reporting might 
induce reporting bias in cohort studies and selection bias in case-control studies if it is done 
differentially for exposure. 
Residual confounding remains a point of concern due to absence of information 
on a number of potentially important confounding factors [eg. smoking, socio-economic 
status, family history, medical history, concomitant drug use). Finally, time effects should 
always be taken into account in view of the rapid developments in the area of HIV/AIDS, 
such as the rapidly changing treatment regimens and the introduction of more sensitive HIV-
RNA measurement techniques. 
Validity issues in studies performed with the ATHENA cohort 
In the nephrotoxicity and lipodystrophy studies, participation rates for the ATHENA cohort 
might have negatively affected the incidence rate estimates if patients suffering from these 
conditions would be less likely to participate. Since data on non-participants are not 
available we cannot verify the extent of a potential bias resulting from selective 
participation. 
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Underreporting of adverse effects could have suppressed the estimated incidence 
rates, whereas diagnostic suspicion might have led to an overestimation. Diagnostic 
suspicion was likely to be differential over time because of the changing and strong 
opinions regarding the causes of the adverse effects. For example, nephrotoxicity and 
lipodystrophy were both considered as a consequence of indinav·rr in part·rcular. We dealt 
with this issue by restricting the study population to indinavir users for the nephrotoxicity 
studies. Stratification for calendar time solved time-dependent diagnostic bias in the 
lipodystrophy study. 
A potential bias we were unable to deal with adequately in the switch studies, was 
the fact that availability of alternative treatment regimens may be different for different 
initial regimens. Suitability of alternative regimens depends on treatment history and current 
treatment. It is tempting to conclude that class switches, such as switches to nev·rrapine, 
would benefit all patients with viral suppression on HIV-protease inhibitors. However, since 
we could not control for underlying reasons for switching to a certain regimen, such as for 
example the availability of alternatives, our findings should be confirmed in a randomised 
study. 
Perspectives and recommendations 
Due to the introduction of HJV-protease inhibitors on the Dutch market, the therapeutic area 
of HIV I AIDS has changed considerably. Apart from a substantial gain in survival, experience 
with the new treatment entities grew quickly. The developments of the past five years 
resulted in a better application of HIV-protease inhibitor containing antiretroviral treatment 
and a better patient management. 
Presently, adverse effects are responsible for the majority of problems, which 
accompany antiretroviral treatment. These problems w"rll have to be tolerated or dealt with 
through effective toxicity management and preventative strategies. For this purpose, risk 
factors and underlying patho-physiological pathways have to be known and potential 
control measures have to be tested. 
In our experience, data from the ATHENA cohort constituted a useful resource for 
performing (pharmo-) epidemiological studies on indinavir nephrotoxicity and on 
lipodystrophy. Many other adverse effects might be studied this way. 
Future studies on indinavir nephrotoxicity 
Following the work of this thes·rs and considering literature reports, a number of issues 
regarding indinavir nephrotoxicity remain to be elucidated in order to develop strategies, 
which may adequately deal with this adverse effect. 
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Therapeutic Drug Monitoring and guided dosing adjustment might be worthwhile 
as an additional control measure for patients with abnormal renal parameters. First 
however, relevant pharmacokinetic parameter(s) will have to be identified. This is especially 
interesting in view of the new 'ritonavir boosted indinavir regimens', which generate either a 
higher Cmax or lower Cmax with higher area under the curve (AUC). Based on information 
about relevant pharmacokinetic parameters derived from studies on the association 
between indinavir nephrotoxicity and individual pharmacokinetic parameters, it may be 
possible to identify patients at risk of nephrotoxicity early in treatment. Moreover, it may be 
possible to test the hypothesis that indinavir crystals occur already at plasma indinavir 
concentrations of 8 mg/L. 
HIV-protease inhibitors are given at standard dosing regimens. Experience with 
indinavir showed that this might cause overdosing and excess adverse effects in some 
patients. Future studies on the impact of dose adjustments on adverse effects and desired 
effects may teach us that dose frequencies should rather be tailored to individual patients 
in order to prevent unnecessary negative effects. 
Future studies on lipodystrophy 
This thesis had no intention of determining the causes of lipodystrophy since this is a subject 
which cannot be adequately sorted out in an observational database without clear case 
definitions. Using the observational database of the ATHENA project however, helped 
understanding the coherence of potential risk factors for the syndrome even though the 
underlying mechanism remains unclear. The risk of lipodystrophy was most clearly 
associated with the use of stavudine and was hardly associated with the use of indinavir or 
any other HIV-protease inhibitor. This raises the question whether the use of stavudine should 
be avoided as much as possible. 
Ideally, causal factors for lipodystrophy are investigated in a prospective cohort of 
incident users of antiretroviral regimens, employing objective and systematic lipodystrophy 
assessments supported by laboratory parameters. By focussing on a comparison between 
stavudine users and non-users as done in the Prometheus study (74, 78), the sample size of 
such an elaborate study may be kept manageable. 
Treatment continuity 
Whereas the degree of switching H!V-treatment due to virological failure is low, the degree 
of switching due to other reasons appeared to be extremely high. Especially gastro-
intestinal intolerance and neuropathy are important causes of treatment switches. Studies in 
this thesis and the literature are suggestive of a disappointing effect from switches within the 
class of HIV-protease inhibitors as opposed to switches to other classes. This is in line with 
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class intolerance rather than with drug specific intolerance. The available data provide a 
basis for the development of provisional switching guidelines as a control measure for 
intolerance in patients with viral suppression. 
Naturally, before 'tmplementation, the effect of guidelines should be analysed in 
clinical studies. Such studies· should preferably be conducted in a randomised setting in 
order to overcome potential confounding by differential switching due to unknown 
underlying reasons. 
Finally 
The studies presented in this thesis reported on the scope of and the risk factors for tvvo 
important adverse effects of HIV-protease inhibitor containing antiretroviral therapy indinavir 
nephrotoxicity and lipodystrophy. In addition. the impact of adverse effects on treatment 
continuity and the impact of treatment switch on treatment continuity were reported. 
Obviously, there are numerous other adverse effects {eg. gastro-'tntestinal intolerance, 
neuropathy, lactate acidosis) which deserve scientific attention due to their treatment 
limiting effect or severe impact on wellbeing. 
In addition, the influence of concomitant medication on the risk of adverse effects 
remains to be studied. Disentangling the influence of concomitant medication on the risk of 
vkolog'tcal failure might be equally interesf1ng. 
From the perspective of pharmaco-epidemiology, the ATHENA project is unique in 
the sense that it captures an entire patient population. It may set the stage for other disease 
areas. 
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Chapter 6.1 
Summary 
The accelerated registration procedures and abrupt introduction of the HIV-protease 
inhibitors, which constituted an entirely new generation of medicines, required post-
marketing research more than usual. The objective of this thesis was to provide more insight 
into the safety of HIV-protease inhibitors. 
Within this scope we examined the incidence of renal complications of the HIY-
protease inhibitor indinavir as well as the risk factors and consequences in chapter 2. 
In chapter 2.1 a case of papillary necrosis following an episode of indinavir-
associated nephrolithiasis is described as a potential secondary complication of indinavir 
nephrotoxicity. 
Chapter 2.2 describes plasma indinavir concentration of patients with urological 
complaints in a case series of 17 patients from the Erasmus university Medical Centre 
compared a reference pharmacokinetic curve of 14 patients without complaints. Plasma 
concentrations of patients with complaints appeared to be on average 2.6-fold higher than 
concentrations of reference patients. Hence, an association between urological complaints 
and plasma indinavir concentrations was confirmed. 
In chapter 2.3 the incidence of urological symptoms during treatment with indinavir 
was determined for the Dutch treated patient population. Within the first year of treatment 
the cumulative incidence was 8.3%. which was twice as high as in clinical trials. Risk factors 
for developing urological symptoms were low lean body mass. low HIV-1 RNA, indinavir 
dosing regimens of.::: 1000 mg bid, and high environmental temperatures all pointing at an 
indinavir solubility problem and consistent with a central role for plasma indinavir 
concentrations. 
The subsequent study in chapter 2.4 clarified the location at which indinavir crystals 
might occur in the kidney given the knowledge that the problem underlying indinavir 
nephrotoxicity is a solubility problem. The loop of Henle was identified as the most likely site 
for indinavir crystallisation proximal to the collecting ducts where urine concentration is 
dependent on the hydration status of the body. As opposed to the areas beyond the distal 
tubuli, probably the most effective way of reducing urine indinavir saturation in the loop of 
Henle is dose adjustment. Based on in vitro indinavir solubility tests it was hypothesized that 
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plasma indinavir concentrations above 8 mg/ml can already induce the crystallisation 
process and therefore increase the hazard of nephrotoxicity. 
Chapter 2.5 and 2.6 both report the results of an indinavir nephrotoxicity monitoring 
cohort. In this study, both prevalent and incident users of indinavir were systematically 
screened for signs of nephrotoxicity in urine and blood. Approximately, 25% of adult patients 
on indinavir had repeat sterile leukocyturia, which was attributed to indinavir since 
leukocytes disappeared upon indinavir discontinuation. Sterile Jeukocyturia was even more 
prevalent among children on indinavir. who had a cumulative incidence of 53% in 96 
weeks. For both adults and children sterile leukocyturia remained largely asymptomatic 
whereas serum creatinine tended to increase indicating renal failure. Prevalence of sterile 
leukocyturia was associated with high plasma concentrations of indinavir one hour after 
ingestion {ie. > 9 mg/L}. In conclusion, indinavir treated patients should be monitored 
systematically for presence of leukocyturia or serum creatinine elevation. even if urological 
symptoms are absent. With respect to nephrotoxicity management, indinavir dose 
adjustments may have to be considered. 
The subject of the following section was lipodystrophy, a highly prevalent newly 
identified syndrome with a significant impact. which was believed to be an HIV-protease 
inhibitor effect. In the first chapter three cases of lipodystrophy are presented each 
exhibiting different aspects of lipodystrophy. Cases clearly demonstrate prominence of 
zygoma and veins due to subcutaneous fat loss, abdominal distension due to central fat 
accumulation and buffalo hump. 
In chapter 3.2 the incidence of clinically evident lipodystrophy as diagnosed by 
treating physicians was determined in the treated HIV-infected patient population in the 
Netherlands. After four years of treatment 25% of patients had lipodystrophy the incidence 
of which was 11.7 per 100 patient years. In contrast to many earlier studies, HIV-protease 
inh·ib·rtors only appeared to play a minor part in the development of lipodystrophy. 
Stavudine was established as the most important risk factor. 
Finally, the fourth chapter reports on the differential impact of treatment 
modifications on subsequent treatment continuity and the impact of intolerance on 
treatment continuity. First, patients who substituted nevirapine for their HIV-protease inhibitor 
while HIV-1 RNA was below 500 copies/ml showed susta·rned virological suppression and 
good tolerance (chapter4.1). 
In chapter 4.2 patients who switched to nevirapine while HIY-1 RNA was below 500 
copies/ml were compared to patients who switched to second-line HIV-protease inhibitors 
under the same circumstances. Switching to nevirapine appeared to be three times more 
favorable mainly due to a substantially lower rate of subsequent switches. For patients who 
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achieved sufficient viral suppression on HIV-protease inhibitors, but experienced problems 
on this regimen, substitution by nevirapine seems to be a sate switching strategy. 
The subsequent study in chapter 4.3 describes the rate of intolerance-driven 
treatment switches among patients who already underwent a switch during effective viral 
suppression. Within one year after the first switch, 24% had an intolerance-driven subsequent 
switch. Gastro-intestinal intolerance and neuropathy were the most important causes of 
such switches. Beyond the direct causes of intolerance, the most important risk factor for an 
intolerance-driven switch was having had a previous intolerance-driven switch. Switches to 
nevirapine were the most favorable. Whether switching to other non-nucleoside reverse 
transcriptase inhibitors is equally beneficial remains to be investigated. 
Shortcomings of the studies in this thesis are addressed in the general discussion in 
chapter 5 and recommendations tor further research are given. 
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Chapter 6.2 
Samenvatting 
De versnelde registratie procedures en abrupte introductie van de HIV-proteaseremmers 
legde een extra grate verantwoordelijkheid bij het zogenaamde fase IV ofwel 'post-
marketing' onderzoek. Het was belangrijk om meer informatie te verkrijgen over de effecten 
van deze, toentertijd, nieuwe generatie geneesmiddelen, teneinde de toepassing ervan te 
optimaliseren. Het doel van dit proefschrift was om meer inzicht te krijgen in de veiligheid 
van de HIV-proteaseremmers. 
In het kader van dit doel onderzochten we in hoofdstuk 2 de het voorkomen van 
niercomplicaties bij behandeling met indinaviL alsook de mogelijke risicofactoren en 
gevolgen. 
In hoofdstuk 2.1 wordt allereerst melding gemaakt van papilnecrose no een aan 
indinavir toegeschreven niersteenaanval. 
Vervolgens worden in hoofdstuk 2.2 de concentraties van indinavir in het plasma 
van 17 pati§nten met urologische klachten vergeleken met een controlecurve. Deze 
controlecurve werd gemaakt aan de hand van het verloop van de concentraties tussen 
tween indinavir in names bij 14 patienten zonder urologische klachten. Plasmaconcentraties 
van patienten met klachten bleken gemiddeld 2.6 keer hoger te zijn dan die van de 
controlegroep. 
In hoofdstuk 2.3 wordt het voorkomen van klachten aan de urinewegen in de 
gehele Nederlandse populatie van pati§nten op indinavir beschreven. Binnen een jaar no 
starten van de behandeling had 8.3% van de patienten tenminste een keer last gehad van 
urologische problemen, hetgeen twee keer hoger is dan cijfers uit klinische onderzoek voor 
registratie. Urologische klachten kwamen significant vaker voor bij een loge vetvrije 
lichaamsmassa, een loge hoeveelheid virus in het bleed, bij een hoge dosering van 
indinavir en bij hoge buitentemperaturen. Deze risicofactoren passen bij het feit dot 
indinavir gemakkelijk kristalliseert. Het bevestigt de eerdere bevinding dot 
indinavirconcentraties een belangrijke rol spelen bij het ontwikkelen van klachten aan de 
urinewegen. 
In het volgende hoofdstuk onderzochten we op welke pleats in de nieren 
indinavirkristallen als eerste ontstaan. De lis van Henle, een onderdeel van de niertubuli, 
werd hiervoor de meest aannemelijke plek bevonden. Hierin goat een groot concentrerend 
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vermogen semen met een hoge pH, waardoor indinavir kristallen kan goon vormen. Op 
deze plek, die voor de verzamelbuizen ligt, is de concentratie van de urine nog 
onafhankelijk van de vochtbalans van het lichaam en zal het verhogen van de 
vochtinname weinig effect hebben. Om de verzadiging van indinavir in de urine in de lis 
van Henle te bestrijden is een dosisaanpassing waarschijnlijk het meest effectief. Op basis 
van in vitro oplosbaarheidstesten met indinavir werd geschat dot wanneer de 
concentraties in plasma boven 8 mg/ml uitkomen, het kristallisatieproces al wordt 
geTndvceerd en dot daarmee de kens op niercomplicaties toeneemt. 
In hoofdstukken 2.5 en 2.6 worden resultaten gepresenteerd van systematische 
monitoring van tekenen van nefrotoxiciteit in urine en bleed van respectievelijk 
volwassenen en kinderen, die behandeld worden met indinavir. Hierin werden zowel 
patiEmten, die al indinavir gebruikten, als nieuwe gebruikers onderzocht. Bijna 25% van de 
volwassen pati&nten op indinavir bleek bij herhaling leukocyten in de urine te hebben 
zonder de aanwezigheid van infectie. De leukocyten verdwenen onmiddellijk bij het 
stopzetten van de behandeling. Bij kinderen kwam deze afwijking nog vaker voor. No twee 
jaar behandeling had 53% van de kinderen een of meer keren leukocyten in de urine 
gehad. Hoewel het hebben van leukocyten in de urine vaak niet gepaard ging met fysieke 
klachten, bleek de nierfuncf1e van zowel kinderen als volwassenen met deze afwijking 
achteruit te goon. Ook het voorkomen van leukocyten de urine bleek semen te hangen 
met hoge concentraties indinavir in het plasma. Concluderend werd gesteld dot patienten 
die worden behandeld met indinavir systematisch d"1enen te worden onderzocht op 
leukocyten in de urine en dot hun serum creatinine (een nierfvnctietest) regelmatig dient te 
worden bepaald, onafhankelijk van de aanwezigheid van klachten aan de urinewegen. 
Dosisaanpassingen zouden overNogen kunnen worden bij het bestrijden van deze vorm 
van nefrotoxiciteit door indinavir. 
Hoofdstuk 3 handelt over lipodystrofie, een zeer frequent voorkomende 
aandoening in de vetverdeling van het lichaam, die werd toebedeeld aan HIV-
proteaseremmers. Eerst worden drie ziektegeschiedenissen beschreven van patienten met 
lipodystrofie, die elk verschillende aspecten van het syndroom vertonen. Patienten vertonen 
sterke vaattekening als gevolg van onderhuids vetverlies, toegenomen buikomvang door 
centrale vetophoping en kunnen een zogenaamde 'buffalo hump' ontwikkelen. 
In hoofdstuk 3.2 bepaalden we de frequentie van voorkomen van klinisch evidente 
lipodystrofie, gediagnostiseerd door de behandelend arts, in de Nederlandse behandelde 
HIV-geTnfecteerde patientenpopulatie. No vier jaar behandeling had 25% van de patienten 
lipodystrofie ontwikkeld wat neerkomt op 11.7 gevallen per 100 patient-jaren. In 
tegenstelling tot vele eerdere onderzoeken bleken HIV-proteaseremmers slechts een 
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geringe rol te spelen bij het ontstaan van lipodystrofie. Het gebruik van stavudine, een 
(nuclesoide analoge] reverse transcriptaseremmer, bleek de kons op het krijgen van 
lipodystrofie het sterkst te be pal en. 
Het vierde hoofdstuk beschrijft de effecten van therapiewijzigingen en de effecten 
von het niet kunnen verdragen van de medicatie op het verloop van verdere behandeling. 
Eerst wordt een reeks potienten beschreven, die hun HIV-proteaseremmer lie ten vervangen 
door nevirapine, terwijl de hoeveelheid virus (HIV-RNA) onder de detectiegrens (500 
kopi8en/ml] lag. Zij vertoonden aanhoudende virusonderdrukking en konden de nieuwe 
behandeling goed verdragen (hoofdstuk 4.1). 
In hoofdstuk 4.2 wordt een vergelijking gemaokt tussen patienten, die hun HIV-
proteaseremmer vervingen door de (non-nucleoside anologe) reverse transcriptase rem mer 
nevirapine en pati§nten, die hun HIV-proteaseremmer vervingen door een nieuwe H!V-
proteaseremmer. Hierbij vond de wijzinging pleats tijdens virussuppressie tot onder de 
standaard detectiegrens van 500 HIV-RNA kopi6en/ml in het bleed. Het overgaan naar 
nevirapine bleek in deze gevallen drie keer gunstiger, met name doordat er substantieel 
minder therapiewijzigingen optraden in de periode erna. Concluderend werd gesteld dot 
voor patienten met virusonderdrukking op HIV-proteaseremmers. die de behandeling 
dreigen niet vol te kunnen houden, lijkt het omzetten van de HIV-proteaseremmer in 
nevirapine een veilig alternatief. 
Het volgende onderzoek in hoofdstuk 4.3 beschrijft de frequentie van voorkomen 
van wijzigingen in de behandeling als gevolg van bijwerkingen. Binnen een jaar no de 
eerste wijziging had 24% van de patienten een dergelijke wijziging vanwege bijwerkingen 
ondergoon. Gostro-intestinale klachten en neuropathie waren de belangrijkste oorzoken 
hiervoor. Het bleek dot wanneer de HIV-proteaseremmer werd veranderd in nevirapine. het 
daaropvolgend beloop het gunstigst was. Of veranderingen naar andere vergelijkbare HIV-
remmers, zeals bijvoorbeeld efavirenz, even gunstig is kon niet worden onderzocht doordat 
deze ten tijde van het onderzoek nog niet voorhanden waren. 
Ge§indigd wordt met enige aanbevelingen voor nader onderzoek. 
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